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Streptococcus pneumoniae is the leading cause of community-acquired 
pneumonia in all ages, with the greatest incidence occurring in children, the 
elderly and HIV-infected individuals. HIV-infected adults are at least 25-fold at risk 
of bacterial pneumonia compared to age-matched HIV-uninfected individuals, but 
the immunological mechanisms for this risk are still unclear. Alveolar 
macrophages (AMs) are the major sentinel phagocytic population found in the 
airway responsible for the early clearance and control of respiratory pathogens. I 
hypothesise that HIV infection is associated with impaired airway alveolar 
phagocyte killing function, leading to survival and propagation of pneumococci. 
 
Methods 
Three groups of participants aged between 18 to 60 years were recruited, 
consisting of asymptomatic HIV-uninfected adults, HIV-infected adults on short-
term or long-term antiretroviral therapy (ART) residing in Blantyre, Malawi. Lower 
airway samples (bronchoalveolar lavage fluid) were collected from the 
participants and used to investigate airway mediated defence immunity against S. 
pneumoniae in an ex vivo model. The airway cells were infected with 
pneumococci (serotype 3 strain) and the number of alveolar phagocytes 
associated with bacteria were measured and phenotyped using flow cytometry. 
Intracellular and extracellular bacterial killing was measured using quantitative 
culture in a gentamicin protection assay (GPA) and bacterial outgrowth assay, 




Alveolar macrophages were the principal phagocytic cells associated with IgG-
opsonised pneumococcal-ST3 following ex vivo infection, irrespective of HIV 
status. AM from HIV-infected adults did not exhibit impaired binding and 
internalisation of IgG-opsonised pneumococcal-ST3, irrespective of ART duration.  
Furthermore, airway cell-mediated control of extracellular S. pneumoniae 
outgrowth during early infection was also not impaired in HIV-infected adults on 
ART. However, HIV-infected adults on ART demonstrated reduced AMs-mediated 
intracellular killing capacity of S. pneumoniae during the late killing phase (24-
hours post infection) with pneumococci persisting in CD206+AMs. The presence of 
extracellular S. pneumoniae 24-hours post infection in a bacterial outgrowth assay 




In summary, the data from this thesis demonstrates that AMs from HIV-infected 
adults on ART have impaired late bacterial killing capacity, leading to intracellular 
bacterial persistence and propagation of extracellular pneumococcal outgrowth. 
Persistence of the pneumococci within CD206+AMs could serve as a reservoir for 
pneumococcal infection in the lung, potentially contributing to increased 
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1.1. History of Streptococcus pneumoniae 
Streptococcus pneumoniae (the pneumococcus) was first isolated and described 
independently by two scientists; Louis Pasteur (France) and George Miller 
Sternberg (America) in 1880-1881 before being confirmed by Albert Fraenkel as 
one of the common causes of pneumonia, and later confirmed to be the major 
cause of mortality during the 1918 influenza pandemic (Brundage and Shanks, 
2008; Fraenkel, 1884; Pasteur, 1881a, 1881b; Sternberg, 1881; Watson et al., 
1993; Wever and van Bergen, 2014). This organism has gone through several 
name changes over the years; initially being named Microbe septicemique du 
salive by Pasteur, then referred to as Micrococcus pasteuri by Sternberg, the 
name Pneumococcus was suggested by Fraenkel in 1886 but it was later renamed 
Diplococcus pneumoniae in 1920 because of its propensity to cause pulmonary 
disease (Fraenkel, 1886; Pasteur, 1881b; Sternberg, 1885; Winslow CEA et al., 
1920). It was only until 1974 that a consensus was reached, and pneumococcus 
was given its present name S. pneumoniae based on its growth characteristic in 
liquid media and its proclivity to cause pneumonia (Deibel and Seeley Jr, 1974).  
 
1.2. S. pneumoniae the organism 
S. pneumoniae is an invasive Gram-positive, diplococcus (but may also be 
observed as single organism in chains), optochin positive, catalase negative, 
aerotolerant anaerobic bacterium (Brooks and Mias, 2018; Facklam, 2002; 
Henriques-Normark and Tuomanen, 2013). When S. pneumoniae is cultured on 
sheep blood agar (7%) supplemented with gentamicin (5µg/L) (SBG), it forms 




Figure 1.1. Growing S. pneumoniae on sheep blood agar supplemented with gentamicin. A. 
colonial morphology of S. pneumoniae serotype 3 on SBG agar plate B. Optochin sensitive S. 
pneumoniae on SBG agar plate. 
 
S. pneumoniae is a commensal and an extracellular bacterium that frequently 
colonises the human nasopharynx without causing disease, a state known as 
carriage, but has potential to cause mild and severe diseases such as otitis media, 
sinusitis, pneumococcal pneumonia, meningitis and bacteraemia (Austrian, 1999; 
Brooks and Mias, 2018). S. pneumoniae can be divided into serotypes based on 
capsule chemical composition and a factor (typing) sera that reacts with the 
capsule giving serogroups which contain antigenically related serotypes (Bentley 
et al., 2006). At least 98 serotypes (in 46 serogroups) of S. pneumoniae are known 
to exist and vary in the frequency at which they are carried within the 
nasopharynx with only a few implicated in disease causation (Bentley et al., 2006; 
Chaguza et al., 2017; Dube et al., 2018; Geno et al., 2015; Kalata et al., 2019; 
Ziane et al., 2016). The pathogenic potential of pneumococcal serotypes varies 
and similarly, their frequencies or prevalence also vary by geographic location 
(Gámez et al., 2018; Jedrzejas, 2001; Mitchell and Mitchell, 2010). Virulence 








1.3. Virulence factors involved in pneumococcal pathogenesis   
Several virulence factors have been identified and these can be grouped based on 
their function namely adhesion, colonisation, breaching tissue barriers, and 
immune evasion (Gámez et al., 2018; Voss et al., 2012).  
 
1.3.1.  The Bacterial capsule 
The capsule is one of the major virulence factors expressed by S. pneumoniae and 
has been studied for more than a century. The capsule thickness, steric hindrance 
and negative charge has been shown to determine the ability of a capsular type to 
inhibit surface deposition of complement, C-Reactive Protein, mannose- binding 
proteins, and antibodies that can bind to receptors found on phagocytes 
(Henriques-Normark and Tuomanen, 2013). The S. pneumoniae capsule inhibits 
the activation of classical and alternative complement pathways, through binding 
of IgM, IgG to the pneumococci, as well as inhibiting the degradation of C3b to 
iC3b which reduces the opsonophagocytosis process (Hyams et al., 2010a, 2013a). 
The ability to regulate the production of the capsule at the transcriptional, 
translational or post-translational level is important for the survival of S. 
pneumoniae in different host environments (Kadioglu et al., 2008).  
 
The capsule is not the only virulence factor required to induce pneumococcal 
infection. Other virulence factors (see Figure 1.2) are also found to be 
glycoconjugated to various proteins on the pneumococcus surface and have been 




Figure 1.2. Schematic drawing of S. pneumoniae structure showing virulence factors involved in 
host pathogenesis. A number of proteins and toxins are expressed by S. pneumoniae and 
thesedrive its pathogenesis within the host. The major virulence factors are highlighted in the 
figure. Abbreviations: PsaA, pneumococcal surface adhesin A; PspA, pneumococcal surface protein 
A; PspC, pneumococcal surface protein C; PiaA, pneumococcal iron acquisition A; PiuA, 






S. pneumoniae is known to express neuraminidases, NanA, NanB, and NanC, with 
NanA and NanB genes present in almost all clinical S. pneumoniae isolates while 
NanC gene is present in ∼50% of isolates (Pettigrew et al., 2006). Neuraminidases 
are critical in cleaving sialic acid-containing substrates from epithelial cell surfaces 
thereby promoting pneumococcal colonisation and exposing host cell receptors 
for bacterial adherence (Tong et al., 2001). Sialic acid is a glycoconjugate and a 
major source of carbon required for the propagation and growth of 
pneumococcus in the upper airway (Burnaugh et al., 2008; Siegel et al., 2014). In a 
mouse co-infection model, neuraminidase from influenza virus and pneumococci 
were shown to promote pneumococcal growth and load during colonisation but 
this was dependent on acquisition of the host sialic acid residues from airway 
mucins (Siegel et al., 2014). In another study, NanA was reported to enhance 
complement activity in whole blood through cleaving sialic acids from cell 
surfaces and predisposing sensitised red blood cells to complement and 




Pneumococci also uses its multimeric filamentous pili encoded by the 
pathogenicity islet (PI) 1 and 2 to attach to the respiratory mucosa (Bagnoli et al., 
2008; Barocchi et al., 2006; Henriques-Normark and Tuomanen, 2013; Novick et 
al., 2017; Shaik et al., 2015). At least 20 – 30% of clinical isolates possess the PI-1 
and its presence has been shown to be critical in pneumococci interaction with 
different types of host cells, including both epithelial and endothelial cells 
(Moschioni et al., 2008). It has been shown that clinical isolates with PI-1 islet 
present are more virulent, readily adhere to lung epithelia and induce severe 
disease in murine model infections compared to pili deficient S. pneumoniae 
isolates (Barocchi et al., 2006). PI-1 is also known as the rlrA and encodes three 
pilins (RrgA, the adhesin; RrgB, the backbone; and RrgC, the bridging element) and 
three class C sortases (Barocchi et al., 2006; Izoré et al., 2010; LeMieux et al., 
2006; Shaik et al., 2015). The RrgA has been shown to be the major adhesin 
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protein on the pilus-1 that binds to the nasopharyngeal epithelium (Iovino et al., 
2020; Nelson et al., 2007). Also, the PI-1 type pilus binds to toll like receptor-2 
(TLR2) using the adhesin. The PI-2 islet encodes two pilins; pneumococcal iron 
transporter (PitA and PitB), two sortases (SrtG1 and SrtG2) and one signal 
peptidase- like protein (SipA) important in bacterial adhesion to host cells (Shaik 
et al., 2015; Shenoy and Orihuela, 2016; Zähner et al., 2010). 
 
1.3.4.  Pneumolysin 
Another important virulence factor implicated in pneumococcal disease is the 
pneumolysin, a 53kDa pore forming toxin released during bacterial autolysis and  
also localises within the pneumococcal cell wall, thereby becoming accessible to 
Pathogen Recognition Receptors (PRR) (Price and Camilli, 2009). It belongs to the 
cholesterol-dependent cytolysin (CDC) family of toxins and oligomerises with 
membrane cholesterol to form macromolecular pores that perforate the host cell 
membranes thus mediating cell lysis (Rai et al., 2016). Pneumolysin has also been 
shown to dampen the pro-inflammatory cytokine secreting potential of alveolar 
macrophages and dendritic cells thus, facilitating intracellular residency of 
pneumococci (Subramanian et al., 2019). Pneumolysin has also been shown to 
induce inflammation during colonisation which in an infant mouse model, was 
shown to promote shedding of the bacteria from the inhospitable host (Zafar et 
al., 2017). Pneumolysin has also been shown induce dysregulation of the 
production of reactive oxygen species (ROS) which in turn causes damage to host 
double-stranded DNA (Rai et al., 2015, 2016). Other key virulence factors and 










Capsule • Inhibits complement and antibody mediated opsonophagocytosis. 
• Prevents mucus entrapment. 
• Allows the pneumococci to escape neutrophil extracellular traps. 
Pneumolysin • Induce lysis of neutrophils leading to expulsion of neutrophil elastase 
which impairs AMs phagocytosis. 
• Binds to host membranes cholesterol.  
• Binds to the mannose receptor (MRC-1/CD206) enabling it to evade the 
lysosomal killing pathway.  
• Inhibits DCs pro-inflammatory cytokine responses and TLR signalling 
• Inhibits DCs maturation. 
• Activates complement. 
PspC/CbpA • Allows pneumococci to traverse from the apical to basal epithelia 
through binding of the human polymeric immunoglobulin receptor 
(hpIgR) or secretory IgA. 
• Invades the host epithelia through binding to platelet-activating factor 
receptor (PAF-R) via ChoP. 
• Improves complement resistance by binding to factor H. 
IgA protease • Cleaves human IgA1 
RrgA  • Adhesin protein on the pilus-1 that binds to the nasopharyngeal 
epithelia. 
• Interacts with CR3 on AMs and DCs thereby promoting internalisation of 
pneumococcus 
Neuraminidase  • Cleaves sialic acid from epithelia cells. 
• Aids bacterial colonisation by revealing receptors for adherence. 
• Promotes pneumococcal growth and survival 
Autolysin • Digests the pneumococcus peptidoglycan, releasing pneumolysin and 
causing lysis of incompetent cells. 
PavA • Inhibits pneumococcal internalisation by DCs and cytokine induction. 
PspA • Prevents binding of C3 onto pneumococcal surface.  
• Also binds lactoferrin and inhibits S. pneumoniae killing by lactoferrin 
 
Table is taken from (Brooks and Mias, 2018) and adapted for this thesis. 
Abbreviations: AMs – alveolar macrophages; C3 – convertase 3; CbpA – choline-binding protein A; ChoP – 
phosphorylcholine CR3 – complement receptor 3; DCs – Dendritic cells; IgA – immunoglobulin A; PAF-R – 
platelet-activating factor receptor; PavA – pneumococcal adhesion and virulence A; PspA – pneumococcal 




The list of pneumococcal virulence factors in the table, is not exhaustive but only few critical 
ones have been selected and are shown.  
1.4. From Pneumococcal colonisation to disease 
1.4.1.  Pneumococcal Carriage 
S. pneumoniae is a common coloniser of the mucosal surfaces of the human 
upper respiratory tract (URT) occurring in 5 – 90% of individuals (Abdullahi et al., 
2012; Conklin et al., 2016; Esposito et al., 2016; Heinsbroek et al., 2015; 
Petraitiene et al., 2015; Weiser et al., 2018; Zhou et al., 2015). Pneumococcal 
colonisation in the absence of disease is higher amongst children, ranging from 40 
– 90%, whereas in adults it ranges between 5 – 50% (Adetifa et al., 2018; 
Heinsbroek et al., 2015; Hill et al., 2006, 2008; Neal et al., 2019; Regev-Yochay et 
al., 2004; Sutcliffe et al., 2019; Swarthout et al., 2020; Usuf et al., 2015). 
Nasopharyngeal colonisation is the first step in the progression to pneumococcal 
pneumonia and yet the carriage dynamics remain incompletely understood (Dube 
et al., 2018). Once colonisation has been established, an individual strain can be 
carried for weeks to months before eventual clearance (Hill et al., 2008; Kadioglu 
et al., 2008; Murad et al., 2019). The nasopharynx has been classified as the main 
reservoir for pneumococcus in humans (Brooks and Mias, 2018). Successful 
colonisation with pneumococcus depends on its ability to outcompete for its 
niche with other microbes, evade mucociliary clearance, withstand environmental 
factors, availability of nutrients and host immunity (Jochems et al., 2017, 2019; 
Siegel et al., 2014). Long-term carriage is thought to be a proxy for immunity, in 
the sense that exposure to pneumococcal antigens via repeated episodes of 
nasopharyngeal colonisation is key to acquiring sustained protective anti-
pneumococcal adaptive immunity (Adler et al., 2017; Weinberger et al., 2008). 
The strength for this protective effect is thought to vary according to serotype, 
age and the individual’s immune status (Weinberger et al., 2008).  
 
Nasopharyngeal carriage occurs naturally and frequently in children under the age 
of 5-years but can also be promoted by the disturbance of the nasopharyngeal 
environment by an upper respiratory viral infection. Acquisition is therefore more 
frequent in winter compared to summer (Gray et al., 1980; Jochems et al., 2018). 
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Similarly, surveillance studies conducted in Malawi have demonstrated that 
pneumococcal disease peaks during the colder and drier months and association 
with seasonality has also been reported to be higher in HIV-infected adults and in 
children (Everett et al., 2011; Wall et al., 2014). Separate studies conducted in 
Kenya, Malawi and Mozambique showed that HIV-infected adults are more 
frequently colonised with pneumococcus (estimated point prevalence of 24.8% - 
52%) compared to asymptomatic healthy individuals (estimated point prevalence 
9.7% - 26.8%), with increased carriage reported in HIV-infected individuals on 
antiretroviral therapy (ART) compared to the ART naïve (Conklin et al., 2016; 
Glennie et al., 2013; Heinsbroek et al., 2015; Nzenze et al., 2015; Sepako et al., 
2014). Moreover, the duration of carriage has been observed to be longer (39.5 
vs 28.5 days) in children under 5-years compared to their mothers (Heinsbroek et 
al., 2015). Furthermore, some serotypes frequently found to cause invasive 
disease are not often isolated from the nasopharynx of healthy children, 
suggesting these serotypes colonise for a short duration (Brueggemann et al., 
2003; Sutcliffe et al., 2019; Sandgren et al., 2004). 
 
The transition from colonisation to disease is a watershed in the relationship 
between S. pneumoniae and its host. The link between pneumococcal 
colonisation and subsequent development of various forms of pneumococcal 
disease (see Figure 1.3) has demonstrated in experimental murine models of 
meningitis, pneumonia and bacteraemia; as well as inferred from studies on otitis 
media, bacteraemia, meningitis and pneumonia in humans (Adler et al., 2017; 
Albrich et al., 2012; Blacklock and Guthrie, 1933; Chiavolini et al., 2008; van Ginkel 
et al., 2003; Gray et al., 1980; Kelly and Gussin, 1924; Neill et al., 2014). The 
transition involves a major switch in the expression of virulence determinants as 








Figure 1.3. Pathogenesis and spread of S. pneumoniae. S. pneumoniae is thought to be transmitted 
from person to person via aerosols and contaminated hands resulting in nasopharyngeal 
colonisation. Colonisation is tightly regulated by the host upper airway immunity. During a 
nasopharyngeal airway disturbance, pneumococcus can evade the host immunity resulting in its 
spread to different parts of the body and causing diseases such as sinusitis, otitis media, 
pneumonia, bacteraemia and meningitis. 
 
1.4.2.  Otitis Media and Sinusitis 
 
Otitis media and sinusitis are known to be facilitated through local bacterial 
spread and are non-invasive or fatal in nature. Otitis media is a common 
paediatric manifestation, affecting at least 80% of children by the age of 3-years  
(Bergenfelz and Hakansson, 2017). S. pneumoniae is the leading bacterial cause of 
otitis media (between 30 – 50%) ahead of Haemophilus influenzae and Moraxella 
catarrhalis (Bergenfelz and Hakansson, 2017; Revai et al., 2008). A newly acquired 
carriage serotype has often been implicated as a cause of otitis media amongst 
children with established carriage (Revai et al., 2008).  
 
S. pneumoniae, M. catarrhalis, H. influenzae, S. pyogenes and Staphylococcus 
aureus are common bacterial pathogens associated with community acquired 
sinusitis (Brook, 2011; Olarte et al., 2014). S. pneumoniae has been reported to 
represent an important pathogen among the aerobic isolates in chronic sinusitis, 
particularly in acute exacerbations of chronic sinusitis and in younger children 
(Olarte et al., 2014). Respiratory viral infections are known to predispose 
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individuals to sinusitis through microbial synergy, induction of local inflammation 
leading to blockage of the sinus ostia, increased bacterial attachment to the 
epithelial cells, and disruption of the local immune defence (Brook, 2011).  
 
1.4.3.  Pneumococcal pneumonia  
 
Bacteremic pneumococcal infection is associated with a high morbidity and 
mortality and typically occurs as a complication of pneumonia (bacteremic 
pneumococcal pneumonia) or, less often, the organism will spread directly from 
its niche to the bloodstream (Kadioglu et al., 2008). Previously, in a study 
conducted in Vietnamese hospitalised children, increased pneumococcal load in 
nasopharynx were associated with radiologically confirmed pneumonia and viral 
co-infection (Vu et al., 2011). In another study conducted in South Africa, 
invasive/bacteremic pneumococcal pneumonia was associated with HIV infection, 
influenza and high S. pneumoniae colonisation density and these were also 
independent predictors of disease severity (Wolter et al., 2014). However, in 
humans, it is still not clear whether higher pneumococcal colonisation density in 
the upper airway precedes pneumonia or is actually  an effect of lower airway 
disease (Siegel et al., 2014). 
 
1.5. Burden of pneumococcal infections 
Pneumococcal disease has been present throughout history and it is postulated 
that the pneumococcus bacterium evolved in parallel with the human immune 
system (Adler et al., 2017; Kilian et al., 2008). The nasopharynx is the reservoir as 
well as a source of transmission and disease. Once the pneumococcus invades the 
respiratory epithelia, it can potentially cause life-threatening diseases such as 
bacteraemia, pneumonia and meningitis (Kadioglu and Andrew, 2004; Klugman 
and Feldman, 2001). Pneumococcus is the leading cause of pneumonia and 
invasive bacterial infections in all ages, with the greatest incidence being in 
children, the elderly and HIV-infected individuals (Azzari et al., 2016; Troeger et 
al., 2017) see Table 1.2. Between these ends of the age spectrum, healthy young 
adults have a much lower incidence and severity of pneumonia (Guillon et al., 
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2020). Moreover, the incidence of pneumococcal infections varies between age 
groups, populations and countries, with differences being attributed to several 
factors such as overcrowding, poverty, underlying immune status, co-infection 
with influenza and malnutrition (Cohen and Levy, 2017; Nightingale et al., 2019). 
Identifying mechanisms protecting healthy young adult lungs against pneumonia 
is a pressing research priority (Dela Cruz et al., 2018; Guillon et al., 2020). 
 
With the introduction of pneumococcal vaccines in children, the burden of 
pneumococcal disease in both adults and children has dropped, although a gap in 
studies estimating the true burden still exists (Troeger et al., 2017; Wahl et al., 
2018a). Current pneumococcal vaccines are efficacious in reducing invasive 
pneumococcal disease (IPD) but less effective against pneumonia (Klugman et al., 
2003; Silaba et al., 2019). It is estimated that pneumococcus causes IPD in 
approximately 1.5-million individuals every year and is the leading cause of 
community acquired pneumonia ahead of influenza, H. influenzae B and 
respiratory syncytial virus (RSV) among children under the age of 5, the elderly 
and HIV infected individuals (Aston et al., 2019; GBD 2013 Mortality and Causes of 
Death Collaborators, 2015; O’Brien et al., 2009; Troeger et al., 2017). In 2015, 
pneumococcal pneumonia was estimated to have caused 55.4% of deaths from 
lower respiratory infections (LRI) in all ages, totalling 1,517 388 deaths (95% 
uncertainty interval (UI), 857 940–2.183 791) (Troeger et al., 2017; Wahl et al., 
2018a). Lower respiratory infections (LRI) are among the leading top five cause of 
mortality in people of all ages (GBD 2013 Mortality and Causes of Death 
Collaborators, 2015). Sub-Saharan Africa (SSA) and southeast Asia are estimated 
to have the highest disease burden and mortality of pneumococcal pneumonia 
(Troeger et al., 2017). Moreover, the burden of the disease is greater in SSA due 
to the high HIV prevalence, malnutrition, poverty, persistent high pneumococcal 
carriage and transmission rates and this is despite the availability of 
pneumococcal conjugate vaccines (PCVs) (Chisti et al., 2009; Cohen et al., 2017a; 
Heinsbroek et al., 2015; Iroh Tam et al., 2017; Troeger et al., 2017). In Malawi, 
pneumococcus is known to be the commonest cause of meningitis and second 
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commonest cause of bacteraemia and community acquired pneumonia 
(CAP)(Aston et al., 2019; Everett et al., 2011; Wall et al., 2013; Wall E.C. et al., 
2014). Furthermore, the incidence of invasive pneumococcal disease in adults is 
estimated at 58.1/100,000 person years with higher incidences (108.8/100,000 
person years) occurring in the HIV-infected individuals aged between 35-40 years 
(Bar-Zeev et al., 2015; Everett et al., 2011).
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Comparator  Community acquired 
Pneumonia 
Bacteraemia Meningitis Otitis media  











pneumococcus to aetiology 
20 – 30% – 20 – 25% 30 – 50% 
Cases/year* 8 910 000 in 
children<5-years 
326 000 in 
children<5-years 
83 900 in children<5-
years 
~300 million 















Vaccine PCV-10/13, although 
it is less efficacious 
against preventing 
vaccine type CAP. 
PCV-10/13 are 
efficacious against 
IPD. PPSV in the 
elderly. 
PCV-10/13 are 
efficacious against IPD 
PCV-10/13, 






Invasiveness Invasive Invasive Invasive Non-invasive 
Common models for 
studying disease 
Mice Mice Mice Mice 
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References  (Borsa et al., 2019; Loughran et al., 2019; Troeger et al., 2017; Wahl et al., 2018a) 
*The number of cases/year is limited to children as data for adults is not available 
Abbreviations: HIV - IPD – invasive pneumococcal disease, PCV-10/13 – 10/13 valent pneumococcal conjugate vaccine.
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1.6. Mucosal innate immunity against S. pneumoniae 
1.6.1. Mucosal airway innate immunity 
 
The human airways (50 – 100m2) are exposed to large number of airborne pathogens as a 
result of inhalation of 10,000 litres of air every single day (Hartl et al., 2018; Joseph et al., 
2013; Martin, 2005). The integrity of the airway depends on a highly regulated host defence 
machinery with both innate and adaptive immunity playing pivotal roles (Bals and Hiemstra, 
2004). Mucosal innate immune responses are critical in the control and clearance of 
pneumococcus infection in the airway. The host’s innate responses have to be robust and 
efficient. Compromised immune responses result in pneumococcus colonisation, dysbiosis, 
followed by infection of the airway and lung parenchyma (non-bacteremic pneumonia), 
together with systemic spread to other anatomical sites (Herta et al., 2018; Shenoy and 
Orihuela, 2016). The innate mucosal immunity involved in pneumococcal defences include 
such cells as epithelial cells, AMs, dendritic cells, monocytes and neutrophils. The innate 
immune response uses pattern recognition receptors (PRR) including transmembrane Toll-
like receptors (TLRs), cytosolic Nod-like receptors (NLRs), RIG-I-like receptors (RLRs) and 
various cytosolic DNA sensors to bind to conserved molecular patterns termed pathogen-
associated molecular patterns (PAMPs) found on the pneumococcus cell surface (Bals and 
Hiemstra, 2004; Byrne et al., 2015; Janssens and Beyaert, 2003; Kohler et al., 2016b; Martin, 
2005; Medzhitov and Janeway, 1997). Epithelial cells, dendritic cells and AMs are the initial 
checkpoints that encounter micro-aspirated pneumococcus and can either trigger 
proinflammatory or tolerogenic/anti-inflammatory downstream immune responses (Hartl et 
al., 2018; Weight et al., 2019). The control of S. pneumoniae invasion in the lower airway in 
humans is yet to be fully understood, hence defining the mechanistic basis for host cellular 
control of S. pneumoniae is critical for the development of therapeutics (Mitsi et al., 2019; 








1.6.2. How S. pneumoniae hijacks the airway epithelia cells for its survival 
The airway epithelium is a fundamental part of the lung innate immunity, forming an 
interface between internal milieu and the external environment, being responsible for the 
binding and transportation of antibodies, bacterial sensing via their PRR and rapidly 
transducing signals to recruit innate and inflammatory immune cells to the site of 
inflammation (Bals and Hiemstra, 2004; Weight et al., 2019). These epithelial cells can be 
subdivided into bronchial and alveolar cells, which are primarily responsible for ion exchange, 
regulating gas exchange, mucin production, inflammation, and providing physical barrier 
though tight junctions and desmosomes (Eisele and Anderson, 2011; Rose et al., 2001).  
Alveolar epithelial cells are divided further into type I and type II cells. The type I alveolar cells 
are responsible for gaseous exchange and are also capable of sensing invading pathogens 
(Eisele and Anderson, 2011). Type II alveolar  epithelia (also called type II pneumocytes) 
function as the lower airway host defence, through their ability to sense pathogens, secretion 
of antimicrobial products such as surfactants, lysozymes, lactoferrins cytokines and 
chemokines (Eisele and Anderson, 2011). Airway epithelial cells express low levels of CD14+ 
and toll-like receptor (TLR) 1-6 and -9, and sense pneumococcus in the mucociliary fluid by 
the same TLR-dependent mechanisms (TLR2, TLR4, TLR9) used by alveolar phagocytes 
(Dessing et al., 2009; Dudek et al., 2016a; Gordon et al., 2013; Janssens and Beyaert, 2003; 
Tomlinson et al., 2014). TLR2 is known to be activated by lipoteichoic acid (LTA), 
peptidoglycan (PGN) and bacterial lipoprotein; TLR4 is activated by pneumolysin whilst TLR9 
is activated by the pneumococcal unmethylated CpG-DNA (Albiger et al., 2007; Domon et al., 
2018; Kohler et al., 2016a; Moffitt et al., 2014; Thorburn et al., 2016; Tomlinson et al., 2014).  
Upon ligand recognition, the nuclear factor-kb (NF-kb) pathway is activated within airway 
epithelia cells, resulting in the production of proinflammatory cytokines and chemokines 
including IL-1b, IL-6, TNF, and IL-8 (Dudek et al., 2016a; Jochems et al., 2018; Weight et al., 
2019). The NF-kb (a transcriptional factor) and the myeloid differentiation factor-88 (MyD88; 
a central adaptor molecule) are crucial to most TLR signalling and their absence has been 
shown to result in uncontrollable pneumococcal outgrowth in the airways (Albiger et al., 
2005, 2007; Kohler et al., 2016a). 
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Most of the data on the interaction of S. pneumoniae and airway cells is derived 
from murine models. S. pneumoniae also exploits the airway epithelia machinery 
using its virulence factors such as the pili to attach to the respiratory epithelia. 
Once S. pneumoniae initiates attachment to mucosal cells, the bacteria partially 
sheds its polysaccharide capsule at the site of adhesion as to provide access to the 
respiratory mucosa and facilitate exposure of adhesive molecules embedded 
within the bacterial cell wall or cytoplasmic membrane (Novick et al., 2017).  
Following attachment of S. pneumoniae to the airway epithelia, the bacteria may 
invade the cells through the binding of phosphorylcholine (ChoP), to the platelet-
activating factor receptor (PAF-R) found on epithelial surfaces lining the 
nasopharynx of the host thus, triggering host cell signalling (Balachandran, 2002; 
Kadioglu et al., 2008; Maestro and Sanz, 2016; Novick et al., 2017; Rosenow et al., 
1997). The Chop found in pneumococcus mimics the platelet-activating factor 
(PAF) and is used as a decoy to evade host response (Kadioglu et al., 2008). Also 
the choline-binding protein A (CbpA also referred to as PspC or SpsA) in the S. 
pneumoniae non-covalently anchors  to ChoP (Kadioglu et al., 2008). Additionally, 
the binding of CbpA to PAF-R is capable of initiating the PAF-R recycling pathway, 
leading to the entry of S. pneumoniae into the host cells, and bacterial 
transportation to the basal membrane of the epithelial cells (Hergott et al., 2015; 
Kadioglu et al., 2008; Maestro and Sanz, 2016; Rosenow et al., 1997). Notably, 
pneumococcus may use ChoP esterase (also known as CbpE) to hydrolyse ChoP 
from host-derived PAF in the lumen of the airway resulting in the PAF-mediated 
suppression of neutrophil activation and effectively limiting bacterial clearance 
(Hergott et al., 2015).   
S. pneumoniae is also able to bind to the human polymeric immunoglobulin 
receptor (hpIgR) or to secretory IgA through the CbpA, thus exploiting the 
recycling pathway and traversing from the apical to the basement of the alveoli 
epithelia membrane (Hammerschmidt et al., 1997; Li et al., 2020; Maestro and 
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Sanz, 2016; Moreno et al., 2012). The hpIgR is an integral membrane protein 
required for transcytosis of IgA and IgM across the mucosal epithelial cells and its 
interaction has been proposed to promote the translocation of S. pneumoniae 
across the mucosal barrier and cause disease (Balachandran, 2002; Li et al., 2020; 
Novick et al., 2017). Thus, by exploiting micro-invasion and hijacking the host 
recycling and trafficking system, the pneumococcus may carefully calibrate the 
host innate immune/inflammatory response thereby propagating its survival or 
dissemination (Weight et al., 2019). The schematic Figure 1.4. summarises the 
mechanism pneumococci utilises to hijack and evade epithelia defences. 
Figure 1.4. Hijacking of the epithelial human polymeric immunoglobulin and platelet-activating 
factor receptors by S. pneumoniae. A. Mucosal epithelial cells transport sIgA across their 
basolateral and apical surfaces through the hpIgR (pink), the receptor is endocytosed and recycled 
back to the basolateral surface. B. S. pneumoniae protects itself by secreting IgA1 protease which 
cleave host sIgA. C. S. pneumoniae is able to bind to the empty hpIgR (pink) and transported across 
the epithelia basolateral and apical surfaces. D. PAF (green) binds PAF-R (orange) to mediate 
intercellular signalling. The S. pneumoniae Chop mimics PAF and able to bind to the PAF-R thus 
initiating the PAF-R recycling pathway resulting in the bacteria being transported across the 
epithelia basolateral and apical surfaces. Abbreviations: HpIgR – human polymeric 
immunoglobulin receptor, IgA – immunoglobulin A, PAF – platelet factor A, SPN –Streptococcus 
pneumoniae. This figure contains some artwork produced by Servier Medical Art 
(http://smart.servier.com), under creative commons license 3.0. 
1.6.3. Role of neutrophils in control of pneumococcal infection 
Neutrophils are critical phagocytes in the airway but are not abundant during  
homeostatic state (Mwale et al., 2018). It has been reported that the neutrophil 
lung marginated pool, constitutes the most prominent reservoir of neutrophils in 
systemic circulation (∼40% of total body neutrophils) (Hartl et al., 2018). There is 
mounting evidence that neutrophils are plastic and display phenotypic and 
IgA
A. B. C. D.
PAFSPN
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functional heterogeneity under different disease states ranging from 
proinflammatory to anti-inflammatory subsets (Deniset and Kubes, 2018). 
Neutrophils are rapidly sequestered in the pulmonary microvasculature and 
migrate into the lung parenchyma and alveolar spaces where they perform 
numerous effector functions (Gomez et al., 2015). However, their effector 
functions can be detrimental in acute and chronic inflammation as 
hyperactivation of these cells leads to lung tissue injury (Tak et al., 2013). Hence, a 
delicate balance is required between neutrophil recruitment and mucosal 
maintenance (Hidalgo et al., 2019). The role of these innate immune cells during 
infection is varied and complex (Bou Ghanem et al., 2015). 
Interestingly, peripheral neutrophils from HIV infected  individuals (ART-naïve and 
ART experienced) have been shown to have reduced effector functions including 
chemotaxis, phagocytosis and oxidative burst (Campillo-Gimenez et al., 2014; 
Elbim et al., 1994; Gupta-Wright et al., 2017; Hensley-McBain and Klatt, 2018; 
Lazzarin et al., 1986). The contribution of this dampened effector function in the 
pathogenesis of pneumococci in lung pneumonia has not been established in HIV 
infected individuals. Patients who are neutropenic are known to be at increased 
risk for pneumonia, and in mice studies, depletion of neutrophils prior to S. 
pneumoniae infection or delay in neutrophil recruitment into the lungs resulted in 
higher pulmonary bacterial loads. On the contrary, enhanced airway recruitment 
of neutrophils following S. pneumoniae infection results in reduced survival of the 
bacteria. 
Neutrophils exhibit the greatest anti-bacterial activity compared to AMs and are 
capable of killing pneumococcus through phagocytosis, and through use of 
oxygen dependent and oxygen independent mechanisms (Kobayashi et al., 2018; 
Silva and Correia-Neves, 2012). Neutrophils can also kill bacteria using neutrophil 
extracellular traps (NET) mediated killing (Jhelum et al., 2018; Kobayashi et al., 
2018). Through the oxygen dependent bactericidal pathway, neutrophils produce 
superoxide (O2-) via NADPH oxidase, which converts the superoxide into reactive 
oxygen species (ROS), which are released and deposited onto the bacteria thus 
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degrading DNA, RNA and extracellular proteins (Kobayashi et al., 2018). 
Neutrophils can use serine granules like neutrophil elastase present in their 
cytoplasm to kill internalised and extracellular bacteria including pneumococci, in 
an oxygen independent manner (Domon et al., 2018).  
 
High levels of neutrophil elastase have been reported in cell free bronchoalveolar 
lavage fluid in severe pneumonia patients compared to that observed in fluid 
from non-severe pneumonia patients (Wilkinson et al., 2012). Paradoxically, 
neutrophil elastase has also  been shown to contribute to the severity of 
pneumococcal pneumonia due to its toxic effect on the host extracellular-matrix 
proteins, as well as epithelial cadherin, a cell-cell adhesion molecule pivotal in 
epithelial cell behaviour and tissue formation thus causing lung epithelial 
disruption (Boxio et al., 2016; Domon et al., 2016, 2018; Hagio et al., 2008). In 
addition, pneumolysin; a cholesterol binding and pore forming toxin found in S. 
pneumoniae has been shown to induce lysis of neutrophils leading to expulsion of 
neutrophil elastase which is known to impair AMs phagocytosis through the 
cleavage of TLR2 and TLR4 enabling immune evasion by the pathogen and AMs 
unresponsiveness (Craig et al., 2009; Domon et al., 2016, 2018). 
 
The extracellular release of proteases and oxidases (e.g., neutrophil elastase and 
myeloperoxidase) within inflamed airways following granule mobilisation to their 
cell surfaces is thought to be the hallmark of neutrophil activity (Hartl et al., 
2018). NETs comprises of chromatin decorated with various antimicrobials 
peptides such as neutrophil elastase, myeloperoxidase (MPO) and peptidyl 
deaminase 4 (PPD4) (Cortjens et al., 2017; Jhelum et al., 2018; Mohanty et al., 
2019). NETs are thought to be the option of last resort to kill invading bacteria, 
but pneumococcus has developed ways to escape NETs including their 
degradation by endonucleases such as DNases 1 (Beiter et al., 2006; Cortjens et 
al., 2017; Jhelum et al., 2018). 
 
In mice models it has been demonstrated that the efficacy of neutrophils changes 
during the course of pneumococcal pneumonia disease from clearing bacteria 
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early on to promoting infection at later time points (Bou Ghanem et al., 2015). 
Extracellular adenosine (EAD) production has been shown to be crucial for the 
ability of both murine and human neutrophils to kill S. pneumoniae with CD73 
controlling the neutrophil antimicrobial phenotype during infection (Siwapornchai 
et al., 2020). Upon cellular damage due to a variety of insults including infection, 
adenosine triphosphate (ATP) is thought to leak from damaged cells into the 
extracellular space and is converted into EAD by the sequential action of two 
exonucleosidases, CD39 and CD73 (Siwapornchai et al., 2020; Thompson et al., 




Figure 1.5. Mechanisms employed by neutrophils in killing S. pneumoniae. Neutrophils can kill 
pneumococcus through phagocytosis of bacteria which have been opsonised through complement 
and antibody or unopsonised bacteria. Neutrophils are also able to control the growth of 
pneumococci through the release of microbiocidal toxic granules (neutrophil elastase and 
myeloperoxidase) extracellularly to inhibit and kill. Neutrophils are able to release cytokines (TNF, 
IL-b, IL-6, MIP-2) to mobilise, recruit or activate other cells. Also, neutrophils can form neutrophil 
extracellular traps (NETs). Neutrophils undergo a process of NETosis, which leads to the formation 
of NETs under influence of various triggers (e.g. cytokines and bacteria). These NETs consist of 
extracellular DNA packed with nuclear (e.g. histones) and granule (e.g. MPO, elastase) proteins, 
can trap and/or neutralise pneumococci. Abbreviations: IgG – immunoglobulin. This figure 
contains some artwork produced by Servier Medical Art (http://smart.servier.com), under creative 













Macrophages were first described in 1892 by Metchnikoff, and were first 
recognised for their ability to phagocytose microorganisms (Byrne et al., 2015; 
Cavaillon, 2011). Alveolar macrophages constitute the major resident phagocytic 
and antigen presenting cells in the airway (Guillon et al., 2020; Hartl et al., 2018). 
Metabolically, AMs exhibit a high basal glucose consumption and respiratory rate 
but a low respiratory burst activity (Hartl et al., 2018). Alveolar macrophages 
recognise immunoglobulin (IgM and IgG) opsonised pneumococci through their Ig 
receptors or complement opsonised pneumococci through the complement 
receptor 1 (CR1) which is covered in later text (sub sections 1.6.6). For example, 
the RrgA present on the pili, has been shown to interact with complement 
receptor CR3 on the surface of macrophages thereby promoting bacterial 
internalisation (Andre et al., 2017). 
 
Alveolar macrophages also express various PRRs such as scavenger receptors and 
TLRs that are involved in innate immunity signalling and phagocytosis in response 
to pneumococcal infections (Albiger et al., 2007). Some TLRs are also located 
within phagosome membranes, and can be activated by phagocytosed bacteria 
(Periselneris et al., 2019; Wolf et al., 2011). AMs produce proinflammatory 
mediators such as IL-1b, IL-6, TNF and NO in response to TLR stimulation and 
these are critical in the clearance and control of pneumococci. Notably, NOD2 
which is part of the family of intracellular PRR found on macrophages and 
dendritic cells; has been shown to sense pneumococcal peptidoglycan fragments 
following their digestion by lysozymes and is also thought to be important during 
bacterial internalisation (Craig et al., 2009; Liu et al., 2017; Wiese et al., 2017). For 
bacteria with an intracellular phase, NOD1 and NOD2 receptors have direct access 
to the peptidoglycan and other potential ligands on the cell wall (Wolf et al., 
2011). However, shedding of the pneumococcal capsule has been shown to 
impair its recognition by the NOD2 receptor (Wiese et al., 2017). NOD2 receptors 
function by activating inflammasome, responsible for mediating the activation of 
caspase-1 which in turn promotes the cleavage and secretion of IL-1β and IL-18 
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(Fang et al., 2011; Paterson and Orihuela, 2010). An inflammasome is a cytosolic 
multiprotein complex composed of nucleotide- binding oligomerisation domain-
like receptor (NLR) molecule and procaspase (McNeela et al., 2010; Witzenrath et 
al., 2011). Pneumolysin has been reported to be critical in NOD2 sensing of 
pneumococcus (Wiese et al., 2017). Furthermore, pneumolysin has been shown 
to induce the maturation and secretion of IL-a, IL-1β and IL-18 following NOD2 
activation but not their expression on AMs and DCs during S. pneumoniae 
infection (McNeela et al., 2010; Shoma et al., 2008; Wiese et al., 2017; Witzenrath 
et al., 2011). In Figure 1.6. I summarise the AMs control of pneumococci. 
 
Figure 1.6. Pneumococcal control by alveolar macrophages. A. Once the pneumococcus 
microaspirates into the lower airway, it is recognised by AMs via the pattern recognition receptors 
or as immunoglobulin/complement opsonised pneumococci through their 
immunoglobulin/complement receptors and cleared from the airway. B. When the AMs fail to 
clear the pneumococcus, they release cytokines such as TNF, IL-1b and IL-8 resulting in the 
recruitment and activation of AMs, DCs, neutrophils and monocytes leading to pneumococcal 
clearance or disease. Arrow in purple represents the chemotaxis of towards site of pneumococcal 
infection. Abbreviations: AMs – alveolar macrophages, DC – dendritic cells, IgG – immunoglobulin 
G, TNF – tumour necrosis factor. This figure contains some artwork produced by Servier Medical 

















1.6.5. Dendritic cells 
Dendritic cells (DCs)  are professional antigen presenting cells, which can initiate 
primary immune responses and represent 0.6 – 1.0% of all total leukocytes in the 
airway (Mwale et al., 2018; Tsegaye and Pöhlmann, 2010). Chronic HIV has been 
shown to be associated with disruption of the myeloid but not plasmacytoid 
dendritic cells in the airway (Mwale et al., 2018). Immature DCs have been shown 
to be particularly adept in antigen capture and processing antigens into cell 
surface-presentable forms, whilst mature DCs efficiently present antigen to T cells 
(Noske et al., 2009; Tsegaye and Pöhlmann, 2010). Maturation of DCs is 
associated with changes including; surface expression of MHC, expression of 
adhesion and co-stimulatory molecules (CD40, CD80, and CD86), enhanced 
production cytokine (IL-6, IL-12, TNF) and results in DCs migrating to tissue 
draining lymphoid organs like the mediastinal lymph node, where they can 
activate antigen specific T-cells (Noske et al., 2009). Interestingly, in vitro studies 
have shown that pneumococcal pneumolysin inhibits human DCs maturation, 
induction of proinflammatory cytokines and activation of the inflammasome 
(Khan et al., 2014; Littmann et al., 2009). Furthermore, it has also been reported 
that the  pneumococcal adherence and virulence factor A (PavA); a virulence 
factor present on cell outer surface of S pneumoniae  inhibits pneumococcal 
internalisation by DCs and cytokine induction (Holmes et al., 2001; Kanwal et al., 
2017; Noske et al., 2009; Obert et al., 2006). Recently, it was reported that the 
binding of pneumolysin to the MRC1 (CD206) inhibited pro-inflammatory cytokine 
responses and TLR signalling in on human  DCs (Subramanian et al., 2019). Figure 




Figure 1.7. Pneumococcal control by dendritic cells. Once pneumococcus microaspirates into the 
lower airway, it is recognised by immature DC via the pattern recognition receptors or as 
immunoglobulin opsonised pneumococci through their Ig receptors and processed for 
presentation to B and T-cells. Through this process immature DCs mature and start expressing 
costimulatory and adhesion molecules (CD40, CD80 and CD86) and cytokine production. 
Abbreviations: CD- Cluster of differentiation, DC – dendritic cells, TNF – tumour necrosis factor. 
This figure contains some artwork produced by Servier Medical Art (http://smart.servier.com), 
under creative commons license 3.0. 
 
1.6.6. Role of complement in control of pneumococcus 
Complement is a system composed of a network of fluid-phase and membrane-
bound proteins that act as a rapid immune surveillance system, triggering an 
enzymatic cascade of protein-protein interactions upon stimulation (Huson et al., 
2015; Ricklin et al., 2010). It is composed of more than 40 soluble and cell surface 
anchored proteins with the soluble ones being produced mainly by the liver 
(Merle et al., 2015). Complement–driven opsonophagocytosis has been 
demonstrated to be important for opsonisation of the bacteria for neutrophil 
phagocytosis and in systemic clearance of S. pneumoniae infection (Ali et al., 
2012; Andre et al., 2017; Brown et al., 2002; Hyams et al., 2010b). Complement is 
important in innate immunity to S. pneumoniae as it provides protection through 
both antibody-dependent and -independent mechanisms (Ali et al., 2012; Brown 
et al., 2002) see Figure 1.8. Complement is activated by three enzyme cascades: 
the classical, the alternative, and the mannose-binding lectin (MBL) pathways 
(Walport, 2001). Complement receptors (CRs) found on phagocytes important in 
pneumococcal control include CR1 (CD35), CR3 (CD11b/CD18), and CR4 









Querol, 2017). CR1 reportedly has high affinity for C3b and lower affinity for iC3b, 
but also binds C4b, C1q, and MBL (Ren et al., 2004; Roozendaal and Carroll, 2006; 
Walport, 2001). CR2 (CD21) is a non-phagocytic receptor reportedly binding to 
C3dg/C3d thereby influencing B cell activation and development (Tedder et al., 
1997). Contrary to CR1, CR3 and CR4; CR2 has higher affinity to iC3b lower affinity 
for C3b (Roozendaal and Carroll, 2006; Tedder et al., 1997). CR3 is an important 
adhesion molecule involved in migration of neutrophils and monocytes from the 
periphery to sites of inflammation (Ren et al., 2004). 
 
Figure 1.8. Pneumococcal control by complement. A. The mannose binding pathway lectin 
pathway may be activated directly by the bacterial cell surface components resulting in the 
clearance of pneumococcus through a downstream cascade reaction. B. In the alternative 
pathway, complement may opsonise pneumococcus through an antibody independent 
mechanism resulting in its internalisation via the complement receptors found on the surface of 
the phagocytes C. The classical pathway may be activated by an antibody (IgM) pneumococcus 
complex via its Fc portion resulting an immune complex which is then internalised through the 
complement receptors found on the surface of phagocytes. After internalisation the phagosome 
formed fuses with lysosomes to form a phagolysosome resulting in the killing and clearance of 
pneumococcus. This figure contains some artwork produced by Servier Medical Art 
(http://smart.servier.com), under creative commons license 3.0. 
The classical pathway mediated by the binding of C1q to the Fc portion of 
IgM/IgG–antigen (phosphorylcholine) complexes on the bacterial surface, is the 
most important portion of the complement system for innate immunity to S. 
pneumoniae (Brown et al., 2002; Kang et al., 2006). The alternative and MBL 














considered to be effectors of the innate immune response (Ricklin et al., 2010; 
Walport, 2001).  
Interestingly, HIV infection has been shown not to affect the deposition of 
C3b/iC3b (major opsonin of complement system) on S. pneumoniae and the levels 
were found to be similar in the HIV-uninfected (Hyams et al., 2010b). 
Furthermore, the internalisation of complement opsonised S. pneumoniae by AMs 
was also not affected by HIV infection (Gordon et al., 2001). In murine models, it 
has been reported that mice lacking C3 failed to control growth of pneumococci 
within the lungs and bloodstream (Kerr et al., 2005). Mice deficient of Mannan-
Binding Lectin Associated Serine Protease-2 (MASP-2), were shown to be highly 
susceptible to pneumococcal infection and failed to opsonise S. pneumoniae in 
the none-immune host (Ali et al., 2012). Moreover, in mice splenic macrophages, 
it was reported that SIGN- R1, a transmembrane C-type lectin expressed by 
macrophages, can recognize carbohydrates on the pneumococcal surface and 
binds to C1q (Kang et al., 2006). All the three complement pathways are 
important in the control of pneumococci; however, some pneumococcal virulence 
factors have been reported to inhibit complement activities and these are listed in 
and Table 1.3. 
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Table 1.3. Pneumococcal virulence factors: anti-complement activities  
Factors Target Molecule 
Capsule IgM, IgG, CRP, C3, and 
iC3b 
Prevents complement activation. 
Inhibits bacterial opsonization by 
C3b and iC3b. 
PspAa CRP and FB Inhibits CRP deposition and C3 
convertase formation 
PspC FH, C4BP, Vitronectin, 
C3  
Inhibits C3 convertase formation 
and MAC assembly. 
Ply C1q, IgG, and L-Ficolin Activates complement away from 
bacterial cells and depletes 
complement components.  
Phtsa∗  FH and C3  Inhibits C3 convertase formation 
NanA/BgaA/StrH − Deglycosylate complement 
components. 
LytAb FH, C4BP, C3b, and 
iC3b 
Inhibits C3 convertase formation 
and reduces opsonisation by iC3b. 
LytBa  − Lytic activity promotes bacterial 
dispersion which limits 
complement deposition 
PepOc C1q, C4BP, PLG Activates and depletes 
complement. Inhibits C3 
convertase formation. 
GAPDHacd  C1q, PLG Activates and depletes 
complement. 
Enocd C4BP, PLG Inhibits C3 convertase formation 
and depletes complement. 
PGKe  C5, C7, C9, and PLG Inhibits MAC formation and 
depletes complement. 
Tufspe  FH, FHL-1, CFHR-1, 
and PLG 
Inhibits C3 convertase formation 
and depletes complement. 
RrgA CR3 Promote adhesion to and invasion 
of macrophages. 
Taken from (Andre et al., 2017) and adapted for this thesis. 
aPossible mechanism; not completely elucidated. 
bIndirect activity. Inhibits binding between C1q and CRP. 
cExplores PLG in order to improve adhesion and colonization. 
dPossibly cleaves/depletes complement components by binding to PLG, but this was not 
investigated.          
eBinding to PLG possibly improves adherence and invasion, but this was not investigated. 
∗Two studies found conflicting results for Pht binding to FH.  
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1.6.7. Cytokines  
The cytokine milieu in the lung plays an essential role in shaping both the cellular 
composition and immune response in this compartment (Jambo et al., 2017; 
Yosef and Regev, 2016). The outcome of pneumococcal infection is strongly 
influenced by the efficiency of the innate and adaptive immune responses in 
controlling and clearing S. pneumoniae (Madouri et al., 2018; Wilson et al., 2015). 
In the lung, macrophages and other innate immune cells serve central immune 
defence functions through phagocytosis, communicating with adaptive immune 
cells through antigen presentation and secretion of and response to cytokines and 
chemokines (Amit et al., 2016; Lavin et al., 2015; Wynn et al., 2013; Yosef and 
Regev, 2016).  
During pneumococcal infection the host cells release or respond to cytokines and 
chemokines induced by the invading pathogen. It has been shown previously, that 
pneumococcal carriage results in a modest increases in levels of GM-CSF, IFN-g 
and IFN-a in airway fluid (Mitsi et al., 2019). In mice, TNF and IL-1b are among the 
first cytokines that become immediately detectable in the airway and have been 
demonstrated to be important in the recruitment and activation of AMs, dendritic 
cells and neutrophils leading to pneumococcal clearance (Hatta et al., 2010; Kafka 
et al., 2008; Puchta et al., 2016). On the contrary, increased levels of TNF as 
observed in the elderly, predisposes them to pneumococcal pneumonia with 
inflammatory monocytes being implicated as the major source cause (Puchta et 
al., 2016). Reduction or neutralization of TNF is detrimental as patients treated 
with anti-TNF-α therapies have been shown to be at increased risk of invasive 
pneumococcal disease (Ali et al., 2013; Takashima et al., 1997). Therefore, both 
decreased and increased levels of pro-inflammatory cytokines lead to immune 
alteration and dysregulation of pneumococcal control (Puchta et al., 2016; Yende 
et al., 2008). In HIV-infected adults, IL-1 and TNF have been shown to be higher in 
cell culture supernatants following ex vivo infections of AMs with pneumococci-
ST1 compared to HIV-uninfected cell cultures (Gordon et al., 2013). Furthermore, 
unstimulated airway supernatants from chronic HIV infected individuals have 
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been shown to be associated with disruption of key cytokine networks involved in 
immune defence and maintenance of immune cell homeostasis in the lung 
(Jambo et al., 2017).  
Whilst a robust inflammatory response is generally thought to be protective 
against infection, high levels of circulating pro-inflammatory and anti-
inflammatory cytokines (TNF, IL-6, IL-8, IL-10, IL-18 and G-CSF) during community 
acquired pneumonia (CAP) have been associated with more severe disease and 
higher mortality (Bordon et al., 2015; Haugen et al., 2015; Paats et al., 2013; 
Yende et al., 2008). On the contrary in mice models, pneumolysin has been shown 
to be associated with dampening of pro-inflammatory cytokine responses (TNF, 
IL-1b, IL-6 and IL-12) with heightened anti-inflammatory (IL-10 and TGF-b) 
responses. This is thought to promote intracellular residency of pneumococci 
within AMs and DCs expressing MRC-1/CD206 (Subramanian et al., 2019). On the 
other hand, the pneumococcal capsule and extracellular bacteria have been 
shown to induce enhanced macrophage pro-inflammatory cytokine responses 
(TNF and IL-b) following S. pneumoniae infection compared to unencapsulated 
strains (Periselneris et al., 2019). It has also been demonstrated previously that 
early induction of IL-10 during pneumococcal infection resulted in reduced 
bacteria clearance, reduced TNF and IFN-g levels and detrimental effects on host 
resistance (Poll et al., 1996; Siwapornchai et al., 2020). 
In mice models, neutrophils have been shown to be the major producers of IFN-g 
during pneumonia induced by S. pneumoniae and S. aureus, but not in pneumonia 
caused by Escherichia coli and Pseudomonas aeruginosa (Gomez et al., 2015; 
Yamada et al., 2011). IFN-g has been reported to be important in regulating the 
induction of NETs and in priming macrophages to take up pneumococcus (Gomez 
et al., 2015; Mitsi et al., 2019; Zhang et al., 2006). Furthermore, pneumolysin has 
been reported to be involved in the induction of IFN-g from human adenoid cells 
following pneumococcal stimulation (Zhang et al., 2006).  
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1.7. Adaptive immunity against S. pneumoniae 
1.7.1. T-cell mediated immunity 
The establishment and maintenance of immune responses, homeostasis, and 
memory depends on T-cells (Kumar et al., 2018). T-cells express a receptor which 
has potential to recognise diverse antigens from pathogens including S. 
pneumoniae, the environment and also to maintain immunological memory and 
self-tolerance (Kumar et al., 2018). T lymphocytes can be categorised into 
conventional T-cells (CD4+ and CD8+) and non-conventional T-cells (gd T-cells, 
natural killer T-cells) based on their T-cell receptor. 
 
It has been previously observed in the Experimental Human Pneumococcal 
Carriage (EHPC) model that pneumococcal carriage increases the proportion of 
lung IL-17A secreting CD4+ memory T-cells which are thought to be key in the 
maintenance of mucosal surfaces through recruitment of neutrophils and 
augmenting AMs killing of opsonised pneumococci (Wright et al., 2013). 
Furthermore, in another study, it was demonstrated that there’s a dynamic 
relationship between T regulatory (Tregs) and T helper 17 (Th17) cells in 
nasopharynx associated lymphoid tissue (NALT). The ratio of Th17:Treg appears to 
be a key determinant in pneumococcal clearance and increases with age and in 
carriage negative individuals (Mubarak et al., 2016). 
 
In another study, using a mice murine model, it was shown that pneumococci -
induced Th17 mediated immunity was critical in sustaining local recruitment of 
neutrophils, monocytes and macrophages in the upper airway, since this was 
important in the clearance pneumococci (Zhang et al., 2009). Autologous CD4+ T-
cells have been shown to prime and increase AMs uptake of pneumococcus in 
carriage positive and carriage negative individuals compared to AMs alone in a 
coculture ex vivo experiment (Mitsi et al., 2019). MRC-1 found on macrophages 
and DCs has also been shown to induce immune tolerance of T-cells, with 
pneumolysin required for robust regulatory T-cell induction (Subramanian et al., 
2019). Interestingly, mice deficient of the major histocompatibility complex class 
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(MHC) II have been shown to have prolonged carriage, which indicates an 
important role for CD4+ T cells rather than humoral immunity in pneumococcal 
clearance (Basset et al., 2007; Kadioglu and Andrew, 2004; Malley et al., 2005). In 
another study of pneumonia in a mouse model, it was shown that although CD8+ 
T-cells were required, CD4+ T-cells were dispensable for resistance to serotype 
(ST)3 pneumonia. However, the authors failed to identify the specific phenotype 
of the CD8+ T-cells and how these cells mediate the responses against 
pneumococcus (Weber et al., 2011). Furthermore, the same study also suggested 
that the Th17 cells could play different roles during colonisation and acute 
infection in naïve and immune hosts (Weber et al., 2011). 
 
In addition, there is increasing appreciation of the role of non-conventional T-cells 
in orchestrating early responses to extracellular pathogens such as S. pneumoniae 
and S. aureus (Godfrey et al., 2015). These include natural killer T-cells (NKT), 
gamma delta (gd) T-cells and mucosal associated invariant T (MAiT) cells with 
features of both innate and adaptive cells (Ivanov et al., 2014; Kurioka et al., 2018; 
Nakasone et al., 2007). When these cells emerge from the thymus, they have the 
capability of undertaking cytolysis and cytokine release (Ivanov et al., 2014). 
Natural killer T-cells are a subset of non-conventional T-cells capable of 
recognising and being activated by lipid antigens presented by the non-
polymorphic CD1d on antigen presenting cells (Chandra et al., 2018). Whereas gd 
T-cells can be activated by Class I like molecules such as T10/T22 (in mice) and 
members of CD1 family; they can also be activated by MHC-unrelated molecules 
such as viral glycoproteins and F1-ATPase complex in humans (Gao and Williams, 
2015; Kalyan and Kabelitz, 2013; Russano et al., 2007; Uldrich et al., 2013). Va14+ 
NKT and Vg4 gd T-cells have been reported to accumulate in the lower airway of 
inflamed tissue during murine pneumococcal pneumonia (Nakasone et al., 2007; 
Kawakami et al., 2003). It was further reported that these cells accelerate the 
infiltration of neutrophils into the lower airways by promoting the synthesis of 
macrophage inflammatory protein (MIP)-2 and TNF-a (Kawakami et al., 2003; 
Nakamatsu et al., 2007; Nakasone et al., 2007). MIP-2 is major chemokine 
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responsible for attracting neutrophils to the site of infection whilst TNF-a 
enhances the adhesion of neutrophils to endothelial cells (Nakamatsu et al., 
2007). gd T-cells have also been implicated as key regulators of AMs and DCs 
during the resolution of S. pneumoniae-mediated lung inflammation (Kirby et al., 
2007). Other unconventional T-cells like MAiT cells are capable of recognising S. 
pneumoniae through small molecules derived from the riboflavin metabolic 
pathway presented by, a non-polymorphic major histocompatibility complex 
related protein (MR) 1 (Hartmann et al., 2018; Kurioka et al., 2018).  
 
It has been shown that MAiT cells may be activated in an MR1-dependent manner 
in the presence of macrophages and through innate cytokines (IL-12 and IL-18) 
dependent manner in the presence of monocytes (Kurioka et al., 2018). It was 
also reported in another study, that MAIT cells were capable of recognising and 
responding to DCs and airway epithelia cells infected with carriage and invasive 
isolates of S. pneumoniae (Hartmann et al., 2018). However, how the precise role 
of non-conventional T-cells during pneumococcal infection in humans has not 
been fully established. Figure 1.9. summarises how T-cells aid in the control of 
pneumococci. 
 
Figure 1.9. Pneumococcal control by T-cells. Mature DCs migrate to the regional lymph nodes, 
where they encounter cognate T-cells and crosslink resulting in T-cell activation. The antigen 
specific T-cell is then capable of undergoing activation and proliferation resulting in the production 
of cytokines, differentiation of naïve T-cell to memory and effector T-cells. Abbreviations: CD- 
Cluster of differentiation, TNF – tumour necrosis factor. This figure contains some artwork 












1.7.2. B-cell mediated immunity 
B cells play a central role in pneumococcal defence as they produce 
immunoglobulins directed against antigens (capsule, polysaccharide, lipoprotein, 
pneumolysin) embedded within the bacterial cell wall, thus promoting pathogen 
clearance (McKay et al., 2015a; Moore et al., 2001). When a naïve B cells 
encounters pneumococcal antigen, it can differentiate into IgM+ memory B cells 
to produce pneumococcal-specific IgM without T-cells help (T-independent 
activation); later, during somatic hypermutation the activated B-cell undergoes 
class switching, and some pneumococcal- specific IgM+ B cells will differentiate to 
pneumococcal-specific IgG+ or IgA+ memory B cells or plasma cells (Richards et al., 
2010; Zhang et al., 2015). T-independent antigens are highly repetitious 
structures present on bacterial cell walls (lipoproteins, pneumococcal 
polysaccharide, proteoglycan) and form a major protective immune response 
generated against encapsulated microbes (Moore et al., 2001). On the contrary, 
T-dependent immune response, requires a complex interplay between antigen 
presenting cells (APC), antigen, direct B-cell and T-cell interaction (Moore et al., 
2001). Following phagocytosis, the APC processes the antigen into small peptide 
fragments and expresses them together with the MHC class II, resulting in the 
complex being recognised by the T-cell receptor. The binding of the TCR to the 
MHC class II and antigen complex on the APC, results in the co-stimulation of the 
CD4+ T-cell and the expression of CD40 ligand (CD40L) on its surface (Doherty et 
al., 2018; Moore et al., 2001; Parker, 1993). The CD40L then binds to the CD40 
receptor molecule on B-cells resulting in its ligation and activation of B-cells 
(Doherty et al., 2018; Parker, 1993). This results in the expression of cytokine 
receptors on the B-cells which can now bind to cytokines secreted by the CD4+ T-
cell and activate the production and isotype switching of immunoglobulins 
(Doherty et al., 2018; Parker, 1993). 
 
It has been shown previously that serum IgM antibodies to pneumococcal 
serotypes 3, 9 and 22 are undetectable at birth but progressively increase with 
age, as well as systemic IgM memory B cells (Kruetzmann et al., 2003). 
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Furthermore, in the same study it was shown that the absence of IgM memory 
predisposes individuals to encapsulated bacterial infections (such as invasive 
pneumococcal disease) and leads to an impairment in their response to 
polysaccharide vaccine (Kruetzmann et al., 2003). In another longitudinal study of 
infants followed from birth, it was shown that serum anti-capsular IgG titres were 
highest in the cord sample (reflecting maternally-derived antibodies), with a 
decline in serum concentration of IgG antibodies within the first 6-months of age  
which was then followed by a modest increase in the serum IgG concentrations 
(Turner et al., 2013). It was also observed that the mean serum IgG antibody titres 
to various pneumococcal proteins declined rapidly after birth to a nadir at 4 
months, with a subsequent increase in serum IgG antibody titres thereafter which 
was largely attributed to post-natal pneumococcal exposure (Turner et al., 2013). 
In an EHPC model, systemic anti-capsule antibodies were only detected in 
subjects that developed carriage after challenge with serotype 6B (Ferreira et al., 
2013a). Moreover, the authors, also further demonstrated in a murine model that 
the passive transfer of post carriage sera to mice confers significant protection 
against invasive disease (Ferreira et al., 2013a). Figure 1.10. summarises the T-
cells dependent and independent ways B-cells use in the control of pneumococci. 
 
Figure 1.10. Pneumococcal control by B-cells. A. During T-independent activation, a naïve B-cell 
encounter pneumococcal antigen through the B-cell receptor, upon getting a second signal via the 
toll-like receptors the B-cell differentiate into IgM+ memory B cells or plasma cells capable of 










encounters pneumococcus, internalise it and process it into small peptides (yellow) for 
presentation together MHC class -II. Upon encounter of a cognate T-cells and crosslink with the 
MHC-II and peptide, the B cells is activated, and it differentiates into a plasma cell, memory B cell 
and resulting in the production of class switched antibodies such as IgG2, IgA and cytokines. 
Abbreviations: Ab- antibody, CD – cluster of differentiation, TLR – toll-like receptor, TNF – tumour 
necrosis factor. This figure contains some artwork produced by Servier Medical Art 
(http://smart.servier.com), under creative commons license 3.0. 
 
1.8. Impact of HIV infection on anti-pneumococcal immunity in humans 
1.8.1. Systemic/peripheral blood responses  
HIV infection is known to preferentially deplete CD4+ T-cells in peripheral blood, 
lymphoid and mucosal tissues (Brenchley et al., 2004; Sedaghat et al., 2008). HIV 
infection is associated with an impaired proliferation response and upregulation 
of CD154 (CD40L) on activated CD4+CD69+ T-cells to pneumococci in individuals 
with a CD4+£ 500 cells/mm3 but not T-cell activation (CD4+CD69+) in response to 
pneumococci (Glennie et al., 2011). Furthermore, it was noted that pneumococci 
IL-17A CD8+ T-cells together with IL-17A, TNF, IL-2 cytokines produced in response 
to pneumococci were preserved but not IFN-g producing CD8+ T-cells (Glennie et 
al., 2011).  
Similarly, in another study, the same authors demonstrated that the proliferative 
capacity of CD3+CD8- T-cells was impaired in HIV-infected untreated, treated and 
symptomatic individuals compared to the HIV-uninfected in response to 
pneumococci antigens (Glennie et al., 2013). The authors further showed that IL-
17A producing CD3+CD8- T-cells were preserved in HIV infected untreated, treated 
and symptomatic individuals but not IFN-g producing CD3+CD8- T-cells, though the 
proliferative capacity was restored in HIV symptomatic and treated individuals 
(Glennie et al., 2013). It has also been further shown that IFN-g producing and 
proliferating CD4+ T-cells responding to pneumococci antigens increase in 
proportion following initiation of antiretroviral therapy (ART), with similar 
proportions observed at 12-months ART between HIV-uninfected and HIV 
infected individuals (Sepako et al., 2014). 
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Untreated HIV infection disrupts B cell populations causing reduction in the pool 
of memory and naïve resting B cells as a consequence of lymph node destruction 
or by the direct effect of HIV leading to apoptosis of B cells (Boliar et al., 2012; 
Kardava et al., 2018; Longwe et al., 2010; Planchais et al., 2018). Phenotypic 
perturbations include B cell hyperactivation, poor expression of CD19+CD21+ 
(naive mature B cells) and increased frequency of immature/transitional B cells 
(CD10+CD21lowCD27-) in the peripheral blood (Iwajomo et al., 2015; Longwe et al., 
2010; Moir and Fauci, 2013; Moir et al., 2010). HIV infection leads to functional 
perturbations of B cells including hypergammaglobulinemia associated with 
polyclonal and HIV-specific activation of B cells, decreased B-cell responses to 
specific immunogens and non-HIV pathogens such as pneumococcus, and a hypo 
responsiveness to vaccines (Buckner et al., 2013; Kardava et al., 2018; Moir et al., 
2010; Tsachouridou et al., 2015). However, early initiation of ART has been shown 
to rescue and preserve some degree of B cell immune capacity but not the 
amount of circulating isotype-switched memory B cells nor their functional 
activity (Moir et al., 2010; Planchais et al., 2018).  
In a study conducted in children, it was observed that the recovery in proportions 
of circulating memory B cells specific to pneumococcal antigens such as CbpA, 
PspA, pneumolysin and PsaA was slow and only became apparent 12-months 
following commencement of ART (Iwajomo et al., 2015). It is hypothesised that 
the pneumococcal-specific B cell memory function may lag behind other indices 
of B cell recovery (Iwajomo et al., 2015). In contrast, another study demonstrated 
an increased serum anti-pneumolysin IgG and IgA and slightly increased anti-PspA 
IgA but no increase in anti-PspA IgG amongst HIV infected untreated individuals 
compared to healthy adults (Collins et al., 2013). It has also been shown that an 
inverse correlation exists between plasma levels of HIV RNA and peripheral blood 
CD4+ with serum opsonic activity against serotype 3 and type 9 strains of S. 
pneumoniae as detected in asymptomatic HIV-infected persons (Segal et al., 2011; 
Titanji et al., 2006). This effect may be attributed to polyclonal B-cell activation 
and hyperglobulinaemia resulting in poorly opsonic immunoglobulins, thus 
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increasing the risk of  invasive pneumococcal disease amongst the HIV infected 
individuals (Collins et al., 2013). It is generally thought that even effective ART 
may not possibly fully restore B-cell function (Zhang et al., 2015).  
1.8.2. Airway responses  
The presence of HIV infection in the lower airway has been shown to disrupt 
airway cellular homeostasis resulting in CD8+ alveolitis, increase in B cells and gd 
T-cells with a reduction in CD4+ T-cells (Collini et al., 2018; Gordon et al., 2013; 
Mwale et al., 2018). Furthermore, HIV infection is also known to perturb the 
airway cytokine microenvironment in individuals with untreated chronic HIV-1 
infection and long-term ART does not completely restore it (Jambo et al., 2017).  
Despite the low proportions of alveolar CD4+ T cells in the bronchoalveolar lavage 
(BAL) of HIV untreated individuals compared to HIV uninfected healthy controls; 
no perturbations in the proportions of IL-17A, TNF and IFN-g-producing alveolar 
CD4+ T-cells were observed following airway cell stimulation with S. pneumoniae 
in cell culture supernatants of ART- naïve HIV-infected and HIV-uninfected adults 
(Jambo et al., 2011; Peno et al., 2018). At the same time, it has also been 
demonstrated that long-term ART results in an increased proportion of IL-17A and 
TNF but not IFN-g-producing alveolar CD4+ T-cells against S. pneumoniae in HIV-
infected adults (Peno et al., 2018). However, it has been demonstrated that an 
alveolar subset of the CD103 expressing airway CD8+ MAiT cells were selectively 
depleted in untreated HIV-infected adults compared to healthy controls (Mvaya 
et al., 2019). This subset has been shown to be critical for mucosal maintenance 
and recently it has been shown that human MAiT cells respond to a diverse 
strains of S. pneumoniae through MR1 or co-stimulation provided by innate 
cytokines (Kurioka et al., 2018). So, the depletion of MAiT cells by HIV could 
potentially affect early pneumococcus control in the lung. 
Previous reports have also shown that HIV infection results in the accumulation of 
B-cells in the lower airway (Mwale et al., 2018). It has been shown previously that 
airway levels of total IgG and total IgM and pneumococcal-specific IgG and IgM 
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are increased in HIV-infected subjects compared to their HIV negative 
counterparts (Gordon et al., 2003). Furthermore, following invasive 
pneumococcal infection, HIV-infected patients had higher bronchoalveolar lavage 
levels of pneumococcal specific IgG than HIV-infected patients without recent 
infection (Gordon et al., 2003). It has also been demonstrated that HIV-infected 
patients have higher levels of pneumococcal specific IgG but not IgA (anti-
pneumolysin and anti-PspA) in their airway than healthy controls (Collins et al., 
2013). Yet, another study demonstrated impaired bacterial binding of 
pneumococcus serotype-1-specific IgG and impaired opsonophagocytosis of 
pneumococci in asymptomatic HIV-untreated individuals compared to healthy 
volunteers (Eagan et al., 2007). Taken together, it is possible that HIV infected 
individuals have limited airway IgG diversity despite the increased local 
production within the airway (Eagan et al., 2007). The increased IgG responses 
observed in airway fluid in the HIV-infected adults might be a consequence of 
their higher rates of carriage or HIV-induced hypergammaglobulinemia (Collins et 
al., 2013; De Milito et al., 2004; Heinsbroek et al., 2015). 
AMs are susceptible to HIV infection through CCR5 and CXCR4 receptors on their 
surfaces. These are similarly expressed on CD4+ where these receptors mediate 
the entry of the HIV into cells (Boliar et al., 2019; Clayton et al., 2017; Jambo et 
al., 2014a; Kruize and Kootstra, 2019). In HIV-infected individuals, approximately 3 
– 10% of whole bronchoalveolar fluid AMs are infected with HIV and this reservoir 
persists even during long-term ART (Costiniuk et al., 2018; Jambo et al., 2014a). 
Following HIV infection, it has been shown that HIV impairs the functions of AMs 
such as phagosomal proteolysis (Jambo et al., 2014b). On the contrary, it has also 
been demonstrated that during early pneumococcal ex vivo infection, pathogen 
binding and internalisation are similar between HIV-uninfected and HIV-infected 
individuals (Gordon et al., 2000, 2001; Jambo et al., 2014b). Interestingly, despite 
the HIV associated classical activation observed in AMs, the AMs and 
pneumococcal interaction were not impaired by HIV in ex vivo infection studies 
(Gordon et al., 2013). Classical activation occurs following activation of AMs by a 
 41 
cognate CD4+ T-cell and is mediated by gamma interferon (IFN-g) released by the 
CD4+ T-cell resulting in increased expression of major histocompatibility complex 
class II (MHC-II), antigen presentation, increased intracellular killing, cytokine 
production and microbicidal functions (Gordon et al., 2005, 2013). In a separate 
study from the United Kingdom, (Collini et al., 2018) demonstrated a selective 
deficit in delayed, apoptosis-associated pneumococcal killing in AMs from ART-
treated HIV-infected individuals. The authors further demonstrated that the HIV 
glycoprotein gp120 upregulated the myeloid leukaemia cell (Mcl) 1 thus 
preventing apoptosis induction of infected AMs and down regulating caspase 
activation despite baseline increased ROS generation (Collini et al., 2018). This 
observation has been observed in other disease states like chronic obstructive 
pulmonary disease (COPD) (Bewley et al., 2017; Preston et al., 2019).  
1.9. Intracellular replication of S. pneumoniae within phagocytes  
The success of S. pneumoniae to establish infection within the host is partly 
attributable to its ability to evade the immune responses, which includes resisting 
phagocyte intracellular killing. It was not only until recently that S. pneumoniae 
was reported to survive and replicate intracellular within the splenic CD169 
macrophages, after establishing an “eclipse phase” early during infection (Ercoli et 
al., 2018). However, when anti-CD169 antibody was used to block the CD169 
receptor, this resulted in diminished bacterial uptake into these cells and 
protected the murine against subsequent invasive disease. In other studies, it was 
reported to that the MRC-1 is able to influence pneumococcal endocytosis and 
escape of intracellular bacterial killing in Schwann and olfactory cells (Macedo-
Ramos et al., 2011, 2014). Additionally, it has been shown that the MRC-1 on AMs 
and DCs binds pneumolysin, enabling pneumococci to invade immune proficient 
cells (Subramanian et al., 2019). This interaction between pneumolysin and MRC-
1, inhibits the fusion of phagosome containing pneumococci with lysosomes 
thereby promoting its survival within the host (Subramanian et al., 2019).  
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Other “extracellular” gram-positive bacteria such as S. aureus have been also 
shown to have developed mechanisms of escaping intracellular bacterial killing, 
surviving within primary macrophages until bacterial proliferation and lysis of 
infected macrophages occur (Flannagan et al., 2016; Hamza and Li, 2014; Kubica 
et al., 2008). Bacterial intracellular replication is thought to precede the onset of 
host cell death and enabling their escape to the extracellular compartment where 
they can disseminate and propagate further(Flannagan et al., 2016). 
 
1.10. Models for studying anti-pneumococcal immunity 
For several years, scientists have been developing different models to understand 
the mechanisms of natural carriage, establishment of local or disseminated 
disease as no single model can help fully explain the various processes involved. 
Models developed include those of primary cells (nasal scrapes, nasal biopsies, 
bronchoalveolar lavage, peripheral cells), cell models line (epithelial cell, airway), 
animal models (mice, rats, rabbits, guinea pigs and rodents), as well as the 
Controlled Human Infection model (CHIM). Below I will discuss the models and 
their applicability in understanding the mechanism of pathogenesis of the disease, 
testing novel drugs or vaccines and characterising host or bacterial factors 
(Chiavolini et al., 2008; Ramos-Sevillano et al., 2019). 
 
1.10.1. Primary cells and cell line models 
When studying host responses to pathogens there is a tendency to focus on the 
cell types that comprise the biological barriers to microbes to uncover the host 
signalling events and virulence traits that are involved in the initial phase of 
carriage and disease (Duell et al., 2011). Primary cells and cell lines are the 
commonly used models that can define the broad range of mechanisms that 
underlie strategies of microbial virulence such as host receptor ligand binding and 
can afford critical insight into what drives host defence strategies (Duell et al., 
2011). Furthermore, classical cell culture models are useful for the mechanistic 
and functional analysis of the one-to-one interaction between cell and microbe 
(Hocke et al., 2017). 
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During ex vivo cell culture, one can utilise single lineage cells (primary epithelia 
cells, human pharyngeal carcinoma Detroit 562 epithelial cells, human bronchial 
carcinoma Calu3 epithelial cells and human alveolar epithelial carcinoma A549 
epithelial cells) or multiple lineage (adenoidal mononuclear cells tissue, peripheral 
blood mononuclear cells and bronchoalveolar lavage cells) to study pneumococcal 
responses in the airway and peripheral blood (Gordon et al., 2001; Jambo et al., 
2011; Pido-Lopez et al., 2011; Weight et al., 2019; Zhang et al., 2011). The benefit 
of coculture compared to monoculture, is the capacity to better reflect the in vivo 
biology of cytokines, growth factors, and transcriptional regulators activated or 
repressed in response to pneumococcal carriage or disease (Duell et al., 2011). 
However, in the context of cytokine production and T-cell proliferation, 
coculturing yields results closer to the in vivo system than cell lines (Kasurinen et 
al., 2018; Tikhomirova et al., 2018).  
Moreover, when comparing primary cells and cell lines; cell lines are robust, easily 
propagated, and may be preferable for long-term assays and where collection of 
primary cells is technically demanding or time consuming such as collection and 
processing of bronchoalveolar lavage airway samples (Duell et al., 2011; Gordon 
et al., 2001; Jambo et al., 2014a; Weight et al., 2019). Cell lines may also be used 
to understand biofilm formation, carriage and S. pneumoniae epithelia evasion 
(Marks et al., 2012; Weight et al., 2019). However, it is important to note that 
though in vitro systems are useful, they neither reflect tissue diversity at a cellular 
level, nor recapitulate the typical cell-cell interaction in the natural matrix (for 
example alveolar epithelial cell interaction with alveolar macrophage and the 
capillary endothelium) of the three-dimensional architecture (Hocke et al., 2017). 
Hence, other models like the animal models and controlled human infection 
models allow for the sophisticated analysis of host-pathogen interaction which is 
absent in primary cells or cell lines. 
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1.10.2. Animal models 
Numerous animal models of carriage and disease caused by S. pneumoniae are 
available for clarifying mechanisms of disease pathogenesis, testing novel drugs 
and vaccine candidates, and characterizing the role of bacterial and host factors 
(Chia et al., 2005; Chiavolini et al., 2008). Animal models for pneumococcus 
infection and disease available include; rodents, rabbits, rats, with inbred mice 
strains (including BALB/c, C57BL/6, CD1, and MF1) being the most utilised (Borsa 
et al., 2019; Chiavolini et al., 2008; Trzciński et al., 2015; Yershov, 2005). The 
specificities and their importance in studying carriage and disease have been 
summarised in a review (Chiavolini et al., 2008). Interestingly, new porcine spleen 
perfusion model for bacterial sepsis which closely resembles the human spleen 
have gained traction, as they have comparable microanatomy and subpopulations 
of splenic macrophages (Chung et al., 2019; Ercoli et al., 2018). However, for 
many results obtained in these animal models, their translation to humans 
remains unclear (Mak et al., 2014). Moreover, there is a large discrepancy in the 
outcomes of S. pneumoniae infection in experimental animal models and this 
primarily depends on the pneumococcal strain used or its genetic background  
(Chiavolini et al., 2008). For example, it is widely known that certain human 
disease-causing isolates are poorly virulent in vivo, whereas other pneumococcal 
strains that are highly virulent in mice have less relevance for human disease 
(Briles et al., 1992). Despite the limitations associated with animal models, their 
use in clarifying the pathogenic mechanisms of disease remains an 
unquestionable (Chiavolini et al., 2008).  
1.10.3. Controlled Human Infection Models (CHIMs) 
Human challenge studies have been in existence for nearly 300 years, as a 
deliberate exposure of participants with an infectious agent and developing to 
highly controlled, ethical and accountable research studies (Darton et al., 2015). 
CHIMs are used in research to understand disease processes, for assessing the 
efficacy of vaccines or novel therapeutics developed against specific infections 
(Darton et al., 2015; Harro et al., 2011; Stanisic et al., 2017). Several terms have 
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been coined and are used to describe the challenge process. These include; 
experimental, artificial, or induced, in addition to controlled human infection or 
deliberate exposure (Darton et al., 2015). CHIMs have gained a lot of interest over 
the years and are being used to study the following pathogens; Salmonella 
enterica serovar Typhi, Vibrio cholerae, Plasmodium falciparum, enterotoxigenic 
E. coli (ETEC), influenza, Giardia lamblia, Shigella flexneri, Neisseria gonorrhoeae 
and S. pneumoniae (Cohen et al., 1999, 2002; Harro et al., 2011; Khamesipour et 
al., 2005; Killingley et al., 2012; McCool et al., 2002; Snyder et al., 1963; Spring et 
al., 2014; Stanisic et al., 2017; Wright et al., 2012). 
The Experimental Human Pneumococcal Challenge model was first demonstrated 
in American adults in early 2000 (McCool et al., 2002, 2003) before being 
established in Liverpool, United Kingdom (2011) (Ferreira et al., 2011; Wright et 
al., 2012) and Malawi (2018) (Gordon et al., 2017; Morton et al., 2020). Current 
EHPC models induces carriage rather than disease and provides the opportunity 
to study mucosal immunity from mucosal samples such as (nasal scrapes, nasal 
wash, saliva and bronchoalveolar lavage fluid) and peripheral blood samples in a 
setting where the onset and termination of carriage events are known (Ferreira et 
al., 2011). EHPC can be used to study healthy individuals as well as at risk 
population such as the elderly, asthmatics and smokers. Pneumococcal serotypes 
being tested include type 6B, 23F (McCool et al., 2002; Mitsi et al., 2019; Wright 
et al., 2012) and recently type 3. Table 1.4. compares the differences and 
similarities between the EHPC and animal studies. 
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Table 1.4. Similarities and differences between EHPC and animal model.  
 
Feature under study CHIMs - EHPC Animal model 
Studying natural immunity It can be used to study new preventative 
strategies that could aid in defining the 
mechanisms of innate and adaptive 
immunity to S. pneumoniae, which could 
then be targeted to enhance immunity 
against infection in high risk groups 
(Darton et al., 2015; McCool et al., 2002; 
Ramos-Sevillano et al., 2019). 
Animal models are an essential tool for the study of 
mechanisms of pneumococcal disease 
pathogenesis, transmission dynamics, testing novel 
drugs and vaccine candidates, and characterizing 
the role of bacterial and host factors (Chiavolini et 
al., 2008; Hergott et al., 2015; Ramos-Sevillano et 
al., 2019; Reglinski et al., 2018; van Rossum et al., 
2005; Zafar et al., 2017). 
Number of serotypes 
involved  
Normally used to study one serotype at a 
time but multiple serotypes can be 
studied. 
This model can be used to study one or more 
serotypes at once. 
Carriage events Perfect model for studying short and long 
colonisation events and how 
pneumococcus interacts with other 
serotypes or nasal microbiome 
The model can be used for studying short 
colonisation events and how pneumococcus 
interacts with other serotypes or nasal microbiome 
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Site of study Blood, lung, nose Blood, lung, nose, brain, spleen, liver 
Applicability  Very applicable as one can study events, 
mechanisms following colonisation. 
Can study mechanisms but is of more limited utility 
due to potential differences in immune function 
between species (Ramos-Sevillano et al., 2019). 
Reproducibility of immune 
response associated with 
prior exposure 
Immune response associated with prior 
exposure is reproducible (McCool et al., 
2002, 2003). 
Prior exposure to S. pneumoniae over many years is 
difficult to replicate in mouse models (Ramos-
Sevillano et al., 2019) 
Proof of concept  Provides potential correlations between 
effectors and host protection against 
disease. It provides a platform to study 
pathogen transmission dynamics and how 
evaluation of interventions transmission 
(Killingley et al., 2012). 
Provides direct proof between a specific immune 
effector and protection against disease (Hergott et 
al., 2015; Reglinski et al., 2018; Siegel et al., 2014).  
 
Infection endpoint The endpoint is carriage and is detected 
through classical microbiology methods or 
lytA PCR (Gritzfeld et al., 2011, 2014; 
The endpoint depends on the type of study and 
could be diagnosis of infection (measured by a 
diagnostic test), carriage or infection by specific 
strain types, development of infection signs and 
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McCool et al., 2002; Mitsi et al., 2019; 
Wright et al., 2012). 
symptoms, or assessment of infection severity 
(Chiavolini et al., 2008; Darton et al., 2015; Ercoli et 
al., 2018; Neill et al., 2014) 
Dose and route  Doses ranges between 5,000 – 160,000 
colony forming units (CFU)/100µl are 
instilled into each nostril of a participant 
(Ferreira et al., 2013b; Gritzfeld et al., 
2014; Jochems et al., 2018; McCool et al., 
2002; Mitsi et al., 2019; Wright et al., 
2012). 
Doses ranges between 105-7 CFU/10µl (Ercoli et al., 
2018; Hergott et al., 2015; Hyams et al., 2013b; 
Trzciński et al., 2015; Zafar et al., 2017). The route 
(intramuscular, intravenous, intranasal, 
intraperitoneal, intratracheal, intracranial) depends 
on the outcome of interests; carriage, pneumonia, 
sepsis, meningitis, otitis media (Chiavolini et al., 
2008)  
Challenge strain  Common strains used for the challenge 
include serotype 6B (BHN418), 23F(P833) 
and type 3 (Wright et al., 2012) 
Several strains have been used in animal models 
depending on the outcome of interest and these 
including serotypes 1, 2 (D39), 3, 4 (TIGR), 6B, 14, 
19A, 19F, 23F, 35B (Ercoli et al., 2018; Neill et al., 
2014; Trzciński et al., 2015). Pneumococci mutants 
have also been used as challenge strains.  
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1.11. Prevention of disease  
With the rise and wide spread of antibiotic resistance, pneumococcal infections 
augmented with deficits of active antibiotics, vaccination against S. pneumoniae 
has become the primary option for controlling this pathogen and preventing 
disease (Gupalova et al., 2019). The current vaccination against S. pneumoniae is 
safe, effective and is being implemented in many developing countries through 
the GAVI, the Vaccine Alliance initiative (Kalata et al., 2019). Despite being 
efficacious, the vaccines are relatively expensive to produce and require 
modification due to the immunological changes of the epidemic strains (Gupalova 
et al., 2019). Furthermore, all vaccines in use are injectables and so do not 
provide optimal mucosal protection at the port of pathogen entry (nasopharynx) 
and the lower airway (lungs) (Gupalova et al., 2019). In this section, I will discuss 
the vaccines and antimicrobials in use and those in the pipeline for controlling the 
pneumococcus burden. 
1.11.1. Vaccines 
There are two main types of vaccines in use and these are the pneumococcal 
conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV23). 
These vaccines comprise of a polysaccharide or polysaccharide covalently 
attached to protein (glycoconjugate vaccine) and induce a polysaccharide-specific 
IgG which confers protection against infection with extracellular bacteria by 
mediating complement-dependent- opsonophagocytosis (Mitchell et al., 2014; 
Pollard et al., 2009). These vaccines have saved millions of lives but also have 
some limitations related to the heterogeneity of capsular polysaccharides of the S. 
pneumoniae strains and short T-independent immunological memory.  
1.11.1.1. Polysaccharide vaccines 
The  PNEUMOVAX23Ò (PPSV23) is a 23-valent pneumococcal polysaccharide 
vaccine for serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 
18C, 19F, 19A, 20, 22F, 23F, and 33F), developed in 1983 (Pollard et al., 2009). 
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The vaccine is in widespread use in >75 countries and is approved for use in the 
elderly (>65 years) and persons aged ≥2 years who are at risk of pneumococcal 
disease (Pollard et al., 2009; Wang et al., 2018). In children below 2-years of age, 
PPSV23 has been demonstrated to elicit poor protective antibody responses 
(Wang et al., 2018).  
Capsular polysaccharides are known to be T-cell-independent antigens, and 
generally stimulate short-lived B-cell responses by cross-linking the B-cell 
receptors, which drives the differentiation of B cells to plasma cells to produce 
antibodies (McCool et al., 1999; Mitchell et al., 2014; Obukhanych and 
Nussenzweig, 2006; Pollard et al., 2009). The production rate of antibodies 
against 23-valent serotype vaccine is not constant though more than 80% of 
adults demonstrate the presence of antibodies 2-3 weeks post vaccination (Chang 
and Woo, 2016). Immune responses to polysaccharide antigens is characterized 
by high levels of IgM and IgG antibodies primarily of the IgG3 subclass in mice and 
IgG2 in humans (McCool et al., 1999). However, the levels of antibodies that 
correlate with protection against pneumococcal disease remain to be clarified. 
It has been shown that during vaccination with polysaccharide vaccines, new 
memory B cells are not produced; instead, terminal differentiation of memory B 
cells to plasma cells occurs, leading to the depletion of memory B-cell pool, and 
causing hypo-responsiveness to subsequent vaccine doses (Kelly et al., 2006). 
Memory B cells have been shown to increase in frequency with age and are 
inversely proportional to the prevalence of S. pneumoniae infections, whereas the 
elderly have lower numbers of memory B cells and this may in part contribute to 
their increased susceptibility to pneumococcal disease (Jha and Janoff, 2019; 
Khaskhely et al., 2012; Kruetzmann et al., 2003). Furthermore, young children 
under 2-years of age are capable of producing antibodies of the IgG1 subclass, but 
have limited ability to produce the IgG2 subclass and this potentially predisposes 
them to pneumococcal pneumonia, bacteraemia, and meningitis due to their 
inability to mount responses to PPSV23 (Jha and Janoff, 2019). This renders 
PPSV23 ineffective among the those aged <2-years. High PPSV23 antibody titres 
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generated have been shown to be protective against IPD for a period of 3-5 years 
post vaccination amongst healthy adults, but the protective immunity wanes 
faster in individuals with the underlying diseases (Andrews et al., 2012; Chang and 
Woo, 2016; Remschmidt et al., 2016). Revaccination is recommended in those 
aged 65 years and above, at least 5 years after the last vaccination (Kawakami et 
al., 2016, 2018). Amongst the HIV infected individuals on ART, significantly higher 
antibody levels against pneumococcal vaccine antigens are observed; however, 
memory B cells still diminish over time with the exception of activated memory 
and isotype-switched memory B cells (Papadatou et al., 2019; Tsachouridou et al., 
2015). A study conducted in Uganda that followed a cohort of HIV-infected 
individuals vaccinated with PPSV23 and placebo demonstrated that the risk of 
pneumonia was actually higher in PPSV23 recipients than in controls, and this 
difference persisted for at least six years post vaccination with rate of survival 
favouring vaccination particularly those with a CD4 cell counts of 200 – 500µl/ml 
cells at enrolment (French et al., 2000; Watera et al., 2004). 
1.11.1.2. Pneumococcal Conjugate Vaccines 
The frequency of invasive pneumococcal disease (IPD) has dramatically decreased 
throughout the world as a result of the introduction of pneumococcal conjugate 
vaccine (PCV) (van Aalst et al., 2018; Bar-Zeev et al., 2015; Harboe et al., 2014; 
Iroh Tam et al., 2017; Riaz et al., 2018; Troeger et al., 2017). The PCVs are licenced 
for immunisation of children aged between 6-weeks and 5 years and also 
approved for use in adults >50 years. Importantly, the beneficial effects have 
been observed amongst the vaccinated and unvaccinated age groups but not in 
the elderly as observed in other countries (Galanis et al., 2016; Swarthout et al., 
2020). PCVs are immunogenic in the infants and became available in many 
developed countries in 2000, initially with 7-valent Prevnar (4, 6B, 9V, 14, 18C, 
19F, and 23F), subsequently being switched to 10-valent SynflorixÒ (1, 4, 5, 6B, 7F, 
9V, 14, 18C,19F, and 23F) or 13-valent Prevnar13Ò (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, and 23F) (Cohen et al., 2017b; Swarthout et al., 2020). Despite the 
beneficial effects of the PCVs, some countries have started seeing a dramatic rise 
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in the prevalence of the non-vaccine serotype carriage and disease (Kwambana-
Adams et al., 2017; Ladhani et al., 2018; Obolski et al., 2018; Swarthout et al., 
2020). PCVs have been unsuccessful in reducing carriage and disease burden 
associated with certain vaccine serotypes such as type 3, 19F and 23F (Azarian et 
al., 2018; Iroh Tam et al., 2017; Swarthout et al., 2020). Also, the elimination of 
vaccine serotypes amongst healthy carriers might create profound changes in the 
global pneumococcal population structure within a community, as different 
strains likely coevolve as a result of reciprocal adaptation and counter-adaptation 
between interacting strains (Galanis et al., 2016).  
Conjugation of the capsular polysaccharides to protein carriers was first reported 
in the 1920s and 1930 and has been shown to require a constant increase in the 
number of polysaccharides included in the vaccine due to the rise of non-vaccine 
serotypes within the population (Croucher et al., 2011; Gladstone et al., 2012; 
McCool et al., 1999). All the PCV13 capsular polysaccharides serotypes are 
conjugated to a non-toxic Corynebacterium diphtheria CRM197 protein, whereas 
the PCV10 uses protein D (derived from non-typable H. influenzae) as the carrier 
for eight of the serotypes, one serotype (type 18C) is conjugated to tetanus toxoid 
and another (type 19F) is conjugated to diphtheria toxoid protein (Cohen et al., 
2017b). The PCV7 has since been phased out and most countries are using the 
PCV10 and PCV13 in their infant immunisation schedules. 
Although the immunogenicity of pneumococcal vaccines is increased by protein 
conjugation of pneumococcal polysaccharides, thus leading to T-cell recruitment, 
strategies for boosting IgG antibody production and the generation of memory B 
cells are still needed (Abudulai et al., 2019; Snapper, 2016). When vaccinated with 
the PCVs, infants are able to generate robust IgG1 subclass responses to the 
pneumococcal polysaccharide capsule , which provides more effective protection 
against IPD (Black, 2011; Jha and Janoff, 2019). In immunocompromised children, 
circulating numbers of CD27+ memory B cells, rather than CD4+ T cells have been 
shown to predict the effective PCV responses (Hoshina et al., 2016). A previous 
study demonstrated that naïve infants aged <12 months had no pre-existing 
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switched memory B-cells at baseline, suggesting that the amount of 
pneumococcal carriage experienced during the first year of life may not be 
sufficient to maintain detectable levels of switched memory B-cells against 
pneumococcus serotype-specific rates of colonisation in this age group 
(Clutterbuck et al., 2008). It was further demonstrated by the same authors, that 
at least 2 doses of PCVs are required in infants to generate memory B-cell 
frequencies and antibody class switching comparable to those seen in adults 
(Clutterbuck et al., 2008). Contrary to infants, vaccine-naïve adults demonstrate 
pre-existing pneumococcal serotype-specific memory B-cells prior to vaccination 
with PCVs (Papadatou et al., 2019). Another study, demonstrated that HIV 
infected individuals vaccinated with PCV13/PPSV23 show a rise in polysaccharide 
antibodies from baseline but a low baseline CD4+ T-cell count had significant 
negative effects on the magnitude of the change in antibody kinetics (Farmaki et 
al., 2018). Even though, PPSV23 receipt 12 months after PCV13 receipt improved 
PCV13 immunogenicity, a reduction in IgM+ memory B cells was also observed 
after PPV23 demonstrating that PPVS23 may have a depleting effect on PCV13-
associated immunological memory (Farmaki et al., 2018). Data from a randomised 
trial showed that despite PCV13 being more effective than the PPV23 in the HIV 
infected, their IgG antibody responses remain lower than those in healthy 
individuals (Abudulai et al., 2019; Crum-Cianflone et al., 2010; Lee et al., 2014). 
Another earlier study conducted amongst the elderly population (50 – 70-year 
olds), demonstrated that PCV7 induced significant increases in serotype-specific 
memory B-cell populations in peripheral blood whilst immunization with PPV23 
resulted in a decrease in memory B-cell frequency (Clutterbuck et al., 2012). Table 
1.5. summarises the differences of the licenced capsular polysaccharide vaccines 
available on the market. 
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Table 1.5. Differences in current licenced Pneumococcal vaccines  
 PPSV23 PCV10 PCV13 




polysaccharide   
Glycoconjugate 
capsular 
polysaccharide   
Valency 23 10 13 
Serotypes 
contained 
1, 2, 3, 4, 5, 6B, 7F, 
8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 
18C, 19F, 19A, 20, 
22F, 23F, 33F 
1, 4, 5, 6B, 7F, 9V, 14, 
18C,19F,23F 
1, 3, 4, 5, 6A, 6B, 7F, 




None Protein D, Tetanus 
toxoid, Diphtheria 
toxoid 
C. diphtheria CRM197 
protein 
Immunity 
induced   
Antibody and B-cell 
immunity.  
Antibody, B-cell and 
T-cell. In 
immunocompromised 
infants, high levels of 
circulating CD27+ 
memory B cells are 
protective. 
Antibody, B-cell and 
T-cell. In 
immunocompromised 
infants, high levels of 
circulating CD27+ 
memory B cells are 
protective 
T-cell memory  No immunological 
memory established  
Immunological 





The elderly and ≥2 
years at risk 
Healthy infants Healthy infants, 
individuals at risk and 
the HIV-infected  
Manufacturer, 
Country 





1.11.1.3. Next generation of pneumococcal vaccines 
Several studies in Europe, United Kingdom, Malawi, Taiwan and the United States 
of America have shown that, the implementation (vaccine schedules or vaccine 
coverage) of PCVs has resulted in carriage and IPD serotype redistribution and this 
may potentially affect the evolution of pneumococcal epidemiology (Galanis et al., 
2016; Kwambana-Adams et al., 2017; Ladhani et al., 2018; Lee and Kuo, 2019; 
Levy et al., 2019; Obolski et al., 2018; Ouldali et al., 2018; Swarthout et al., 2020). 
Moreover, S. pneumoniae has a higher propensity to acquire new genetic 
materials via natural transformation and recombination thus, enabling it to evolve 
with its host environment (Donati et al., 2010; Masomian et al., 2020). PCVs and 
PPSV23 only covering a limited range serotypes, are unable to protect against 
non-vaccine serotypes or unencapsulated S. pneumoniae and this has led to a 
rapid increase in antibiotic-resistant non-vaccine serotypes (Lee and Kuo, 2019; 
Masomian et al., 2020). Following vaccine introduction, pneumococcal capsular 
switching was reported to occur more frequently (Chaguza et al., 2017; Chang et 
al., 2015).  
Despite the reduction in IPD burden after the introduction of PCVs and PPSV23; 
the cost of manufacturing PCVs remains high and the vaccines have insufficient 
serotype coverage for new emerging clinical serotypes (Croucher et al., 2011; Hsu 
et al., 2009; Xu et al., 2015). There is therefore an urgent need to develop novel 
pneumococcal vaccines with broad serotype coverage that induce mucosal and 
systemic immunity, and hinder primary intranasal carriage and invasive disease 
(Masomian et al., 2020). Below, I summarise the different types of vaccine 
candidates that are in the pipeline, developmental and clinical trial phase, 
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6B Intraperitoneal  Mice  Systemic  Ab in sera  Sepsis  (Ferreira et 
al., 2006) 
PSPF Live E. 
faecium  
 
- Intranasal Mice  Mucosal  Ab in sera, 
Ab in nasal 
washes 
Pneumonia  (Gupalova 
et al., 2019) 
PspA Plasmid  - Intramuscular Mice  Systemic Ab sera Sepsis (McDaniel 
et al., 1997) 
PspA3 DNA 
vector 
























- 2 (D39) Intranasal  Mice  Mucosal  
Systemic  
Carriage load 
nasal wash and 
nasopharyngeal 
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sera, cytokines 




(Babb et al., 
2016) 




1.11.2. Preventative antimicrobials 
Present vaccination strategies pose challenges related to increase in non-vaccine 
serotypes, selection and spread of antimicrobial resistant strains such as serotype 
14, 19A and 15A (Cho et al., 2014; Kwambana-Adams et al., 2017; Ladhani et al., 
2018; Yahiaoui et al., 2018; Zhao et al., 2017). On the contrary, before Algeria 
introduced PCVs into their child immunisations programme, the country had 
already started experiencing antimicrobial resistance within vaccine serotypes 
such as 6B, 14, 19A and 19F associated with pneumococcal disease (Ramdani-
Bouguessa et al., 2015). Therefore, this rise in antimicrobial resistance within S. 
pneumoniae pre- and post-vaccination is a topical issue that remains unresolved. 
Pneumococcal diseases are treated with b-lactams, fluoroquinolones, macrolides, 
and vancomycin (Mandell et al., 2007; Metlay et al., 2019). As vaccines are not 
100% effective in the prevention of pneumococcal infections, children (≤ 5 years) 
and the elderly (>65 years) with spleen dysfunction (asplenia, hyposplenia) are 
recommended to take oral penicillin as prophylaxis (Bonanni et al., 2017; Chang 
and Woo, 2016; Salvadori and Price, 2014). Amongst individuals with 
anaphylactic-type reaction to penicillin, erythromycin is a recommended 
alternative (Salvadori and Price, 2014). However, in some settings 
chemoprophylaxis may not be useful because of the increased penicillin and 




1.12. The problem  
HIV infected adults, even those on ART, are at an increased risk of pneumococcal 
pneumonia and have high pneumococcal carriage rates than their HIV-uninfected 
counterparts (Glennie et al., 2013; Sepako et al., 2014; Swarthout et al., 2020; 
Wolter et al., 2014). To date, the immunological basis for the increased 
propensity to pneumococcal pneumonia in HIV-infected adults is still unclear. 
Previous studies failed to identify evidence of impaired pneumococcal-specific 
airway CD4+ T-cells, reduced anti-capsular polysaccharide or protein IgG 
antibodies in the lung or poor AM binding and internalisation of pneumococcus 
(Collins et al., 2013; Eagan et al., 2007; Gordon et al., 2000, 2001, 2013; Jambo et 
al., 2011; Peno et al., 2018) in adults from a high disease burden low income 
setting. In murine models of pulmonary infection, AMs are known to clear 
bacteria up to a defined threshold without overt features of pneumonia (Dockrell 
et al., 2003a). But their failure in controlling these subclinical infections has been 
shown to result in the recruitment of inflammatory cells which give rise to 
inflammation and if not controlled leads to pneumonia (Aberdein et al., 2013; 
Dockrell et al., 2003a, 2012; Duan et al., 2012). I, therefore, hypothesise that HIV 
infection is associated with impaired airway alveolar phagocyte killing function, 







HIV-uninfected  HIV-infected 
Pneumococci receptor Intracellular compartment Bacterial killing HIV
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Figure 1.11. The model summarises the hypothesis for the thesis. A. Alveolar phagocytes from HIV-
uninfected individuals internalise opsonised pneumococci through their Fc portion resulting in 
pneumococcal killing and clearance from the intracellular and extracellular compartments. B. 
Alveolar phagocytes from HIV-infected individuals internalise opsonised pneumococci through 
their Fc portion but HIV infection impairs their ability to kill internalised pneumococci from the 
intracellular compartments, leading to its survival. Abbreviations: AMs – alveolar macrophage, HIV 
– human immunodeficiency virus. This figure contains some artwork produced by Servier Medical 
Art (http://smart.servier.com), under creative commons license 3.0. 
 
1.13. Aims and Objectives 
1.13.1. Overall aim  
To investigate airway phagocyte immune responses against S. pneumoniae in HIV-
infected adults compared to asymptomatic healthy controls. 
 
1.13.2. Specific objectives  
a. To determine airway phagocyte pneumococcal binding/internalisation 
capacity in HIV-infected adults compared to asymptomatic healthy 
controls. 
b. To determine alveolar macrophage intracellular killing capacity of S. 
pneumoniae in HIV-infected adults compared to asymptomatic healthy 
controls. 
c. To determine airway cell control of S. pneumoniae extracellular outgrowth 





2.0. Materials and Methods 
This chapter provides the clinical and laboratory experimental methodologies 
used to generate the data which are presented in later chapters. 
 
2.1. Study design and population  
Chapters 4, 5 and 6 summarise results from a comparative cross-sectional study 
enrolling asymptomatic HIV-uninfected and asymptomatic HIV-infected adults on 
antiretroviral therapy (ART) for <3-months and ART for >3-years. 
      
2.2. Study site  
The study discussed in this thesis was conducted at Malawi-Liverpool Wellcome 
Trust Clinical Research Programme (MLW) and the Queen Elizabeth Central 
Hospital. The asymptomatic HIV-infected adults on ART were recruited from 
health centres around Blantyre (Gateway and Ndirande), whilst the asymptomatic 
HIV-uninfected were recruited the communities surrounding the health centres. 
 
2.3. Ethical approval 
The study presented was approved by the College of Medicine Research Ethics 
Committee (COMREC) (Blantyre, Malawi) and the Liverpool School of Tropical 
Medicine Research Ethics Committee (LSTM REC) (Liverpool, United Kingdom) 
(see Table 2.1.; Appendix 1-6). The studies were compliant with Good Clinical 
Practice and the principles set out in the Helsinki Declaration (World Medical 
Association, 2013). 
 
Table 2.1. Ethical approval reference information for the studies 
Study Ethics body Reference Chapters 
Characterisation of HIV- 
associated changes in alveolar 
immune environment that favour 












2.4. Participant recruitment and consent 
All participants volunteering to be part of the studies provided written informed 
consent. The process of consenting and disseminating information to the 
participants was done in both Chichewa (local language) and English (see 
Appendix 7-10). Participants were first screened according to the inclusion and 
exclusion criteria presented in Table 2.2. and were frequency aged matched with 
apparently healthy controls. Both inclusion and exclusion criteria were designed 
to minimise variability within the group of participants being recruited. 
 
Participants were enrolled from the 3 clinical phenotypes described below. 
1) Healthy, HIV-uninfected individuals with no clinical evidence of active 
respiratory disease. 
2) Asymptomatic, HIV-infected individuals on ART for not 
more than 3-months or ART-naïve individuals (irrespective of CD4 count) with no 
clinical evidence of active respiratory disease. For the purpose of this thesis, HIV-
infected individuals on ART<3-months will be termed as HIV-infected on short-
term ART and this may be used interchangeably. 
3) Asymptomatic, HIV-infected individuals on ART for at least 3 years, with no 
clinical evidence of active respiratory disease or progression of HIV infection and 
CD4+ T cell counts of >350 cells/mm3. Plasma HIV viral load results were not be 
available at recruitment for most participants but based on data from the HIV 
clinic at QECH, approximately 90% of adults on ART for > 3years have 
undetectable plasma HIV viremia. For the purpose of this thesis, HIV-infected 
individuals on ART > 3-years will be termed as HIV-infected on long-term ART and 
this may be used interchangeably. 
 
Inclusion criteria 
• Male or female participants aged ≥ 18 years of age. 
• HIV infected or HIV-uninfected. 
• Asymptomatic to respiratory infection. 
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• HIV ART naïve, irrespective of CD4+ T-cell count. 
• HIV-infected individuals on ART for not more than 3-months with a CD4+ T 
cell count ≥350 cells/mm3. 
• HIV-infected on ART for more than 3-years with a CD4+ T cell count ≥350 
cells/mm3. 
Exclusion criteria 
• Refusing HIV testing.  
• Showing symptoms of a respiratory tract infection. 
• Having had a lower respiratory infection in the last 6-months. 
• An individual with anaemia (Hb <8g/dl). 
• An individual suspected or known to be pregnant. 
• A known smoker or previous smoker within past 1 year. 
• An individual with suspected or known to have chronic obstructive 
pulmonary disease (COPD). 
• Having the following contraindications; unstable cervical spine, 
unresponsive hypoxia, unstable angina, bleeding diathesis, malignant 
cardiac arrhythmia. 
 
2.5. Clinical procedures 
This section provides the sequential details of all the clinical procedures involved 
in collecting samples from our participants.   
 
2.5.1. Clinical materials  
All the details pertaining the clinical materials I used in collecting samples from 
the participants are all listed in Table 2.3. together with manufacturer and 








Table 2.3. General clinical consumables  
Name  Manufacturer  Product code  
FLOQSwabsÔ Copan 516CS01 
Rapid influenza A+B test kits  Coris BioConcept K-1512 
Venous blood sample tubes, Sodium 
Heparin, plastic 
Becton Dickinson KFK279 
Venous blood sample tube, K2EDTA, 
plastic  
Becton Dickinson KFK042 
Lidocaine hydrochloride  Hameln 
Pharmaceutical  
PL01502/0021R 
Universal transport media  Copan 330C 
50ml polypropylene conical tubes  Corning 352070 
50ml Syringe  BD plasticpack 300866 
IV cannula  Biomatrix 
Healthcare 
IT0101-20 
Neovac IV cannula with wings and 
injection port 
Neovac  
20ml Disposable syringe   
 
 Abbreviations:  IV – intravenous, EDTA – dipotassium ethylenediaminetetraacetic acid 
 
2.5.2. Nasopharyngeal sample collection and influenza screening 
This procedure is used to detect for the presence of influenza viruses (Flu A and 
Flu B) in nasopharyngeal swabs collected from study participants. The participant 
had their head tilted back at an angle of 70° and a FLOQSwabsÔ swab was 
inserted into the nostril (the swab had to reach a depth equal to distance from 
nostril to outer ear’s opening). Once the swab reached the nasopharynx, the swab 
was left in place for 2-3 seconds and then slowly removed whilst rotating it (this 
was repeated in the other nostril). One swab was collected from each nostril. The 
first swab to be collected was cut into 2, with one half used to test for the 
presence of influenza virus immediately whilst the other half was inserted into a 
tube containing skimmed milk tryptone glucose and glycerine media (STGG) (see 
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figure 2.5.2). The second full swab collected was put into universal transport 
media, chilled on ice and transported to the laboratory for long-term storage.  
 
For influenza screening, a rapid influenza immunochromatographic test cassette 
was first labelled with the participant identifier. This was followed by placing the 
swab into a small semi-rigid tube (that comes with the kit) and 18 drops of 
dilution buffer added, stirred and swab pressed firmly against the sides of the 
tube before being removed and discarded into a biohazard container. The sample 
was mixed thoroughly, and a dropper inserted into the semi-rigid tube, the tube 
was inverted and slowly 3 drops of the diluted sample were added into cassette 
well. Results of the test were read between 15-20 minutes and recorded to the 
participant’s electronic case report form. The collection and screening of influenza 
illustrated in Figure 2.1. 
 
Figure 2.1. Pernasal swab collection and influenza testing procedure. 
2.5.3. Peripheral blood collection 
Participants were prepared for venous blood collection by swabbing the skin 
around the antecubital fossa in circular motion with an alcohol wipe. Blood was 
collected using a vacutainer system and universal precautions were observed. 
Blood was collected according to samples required and the following blood 
samples were collected; serum (2-mls clot activated SST tubes) and plasma (2-mls 
K2EDTA tubes). The labelled blood sample tubes were gently inverted 5-6 times as 
The head of a participant is 
tilted back at an angle 70ᴼ
and a pernasal swab 
inserted into the nostrils all 
the way to the nasopharynx 
Once the samples have been
collected, one swab is cut into 
2 and inserted into STGG
media whilst the other half is 
used for testing the presence 
of influenza virus. Second 
swab is placed in universal 
transport media
The sample for influenza testing is 
diluted by adding 18 drops of 
sample buffer and mixed. 3 drops 
of the sample are added into the 
cassette well and allowed to move 
up by capillary action.
Results are read 
after 15-minutes 
Figure 2.5.2: Pernasal swab collection and influenza testing procedure 
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to allow the anticoagulant or clot activator to mix well with the blood and placed 
on ice and transported in a cooler box to the MLW laboratories. Once the samples 
reached the diagnostic laboratory blood in clot activator was allowed to clot at 
room temperature before the tube being spun at 2,000g for 10 minutes in a 
refrigerated centrifuge. Serum was harvested and stored at -80°C. Peripheral 
CD4+ counts were measured from K2EDTA tubes upon reaching the laboratory. 
 
2.5.4. Bronchoalveolar lavage collection 
Participants were prepared for bronchoscopy by taking blood pressure 
measurements, heart rate, pulse oximetry and respiratory rate. Topical lignocaine 
spray was applied to the nasal and pharyngeal mucosa of semi-recumbent 
participants. A fibre-optic bronchoscope was passed down trachea and 4% 
lignocaine applied to the vocal cords and 2% lignocaine used in the larger airways. 
The bronchoscope was passed down to the level of sub-segmented bronchus of 
the right middle lobe to achieve a seal. Four 50ml aliquots of sterile normal saline 
at 37°C was instilled and lavage fluid removed by using gentle hand suction. The 
aspirated bronchoalveolar lavage (BAL) fluid was placed in four 50ml falcon tubes 
and transported to the laboratory on ice within 30-minutes of collection. All 
participants were reviewed before discharge for any immediate complications 
and returned back within 72-hours for further review and clinical examination. 
 
2.6. Laboratory procedures  
This section provides details of the laboratory procedures and experiments 
conducted that were used to generate data presented in the preceding chapters.   
2.6.1. Laboratory consumables  
All the details pertaining the laboratory materials and consumables used in 
processing the samples from the participants are all listed in the appendix 2. The 
sequence of tables below Table 2.4. to Table 2.7. present the list of laboratory 






Table 2.4. General laboratory consumables 
Name  Manufacturer  Product code  
15 ml Falcon tubes Corning 352097 
50 ml Falcon tubes Corning 352070 
Pasteur pipettes  ELK laboratory products 127-P503-STR 
Nunc 1.8ml Cryovials ThermoFisher Scientific  368632 
Formaldehyde solution Sigma-Aldrich/Merck  F1635 
Blood Agar Base Oxoid  CM0055 
Skimmed milk Oxoid LP0031 
Tryptic Soy Broth Sigma-Aldrich/Merck  ------- 
Glucose Prolabo G/0500/53 
Glycerine Fisher Scientific  -------- 
Yeast Extract Sigma-Aldrich/Merck Y1625 
Sodium azide (NaN3) Sigma-Aldrich/Merck S2002 
Costar Stripette 10ml Costar 4499 
Costar Stripette 25ml Costar 4489 






















Table 2.5. Consumables for airway infections 
  
Name  Manufacturer  Product code  
Sterile treated 6 well plates  Corning 353046 
Sterile treated 12 well plates Corning 353043 
Sterile treated 96 well plates 
(Greiner) 
Corning  3799 
16cm Scrappers SARSTEDT 83.1832 
Hank’s Balanced Salt Solution Sigma-Aldrich/Merck H9394 
Gentamicin Sigma-Aldrich/Merck 1405-41-0 
Saponin Sigma-Aldrich/Merck 47036 




IVIG NIBSC 04/140 
Distilled water Invitrogen 10977-035 
Dulbecco’s PBS CaCl2/MgCl2 (-/-) Invitrogen 20012-019 
CellTracker™ Red CMTPX Invitrogen C34552 
 
Table 2.6. Consumables for tissue culture 
Name  Manufacturer  Product code  
Glycerol  Fisher Scientific  G/P450/08 
Trypan blue 0.4% Gibco 15250-061 
Foetal Bovine Serum Sigma-Aldrich/Merck F9665 
Amphotericin B Gibco 15290-026 
Bovine Serum albumin Sigma-Aldrich/Merck A9414 
100µm nylon cell strainer Corning  352360 





Table 2.7. Consumables for immunophenotyping  
 
Name and Fluorochrome Host 
species 
Clone Manufacturer Product 
code 
anti-human CD206 FITC Mouse 15-2 BioLegend 321104 
anti-human CD163 BV421 Mouse GHI/61 BioLegend 333612 
anti-human CD66b APC Mouse G10F5 BioLegend 305118 
anti-human CD19 PE Mouse SJ25C1 BioLegend 363004 
 
2.6.2. S. pneumoniae culture and quantitation 
An invasive strain of S. pneumoniae serotype 3 (ST3) and sequence type 700 
isolated from a 43-year-old male with meningitis from Blantyre, Malawi in 2017 
was used in the ex vivo infections. The ST3 was first grown into single colonies on 
sheep blood agar (SBG) supplemented with 5mg/L gentamicin overnight (Figure 
2.2). Ten distinct single colonies were then resuspended in 10mls of Todd Hewitt 
broth supplemented with 0.5% yeast (THY) extract. Hourly growth curves were 
constructed by measuring the optical density (OD) of the THY at 490nm using a 
microplate reader (EZ Read 400, Biochrom, Massachusetts, USA) and the number 
of colony forming units accurately quantified per ml in parallel using the modified 
method of Miles and Misra (Miles et al., 1938). Twenty-four serial dilutions log10 
of the suspension were made by diluting 100µl of the suspension with 100µl of 
sterile phosphate buffered saline (PBS) in a 96-well microtitre plate before mixing 
thoroughly using a 200µl pipette. Using a 20µl graduated pipette, three 10µl 
drops of each dilution were then placed onto the 8 equally divided sectors on the 
SBG plate. The drops were allowed to dry and then incubated at 37°C in a 5% CO2 
incubator (MIDI 40, Thermo scientificÔ, USA) overnight for 18 hours (Figure 2.2). 
The number of viable colonies of ST3 were then counted and quantified using the 
Equation: 




Both the ODs and Miles and Misra technique were used to determine the mid-log 
growth phase of ST3. Thereafter, the broth was centrifuged and the sedimented 
ST3 was aliquoted and immediately frozen at -80°C in 1ml vial of 15% THY glycerol 
suspension. All the work was done in a containment level 2 laboratory (CL2). 
 
 
Figure 2.2. Overnight culture plates of S. pneumoniae serotype 3. A. Plate cultured to obtain pure 
single colonies of pneumococci-ST3 B. Overnight bacterial quantitation plate using the Miles Misra 
method.  
 
2.6.3. Opsonisation of S. pneumoniae bacteria  
Frozen aliquots of ST3 were thawed at room temperature, centrifuged 5 times at 
4,000g to obtain a pure pellet. Pellets of ST3 (~1x108 cfu) were then opsonised 
with 25% of 007SP human anti-pneumococcal capsule reference serum and 10% 
intravenous immunoglobulin (IVIG) in a final volume of 200µl infection medium. 
Infection medium was prepared by supplementing RPMI with 10% heat 
inactivated foetal bovine serum (FBS). The ST3 suspension was then incubated for 
30 minutes in a horizontal shaking incubator (ThermoFisher Scientific, USA) at a 
temperature of 37°C and a speed of 170rpm. The suspension was centrifuged at 
4,000g for 5 minutes and then washed with 1% heat inactivated FBS-RPMI 1640 
at 4,000g for 5 minutes. Miles and Misra viability bacteria count was performed in 
a. Overnight culture of ST3 on Sheep blood agar b. Quantitation of ST3 by Miles Misra method










parallel for each ex vivo infection conducted to confirm the multiplicity of 
infection (MOI). 
 
2.6.4. Fluorescent tagging of S. pneumoniae suspension  
To quantify the proportion of cells associated ST3 via binding and/or 
internalisation, frozen aliquots of ST3 were thawed at room temperature, 
centrifuged 5 times at 4,000g to obtain a pure pellet and stained with 
CellTracker™ Red CMTPX. The CellTracker Red CMTPX (C42H40ClN3O4) contains a 
chloromethyl group that reacts with thiol groups on the surface of S. pneumoniae 
forming cell-impermeable reaction products that are retained in living cells 
through several generations. The ST3 pellet (~1x108 cfu) in a 15-ml falcon tube 
was then fully resuspended in 250µl of 10µM CellTracker™ Red CMTPX solution 
and was wrapped in aluminium foil since Red CMTPX is light sensitive and 
incubated at 37°C for 1 hour, whilst gently shaking at 170rpm to ensure even 
staining of bacteria. Once stained, the tube containing the bacteria was 
centrifuged twice at 4,000g for 5 minutes to concentrate the stained ST3 pellet. 
The pellet was then resuspended in 2mls of Hanks balanced salt solution (HBSS) in 
0.2% bovine albumin serum and washed twice at 4,000g for 5 minutes. After the 
final wash, stained ST3 was resuspended in 100µl infection media. Opsonisation 
of bacteria then proceeded using the previously described method (see 2.6.3). To 
confirm staining quality, the bacteria suspension was centrifuged at 4,000g for 5 
minutes, fixed in 3% paraformaldehyde (Sigma-Aldrich, Saint Louis, USA) for 5 
minutes in the dark. The suspension was washed, and the fluorescent tagging 
confirmed using the LSR Fortessa (BD Bioscience, California, USA) flow cytometer. 
Forward and side scatter flow plots were used to identify the ST3 population and 
at least 5,000 events were analysed for CMTPX expression with 405nm violet laser 






2.6.5. Bronchoalveolar lavage processing and resting of cells 
Bronchoalveolar lavage (BAL) fluid from three 50ml falcon tubes obtained as 
stated in section 2.5.4 were filtered using a 100µm cell strainer to remove any 
potential mucus plugs before pooling into three sterile 50ml falcon tubes that 
were centrifuged at 500g at 4°C for 8-minutes. After centrifugation, one tube of 
the 50ml supernatant was stored and the rest decanted. The remaining cell whole 
pellet was resuspended in 50ml of cold PBS and centrifuged at 500g at 4°C for 8-
minutes. After washing, the cell pellet was further resuspended in 5ml of infection 
media and cell count performed using the KOVA® disposable counting chamber 
under bright field microscope (Olympus, Tokyo, Japan). To distinguish between 
non-viable and live BAL cells, trypan blue was prepared by diluting 1-part of 
trypan blue with 9-parts of PBS. A 1:1 ratio of cell suspension to diluted trypan 
blue was used for cell counts after which the airway cells were apportioned for 
the various experiments. The airway cell suspension was centrifuged, supernatant 
discarded, and the cell density adjusted to 1x106 cells/ml by adding appropriate 
Unstained ST3  
Stained ST3 
Figure 2.3. CMTPX stained S. pneumoniae serotype 3 
Red – unstained pneumococci; Blue – stained pneumococci 
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amount of infection media. One millilitre of the airway cells was then transferred 
into each of the 12-wells of a culture plate and incubated for 3-hours at 37°C 
under 5% CO2 to allow adherence of alveolar macrophages before the onset of 
ST3 infections. The collection, processing and resting of cells are illustrated in 
Figure 2.4. 
 
Figure 2.4. Sequential collection and bronchoalveolar lavage processing. 
2.6.6. Airway cell ex vivo infections  
a. Alveolar phagocytes and ST3 association assay 
To determine the number of alveolar phagocytes (macrophages, monocytes, 
neutrophils) associated with S. pneumoniae ST3, rested BAL cells (see 2.6.5) were 
first infected with opsonised fluorescent tagged ST3 at MOI 50 and MOI 10 for 1-
hour. Thereafter, the plates were centrifuged for 3 minutes at 1800rpm to initiate 
an immediate contact between the phagocytes and the ST3. Plates were then 
incubated at 37°C in 5% CO2 with gentle horizontal shaking 50rpm. One-hour post 
infection, the supernatant was aspirated together with the non-adherent cells and 
transferred to FACS tubes. The supernatant was washed twice by centrifugation at 
500g for 8 minutes and then fixed in 4% PFA for 5 minutes in the dark. As for the 
adherent cells, cold PBS was added to the well and the 12-well plate was 
incubated on ice buckets for 20 minutes. This facilitated the adherent cells to 
come off from their bound surfaces. Cells were scraped and transferred to FACS 
A bronchoscope is inserted 
into the alveolar space
The tubes are 
centrifuged to obtain 
a pellet containing 
BAL cells
The supernatant is discarded, pellets 
are pooled into a single tube and  
resuspended in PBS
The tube is centrifuged to wash the 
cells
The resulting cell 
pellet is resuspended 
in complete media 
The number of cells is 
counted under a 
microscope and the cell 
count of the sample is 
calculated
Cell suspension is distributed 
into a culture plate
Cells are rested in an 
incubator at 37oC
Saline fluid is flushed into the alveolar 
space and bronchoalveolar lavage 
(BAL) is collected into 3 falcon tubes
The BAL fluid is 
filtered and pooled 
into three separate 
falcon tube
Fig 2.6.6: Sequential collection and processing of BAL
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tubes and centrifuged at 500g for 8 minutes at 4°C. The adherent cells were fixed 
for 5-minutes in 4% PFA and combined with their corresponding supernatants 
before the cells underwent immunophenotyping (see 2.6.7). The airway cell 
infections ex vivo experiments are summarised in Figure 2.6. 
 
 
b. Gentamicin protection assay experiments 
To determine the number of viable intracellular ST3 in alveolar phagocytes 
(macrophages), rested BAL cells (see 2.6.5) were first infected with opsonised ST3 
at MOI 50. Thereafter, the plates were centrifuged for 3 minutes at 1800rpm to 
initiate an immediate contact between the phagocytes and the ST3. Plates were 
incubated at 37°C in 5% CO2 with gentle horizontal shaking 50rpm. One-hour post 
infection, the supernatant was removed, and the wells washed twice with fresh 
PBS. 450µl of infection media was added to the wells with adherent cells followed 
by 100µg/ml of gentamicin. Plates were further incubated for 30 minutes at 37°C 
in 5% CO2 with gentle horizontal shaking 50rpm. Thirty minutes post gentamicin 
exposure, the wells were washed twice to remove any traces of gentamicin and 
viable extracellular bacteria, leaving phagocytes with internalised ST3. 
Supernatant harvested from the gentamicin protection assay was centrifuged at 
Whole BAL is infected with 
opsonized S. pneumoniae 
(SPN) Serotype 3
1hr post-infection, excess 
bacteria and non-adherent 
cells are removed
2, 3, 24hrs
Flow cytometry – Assess SPN uptake
1hr
Assess SPN control –
Quantitative culture
Figure 2.6. The airway cell infections ex vivo experiments. 
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4,000g for 5-minutes, decanted and to the remaining pellet 1ml of PBS was added 
and any viable ST3 was quantified using the Miles and Misra technique (see 2.6.2).  
 
To the adherent cells in the wells of the cell culture plates, fresh infection media 
with no antibiotics was added and incubation continued for 24-hours. At times 1, 
2, 3- and 24-hours post infection, supernatant was removed and stored. Wells 
corresponding to the different time intervals were washed twice with PBS and 
750µl of 2% saponin solution added. The well/s were incubated with saponin 
solution for 1-minute. The saponin lysed phagocytic cells to release phagocytosed 
ST3. Afterwards, 3mls of PBS was added to the well/s to dilute the effect of the 
saponin. The liquid in the wells was aspirated into a 15ml falcon tube and 
centrifuged for 5-minutes at 4,000g. Supernatant was decanted and 1ml of PBS 
added to the pellet, vortexed and viable intracellular ST3 quantified using the 
Miles and Misra technique (see 2.6.2).  
 
c. Bacterial outgrowth assay 
To determine the growth inhibition of extracellular ST3 by airway cells, rested 
airway cells (see 2.6.5) were infected with opsonised ST3 at MOI 1:50 or 50 
bacteria per phagocyte in infection medium. The infections were done in a class 
IIAB laminar flow biohazard hood. Thereafter, the plates were centrifuged for 3 
minutes at 1800rpm to initiate intimate contact between the phagocytes and the 
ST3. Plates were incubated at 37°C in 5% CO2 for up to 24-hours with gentle 
horizontal shaking 50rpm. After each hour and for three continuous hours post 
initial phagocyte and bacteria contact, plates were taken out and the supernatant 
for the matching hour was removed, and wells washed twice with PBS after which 
fresh infection media was added before the cell culture plate was re-incubated 
(Figure 2.5). For the condition under test, the supernatant and cell wash 
supernatant were combined and centrifuged for 5 minutes at 4,000g. 
Supernatant was then discarded, and 1ml of fresh PBS added to the pellet and 
viable outgrowth ST3 quantified using the Miles and Misra technique (see 2.6.2). 




Figure 2.5. Ex vivo airway infections and ST3 quantification 
2.6.7. Immunophenotyping 
Flow cytometry-based immunophenotyping was used to characterise cells 
associated S. pneumoniae. Firstly, cells were adjusted to 1x106/50µl and 
transferred into FACS tubes. A cocktail of antibodies was prepared using optimum 
antibody concentration. Antibodies were added to appropriate FACS tube and 
incubated in the dark for 15mins. After incubation, 1ml of cold PBS was added to 
resuspend cells. The tubes were then spun in the centrifuge at 500g for 8mins 
and supernatant gently poured off after centrifugation. Cells were gently 
resuspended and fixed in 0.5% paraformaldehyde and acquired on a BD Fortessa 
flow cytometer (Beckman Dickinson, USA).   
 
2.6.8. Gating strategies 
All gating strategies used in the protocols described in this thesis have been 
described in the methods section associated with the result chapter.  
 
2.6.9. Cell sorting 
Harvested airways cells from apparent health HIV-uninfected individuals were 
allowed to rest and incubated at 37°C in a 5% CO2 incubator for 3-hours before 
the supernatant containing non-adherent cells was removed. This was done only 










Lymphocytes were purified from the whole non-adherent fraction through cell 
sorting (BD fluorescence activated cell sorter ARIAIII), followed by reseeding of 
lymphocyte depleted fraction to its cognate 12-well plate and incubated for a 
further 3-hours at 37°C, 5% CO2. Following incubation, rested airway cells were 
infected with CMTPX stained S. pneumoniae ST3, harvested, immunophenotyped 
and acquired on the BD Fortessa flow cytometer as described previously in this 
chapter (2.6.6a and 2.6.7). 
 
2.6.10. Culturing nasopharyngeal swabs for S. pneumoniae  
The swab frozen in STGG media was thawed and vortexed for 30 seconds. 100µl 
of the mixture was pipetted onto the SBG agar and was streaked and incubated 
overnight at 37°C in a 5% CO2 incubator. Pneumococci produce pneumolysin 
which breaks down haemoglobin into a green pigment that can be observed 
around the colonies. The following day, a few well isolated green and alpha 
haemolytic colonies were picked and streaked onto a new SBG and an ethyl 
hydrocupreine hydrochloride (Optochin) disk of concentration 5µg/ml was placed 
onto the streaked area. All pneumococci are sensitive (zone of inhibition ³14 mm) 
to optochin and helps distinguish S. pneumoniae from other streptococci that are 
all optochin resistant.  
   
2.6.11. Preparation of slide for confocal microscopy 
The slides with fixed airways cells (experimental infection) in 4% 
paraformaldehyde were first washed off with PBS three-times to remove any dust 
that could have accumulated during storage. After washing, the tissue (airway 
cells) were then incubated and stained with 200µl of 0.5% wheat germ agglutinin 
(Alexa Flour® 633 WGA, Thermo scientific), to stain the cell membranes (magenta, 
AF633) of the airway cells and the bacteria. Alexa Fluor® 633 WGA binds to sialic 
acid and N-acetylglucosaminyl residues. The slide was then washed 3-times with 
PBS to remove excess WGA before permeabilising the airway cells with 100µl of 
0.1% triton for 10 minutes. This was followed by washing off the triton 3-times 
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with PBS. Fixed airway cells were further incubated for an hour with 
pneumococcus strain serotype 3 capsule antiserum (SSI Diagnostica, Denmark) 
diluted in 5% goat serum. Following incubation, the slides are washed 3-times 
with PBS to remove excess pneumococcus antisera and then incubated for a 
further 45 minutes with secondary antibody (to detect bacteria) conjugated with 
the fluorochrome (anti-rabbit AF488, Thermo Scientific). For slides requiring AMs 
to be identified, anti-human CD206, AF568 (Thermo Scientific) was co-incubated 
with bacterial secondary conjugated antibody. AMs stained red with anti-CD206. 
The slide was then washed for the last time with PBS and once in distilled water. 
Finally mounting media containing 4ʹ,6-diamidino-2-phenylindole (DAPI) was 
added to the slide before mounting with a coverslip. DAPI stains the nucleus blue. 
Nail polish was used to seal the slide before analysis on the confocal or 
fluorescent scanning microscope. The slides were used to detect for the presence 
of intracellular S. pneumoniae within AMs. The confocal slide images were 
acquired using an Olympus FluoView 1000 confocal laser scanning (inverted) 
microscope. Z-stacks were recorded at 1-mm intervals at either 20X and 60X oil 
objectives, and ImageJ (https://imagej.nih.gov/ij/) was used for processing the 
images. 3D images were reconstructed using Huygens Essential deconvolution 
software version 16 (Scientific Volume Imaging) and viewed in Imaris 3D 
reconstruction software 9.4 (Bitplane).  
 
2.7. Sample size  
A total of 150 participants were screened with 76 being recruited into study. 
These comprised of 31 healthy HIV-uninfected; 29 asymptomatic HIV- infected on 
short-term ART (n=27; <3-months) or ART naïve (n=2); and 16 asymptomatic HIV-
infected on long-term ART ≥3-years. The target sample size was 90, with each 
group having an estimated sample size of 30 participants. As this study was a pilot 
in nature, a sample size of 30 was decided upon, as recommended for pilot 
studies which range between 10-40 individuals per group (Johanson and Brooks, 
2010; Julious, 2005; Leon et al., 2011; Viechtbauer et al., 2015). However, our 
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target was not met due to time constraints and bronchoscopy equipment 
challenges.  
 
2.8. Data management and statistical analysis 
a. Data management 
All names of participants recruited were de-identified and assigned a unique study 
participant identifier. All clinical and research data generated from the MLW 
laboratory were merged and anonymised. Results for the participants were 
reported using the unique study identifier. Consent forms and were kept under 
lock and key at MLW and access to these documents was restricted to the 
principal investigator and data manager. Upon completion of data entry and 
cleaning, original forms were stored under lock and key at MLW until final 
analyses and reports were prepared. All paper documents will be destroyed after 
5-years according to MLW policy and prevailing regulations in Malawi.  
 
b. Statistical analyses  
All statistical analyses used in this thesis have been described in the methods 





3.0. Assay development and adaptation 
3.1. Alveolar infection control model for S. pneumoniae  
This chapter provides the experimental methods developed, adapted and 
optimised to generate the data used in the subsequent chapters. Some of the 
methods have previously been published as cited in the sections that follow. 
 
3.2. Specific objectives 
a. To establish pneumococcal serotype 3 (ST3) growth kinetics. 
b. To generate a fluorescent labelled-pneumococcal ST3 for use in a flow 
cytometry-based binding and internalisation assay.  
c. To optimise opsonisation conditions for pneumococcal ST3. 
d. To standardise and quality control the pneumococcal inoculum dose for 
the ex vivo infection.  
 
3.3. Establishing pneumococcal serotype 3 (ST3) growth kinetics 
 
3.3.1. Pneumococcus ST3 growth curve and quantitation 
 The pneumococcus serotype 3 (sequence type 700) optimised in these assays 
and used in subsequent experiments was described elsewhere (2.6.2). The growth 
curve assay is a fundamental technique used in microbiology to determine the 
bacterial growth kinetics (lag phase, log/exponential phase and stationary and 
death phase) and aids in determining the bacteria’s physiological and metabolic 
functions as well as quantifying the actual numbers of the bacteria. The growth 
curve principle is based on the fact that when bacteria replicate, they divide 
asexually through binary fission yielding two daughter cells.  
 
In standardising the ST3 for the infections experiment, the bacteria were cultured 
and quantified as described in section 2.6.2. Of note ST3 was quantified every 2-
hours during the first 6-hours and every 3-hours thereafter up to a maximum of 
24-hours. This was done after observing the growth kinetics of the bacteria. Serial 
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plate dilutions were done and the number of cfu present quantified on SBG as 
previously described (2.6.3). Figure 3.1. shows the ST3 24-hour growth curve 
generated, showing the growth kinetics of ST3 from lag phase through to the 
death phase were the autolytic enzymes of the bacteria are activated. The 
viability of ST3 was not quantified beyond 24-hours as all ex vivo infection 
experiments had a maximum limit of 24-hours. 
 
Figure 3.1. S. pneumoniae ST3 growth curve following incubation in Todd Hewitt Broth 
supplemented with 5% yeast extract. One colony of pneumococcus ST3 was inoculated into 10mls 
of pre-warmed broth and incubated at 37°C in 5% CO2. The total colony forming units were 
quantified every 2-hours during the first 6-hours and every 3-hours thereafter using the Miles and 
Misra technique on sheep blood agar supplemented with 5mg/L gentamicin. Average number of 
replicates at each time point n=3, error bars show standard error of the mean (SEM). 
  





















ST3 24hr growth curve in THY media 
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3.3.2. Viability of pneumococcus ST3 growth in infection media 
and RPMI 
Next we determined whether RPMI alone or infection medium (RPMI +10% FBS) 
best maintains ST3 growth. This was an important component of assay 
development as the media was meant to support the viability of ST3 the first 6-
hours of the ex vivo infection and thereafter the ST3 decayed exponentially as the 
media failed to maintain further bacterial growth. In standardising the viability of 
ST3 for the infections experiment, 5x107 colony forming units (actual infections 
bacterial dosage) of ST3 were grown in 1-ml of liquid culture infection media or 
RPMI alone and quantified as a function of time as described (2.6.2). Of note, ST3 
was quantified every 3-hours over 24-hours. The viability and decay of ST3 in 
infection media is shown in Figure 3.3.1. It was observed that the infection media 
was supportive of the ST3 survival for the first 6-hours and then went through a 
rapid decay until it reached the assay’s limit of detection between 15 and 18-
hours (Figure 3.2).  
Viability of S. pneumoniae in infection media and RPMI overtime 
 
Figure 3.2. S. pneumoniae-ST3 growth kinetics in RPMI or infection medium (RPMI +10% FBS). 
5x107 colony forming units of pneumococcus ST3 were inoculated into 1ml of pre-warmed broth 
and incubated at 37°C in 5% CO2. The total colony forming units were quantified every 3-hours for 


































24 hours using the Miles and Misra technique on sheep blood agar medium supplemented with 
gentamicin with 5mg/L gentamicin. Abbreviation: cfu – colony forming units, SPN – 
pneumococcus. Replicates at each time point n=2, error bars show SEM. 
 
 
3.1. To produce a fluorescent labelled-pneumococcal-ST3 for use in a 
flow cytometry-based binding and internalisation assay. 
 
3.1.1. Optimum staining concentration of pneumococci-ST3 with 
CellTracker™ Red CMTPX dye 
Having confirmed that the infection medium maintains the growth of 
pneumococci-ST3, I further determined the optimum concentration of CMTPX 
dye to use in staining the bacteria. Frozen aliquots of pneumococci ST3 bacteria 
were thawed to room temperature, centrifuged 5 times to obtain a pure pellet. 
The pneumococci-ST3 pellet (~1x108 cfu) was then fully resuspended in 250µl of 
various concentrations of Red CMTPX (0, 0.5µM, 1µM, 1.5µM, 2.5µM, 5µM, 
10µM, 20µM, 50µM, 100µM) and bacteria tagged and acquired as described in 
2.6.4. 10µM CMTPX of was found to be the optimum staining concentration for 
the pneumococci as higher concentrations were not cost effective.  
 











Figure 3.3. Optimum pneumococci CellTracker™ Red CMTPX. A. The gate for unstained CMTPX 
pneumococci-ST3 was used to identify pneumococci positive for CMTPX. B. Histograms were used 
0 10 3 10 4 10 5
CMPTX
Sample Name Subset Name Count
ST3 OPTIMISATION_ST3 cmtpx 100uM_005.fcs SPN 4767 
ST3 OPTIMISATION_ST3 cmtpx 50uM_004.fcs SPN 3536 
ST3 OPTIMISATION_ST3 cmtpx 20uM_009.fcs SPN 4009 
ST3 OPTIMISATION_ST3 cmtpx 10uM_008.fcs SPN 3737 
ST3 OPTIMISATION_ST3 cmtpx 5,2f,1002‘5uM_006.fcs SPN 3910 
ST3 OPTIMISATION_ST3 cmtpx 2uM_005.fcs SPN 4317 
ST3 OPTIMISATION_ST3 cmtpx 1‘5uM_004.fcs SPN 4114 
ST3 OPTIMISATION_ST3 cmtpx 1uM_003.fcs SPN 3944 
ST3 OPTIMISATION_ST3 cmtpx 05uM_002.fcs SPN 3950 











































to compare the staining intensity of pneumococci-ST3 to the different concentrations of CMTPX C. 
Proportion of CMPTPX stained bacteria at various concentrations (average number of replicates at 
each concentration n=3), error bars show SEM. Abbreviations:  FSC-A – forward scatter area, FSC-
H – forward scatter height, SSC-A – side scatter area.  
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3.1.2. Stability of CMTPX stained pneumococci-ST3 over time. 
To determine the stability of CMTPX stained pneumococci-ST3 over time, the 
pneumococci ST3 pellet (~5x107 cfu) was resuspended in 250µl infection media 
and 10µM CellTracker™ Red CMTPX. The 15ml falcon tube was wrapped in 
aluminium foil and incubated at 37°C for 1 hour, whilst gently shaking at 170 rpm 
to ensure even staining of bacteria. Bacterial staining was done as described 
earlier (2.6.4). To determine the stability of CMTPX stained pneumococci, the 
bacteria was further resuspended in infection media alone for 0, 30, 60 and 120 
minutes, then pelleted by centrifuging and prepared for acquisition as described 
in 2.6.4 The CMTPX stained bacteria was observed to be stable for up to 2-hours 
post staining and this was crucial since bacteria are exposed to airway cells for 
approximately 2-hours prior to infection to acquisition.  
 
 
Figure 3.4. Stability of CellTracker™ Red CMTPX stained pneumococci overtime. Histograms were 
used to compare the stability of the CMTPX stained bacteria over time (0, 30, 60 and 120 
minutes). Abbreviations:  SPN – S. pneumoniae. 
 
0 10 3 10 4 10 5
CMTPX
Sample Name Subset Name Count
ST3 OPTIMISATION_ST3 cmtpx 50uM - 2hrs_006.fcs SPN 8399 
ST3 OPTIMISATION_ST3 cmtpx 50uM - 1 hr_005.fcs SPN 5511 
ST3 OPTIMISATION_ST3 cmtpx 50uM- 30 mins_004.fcs SPN 4777 
ST3 OPTIMISATION_ST3 cmtpx 50uM_003.fcs SPN 5783 








3.2. To optimise opsonisation conditions for pneumococci-ST3. 
3.2.1. Defining optimum IgG for pneumococcal opsonisation and 
uptake. 
Having established the optimum staining concentration for CMTPX and its 
stability on stained bacteria, I then determined the to optimum volumes of IgG 
007SP human anti-pneumococcal capsule reference sera and the IgG intravenous 
immunoglobulin (IVIG) individually and in combination (Goldblatt et al., 2017; 
National Institute for Biological Standards Control, 2008). I decided to use 007SP 
as it is pooled serum from 287 healthy volunteers following vaccination with 23-
valent pneumococcal polysaccharide vaccine (PneumovaxII®) that has antibodies 
capable of binding to the pneumococcus serotype 3, thus facilitating its 
internalisation through FcgRI/CD64, FcgRII/CD32, FcgRIII/CD16. Intravenous 
immunoglobulin is a collection of IgG antibodies of varying specificities to a wide 
range of antigens (including S. pneumoniae) and super antigens facilitating 
binding and internalisation by phagocytes (Takei et al., 1993). Pneumococci 
bacteria were stained as described (2.6.4.) and opsonised with varying IgG 
immunoglobulin volumes (IVIG - 10µl, 20µl, 40µl; 007SP - 25µl, 50µl, 100µl) or in 
combination (IVIG-10µl +007SP-50µl) as described (2.6.3). The 007SP human 
anti-pneumococcal sera contains an estimated 1.45µg/ml of IgG antisera against 
pneumococcal serotype 3, whereas 1ml normal IVIG (5% IgG, w/v). Rested airway 
cells (see 2.6.5) were infected with opsonised pneumococci-ST3 at MOI 50 in 
infection medium (2.6.6a). The cells were processed, fixed and  acquired on the 
flow cytometer. A combination of IVIG-10µl and 007SP-50µl was found to be the 
best ratio resulting in a higher association of pneumococci-ST3 to AMs. This is 









Flow plots comparing different IgG volumes for pneumococci opsonisation and 
uptake 
 
Figure 3.5. Representative flow plots comparing different IgG volumes for pneumococci-ST3 
opsonisation and uptake. Uninfected cells were used as the standard gate to identify the 
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3.2.2. Unopsonised pneumococci-ST3 bacteria exhibited 
increased binding and association with AMs 
 
Next, I investigated whether the frequency of AMs associated with opsonised IgG 
(IVIG + 007SP) or unopsonised pneumococcus-ST3 was similar at MOI 1, MOI 10 
and MOI 50. Airway cells from asymptomatic HIV-uninfected individuals were 
infected ex vivo with IgG opsonised and unopsonised CMTPX stained 
pneumococcus-ST3 at various MOI. In this study, the binding index was defined as 
the proportion of pneumococcus associated with each individual cell. The binding 
index for AMs was calculated using equation 2 below. AMs infected with CMTPX 
stained pneumococcus-ST3 and non-infected cells were stained with antibody 
fluorochrome conjugated monoclonal antibodies specific to the cell of interest 
and then acquired on the flow cytometer. The proportion of AMs associated with 
pneumococci-ST3 was increased in the unopsonised pneumococci-ST3 conditions 
(MOI 11, p=0.0039; MOI 50, p=0.039) compared to the IgG opsonised 
pneumococci-ST3. Furthermore, unopsonised pneumococcus-ST3 exhibited 
increased binding to AMs with a 1.02-fold median increase, (n=11, p=0.0078) at 
MOI 10 when compared to opsonised pneumococci-ST3; at MOI 50 a 2.59-fold 
median increase, (n=11, p=0.0039) was observed (Figure 3.6). MOI 1 was not 
included in the final analysis as the number of individuals were fewer and binding 
index below 0.01. Taken together these findings indicate that unopsonised 
pneumococcus-ST3 exhibit higher binding and association with AMs than IgG-
opsonised pneumococcus-ST3. 
 
Equation 2 – Alveolar macrophages  
Binding index =  
MFI (infected AMs*CMTPX SPN+)- MFI (uninfected AMs*CMTPX SPN-) 
2 x rSD (uninfected AMs*CMTPX SPN-) 
 
Equation 3 – Neutrophils 
Binding index =  
MFI (infected neut *CMTPX SPN+)- MFI (uninfected neut*CMTPX SPN-) 
2 x rSD (uninfected neut*CMTPX SPN-) 
Abbreviations: AMs – Alveolar macrophages, MFI – median florescent index, neut – neutrophils 
rSD – robust standard deviation, SPN - pneumococcus-ST3.  
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Proportion of Opsonised and Unopsonised pneumococci 
associated with AMs








Figure 3.6. Differential association of pneumococci-ST3 with AMs in IgG opsonised and 
unopsonised conditions. A. Representative flow plots comparing different MOI of opsonised and 
unopsonised pneumococci-ST3 and their association with airway cells. B. Proportion of AMs 
associated with IgG opsonised and unopsonised pneumococci-ST3 post infection ex vivo in 
asymptomatic HIV uninfected individuals (n=11) at MOI 10 and MOI 50 by Wilcoxon signed-rank 
test, ** p=0.0039, **p=0.0070. C. Pneumococcal binding index per AM associated with IgG 
opsonised and unopsonised pneumococci-ST3 post infection ex vivo in asymptomatic HIV 
uninfected individuals (n=11) at MOI 10 and MOI 50 by Wilcoxon signed-rank test, ** p=0.0078, 
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3.2.3. Quenching inhibits the non-specific binding of pneumococci 
onto airway cells. 
This experiment was designed to identify whether the binding/internalisation of 
unopsonised pneumococci-ST3 was true internalisation and not just some non-
specific extracellular association. Using MOI 50, I infected the airway cells with 
opsonised and unopsonised pneumococci-ST3. Following harvesting of the airway 
cells, I quenched the extracellular pneumococcus with trypan blue at a dilution of 
10µl trypan blue in 990µl of PBS for 5 minutes. Following quenching, trypan blue 
was washed off with 1ml PBS and cells centrifuged and discarded the 
supernatant. Airway cells were then fixed in 3% paraformaldehyde, then further 
washed in PBS and resuspended in PBS before acquisition. Unopsonised 
pneumococci were found to associate non-specifically to airway phagocytes and 
lymphocytes as shown in (Figure 3.7). In summary, unopsonised pneumococci 
associates with more airway phagocytes resulting in less internalisation. 
 
Gating showing pneumococci non-specific binding to lymphocytes 
 
 





































































Effect of quenching on stained S. pneumoniae 
 
 
Figure 3.7. Quenching inhibits the non-specific binding of pneumococci on airway cells. A. 
Representative flow plots comparing airway with IgG opsonised and unopsonised pneumococci-
ST3 after quenching. B. Representative histogram comparing the effects of quenching on AMs. C. 
Comparison of pneumococci association with alveolar cells before and after quenching with trypan 
blue (n=3 HIV-uninfected individuals) by Wilcoxon signed-rank test at MOI 10 or MOI 50. 
Abbreviations: MOI – multiplicity of infection, SPN – S. pneumoniae, TP – trypan blue. 
 











Sample Name Subset Name Count
ST3 OPTIMISATION IVIG+007S_SPN Only_Trypan blue_011.fcs SPN 8873 
ST3 OPTIMISATION IVIG+007S_SPN Only_008.fcs SPN 4130 
Trypan blue + CMTPX SPN
Unquenced CMTPX SPN






















































































































































































Effect of trypan blue on the association of S. pneumoniae 
with alveolar cells
MOI 10 MOI 50
B. 
C. 
    Tr  l   TP  stained SPN 
      No trypan blue + CMTPX stained SPN 
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3.2.4. Defining the correlation between pneumococci-ST3 binding 
index and proportional association 
 
I further investigated the relationship between AMs pneumococcal binding index 
and proportional association in IgG opsonised conditions at MOI 10 and MOI 50. I 
observed a moderate relationship between the proportion of AMs associated with 
pneumococcus-ST3 and the binding index (Figure 3.8).  
 














Figure 3.8. Relationship between pneumococcal binding index and the proportion of AMs 
associated with pneumococcus-ST3. Average number of pneumococcus bound to each AMs (n=56 
individuals) is shown to be positively correlated to proportion of AMs associating with S. 
pneumoniae at A. MOI 10 and B. MOI 50. Individual subjects are shown, and the strength of the 
relationship is denoted by the Pearson correlation test (r), linear regression line with 95% 
confidence interval are shown. 
 
  






























MFI vs Uptake proportion 10 AMs 
r2 =0.3601
r=0.6001; p<0.0001
Y = 11.35*X - 0.03304






























MFI vs Uptake MOI 50 AMs 
r2 =0.5030
r=0.7092; p<0.0001 
Y = 12.64*X +6.965
A. B. 
MOI 10 MOI 50 
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3.3. Reproducibility of inoculum dose for the ex vivo infection. 
 
The last experiment optimised was the inoculum dose used for the ex vivo 
infections. The standard inoculum dose for the experiments is 5x107 cfu/ml. I 
thawed the frozen batch of pneumococcus, resuspended it in infection media and 
cultured it using the Miles and Misra for viable bacteria count to confirm the 
multiplicity of infection (MOI) and its viability. I also did 6 replicates of the 
inoculum doses to demonstrate proficiency and reproducibility of the Miles and 
Misra techniques. The median inoculum density was 4.8 (IQR; 4.5 – 5.1) x107 
cfu/ml with a coefficient of variation of 6.43% (Figure 3.9, Table 3.1.).  
 

















Figure 3.9. Reproducibility of inoculum dose for the ex vivo infection. A. Pneumococcus inoculum 
serially diluted 1:2 was plated anticlockwise on a sheep blood agar plate starting with the highest 
dilution at position 1 and finishing with the lowest dilution at position 8. B. Distribution of 
pneumococcus inoculum dose results after plating on sheep blood agar (n=6 replicates), middle 







































































To investigate the cellular immune response against pneumococci in the lung, 
there was need to develop and optimise ex vivo infection assays that would aid 
understanding of immune control in the airway.  
 
The effectiveness of the pneumococcal conjugate vaccine (PCV)13 to 
pneumococci serotype 3 remains uncertain and conflicting. Little reduction in 
serotype 3 disease has been observed globally compared to disease due to other 
vaccine serotypes (Azarian et al., 2018). Unpublished data from Malawi 
demonstrates that anti-capsular antibodies against pneumococcus serotype 3 do 
not increase with age, as do those for other common serotypes. Surveillance data 
from Malawi has also reported that serotype 3 is among the commonest 
serotypes in pneumococcal carriage. I therefore decided to study pneumococcal 
serotype 3 using airway cells, in order to understand the lung infection dynamics. 
Firstly, I developed a 24-hour growth curve to establish its kinetics of propagation. 
The growth curve results obtained with serotype 3 were similar to those obtained 
with other serotypes of pneumococci (Restrepo et al., 2005; Tóthpál et al., 2019). 
Furthermore, the growth curve results helped me to define the different stages of 
pneumococci growth and in particular, the log phase. The pneumococci used in 
this study for infection studies were all grown to the log phase, which is 
characterised by a higher number a surviving bacterium with a constant doubling 
capacity. I also evaluated the growth potential of pneumococci in RPMI medium 
compared to infection media (RPMI + 10% foetal bovine serum). This was critical 
for the infection studies as the pneumococci were to be maintained in culture 
medium conducive for both bacterial and immune cell survival for 24-hours. This 
enabled ascertainment of the early and late killing kinetics of pneumococci 
serotype 3 in experimental conditions containing airway cells.  
 
AMs are highly auto fluorescent and tend to fluoresce at the same wavelength as 
green fluorescent protein (GFP), a common fluorescent protein used in tagging 
bacteria (Margolin, 2000; Phillips, 2001; Southward and Surette, 2002). An 
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alternative dye was optimised to stain the bacteria, and Cell Tracker Red CMTPX 
was capable of staining the bacteria and was stable for 2-hours. CMTPX has been 
used to stain pneumococci before, in an experiment to demonstrate that 
dendritic cells can transport S. pneumoniae to stromal follicular dendritic cells 
which are important for antibody production as they interact with B cells 
(Heesters and Carroll, 2016). I was able to demonstrate that CMTPX stained 
pneumococci-ST3 is stable for at least 2 hours, as the bacteria is exposed to 
airway cells for approximately 2-hours from infection to acquisition in the binding 
and internalisation assays.  
 
Airway phagocytes can internalise pneumococci using a number of cell surface 
receptors and depending on the receptor system engaged, the ingested 
pneumococci is dealt with differently. In this thesis, I had to optimise the IgG 
immune sera used for pneumococci opsonisation and bacteria internalisation via 
Fc receptors of phagocytes. The combination of IVIG and 007sp gave optimum 
binding and internalisation of at least 30% when using MOI 50. Other authors 
have reported using IVIG and 007SP in ex vivo infection experiments (Gordon et 
al., 2013; Mitsi et al., 2017, 2019). I observed that unopsonised pneumococci 
associated with airway cells non-specifically and this was supported by the 
observation that quenching of CMTPX-stained pneumococci with trypan blue 
reduced the signal on non-phagocytic cells.  
 
Finally, to generate robust data in the ex vivo pneumococcal infection studies, it 
was critical that the inoculum dose had to be reproducible across experiments, 
amongst participants and over a period of time. I was able to reproduce and 
optimise the pneumococcal-ST3 inoculum dose for the infection studies. The 
coefficient of variation was 6.43% from 6 different experiments, with all the 
inoculum infection dose within the same log. This was important as it suggests 
that the variation in the data to be produced is due to the individual host factors 




3.5. Conclusion  
 
In summary, this chapter has shown the development and optimisation of 
important assays for understanding airway cell control of pneumococcal infection. 
Having accomplished this, the appropriate assays were subsequently used in 





4.0. Airway phagocyte binding and internalisation of pneumococcus serotype 3 




S. pneumoniae remains the leading cause of pneumonia, meningitis and 
septicaemia globally, resulting in significantly high morbidity and mortality in the 
under-fives , the elderly and HIV infected individuals (Aston et al., 2019; Iroh Tam 
et al., 2017; O’Brien et al., 2009; Troeger et al., 2017; Wahl et al., 2018b). Despite 
the availability of pneumococcal conjugate vaccines (PCV), which are based on 
polysaccharide capsular antigens against common disease causing pneumococcal 
serotypes, the vaccines have proven less effective against pneumococcal 
pneumonia (Bonten et al., 2015; Cutts et al., 2005; Jacups and Cheng, 2011; 
Madhi et al., 2015; Prato et al., 2018). In Africa, pneumococcal pneumonia 
remains substantially prevalent amongst the HIV-infected individuals despite the 
high roll out of ART. Sub-Saharan Africa harbours the highest burden of HIV 
(Albrich et al., 2017).  
 
Mucosal control of pneumococci in the lung is complex involving both innate and 
adaptive immunity (Wilson et al., 2015). Once pneumococci microaspirate or 
translocate into the lower airway they encounter phagocytes (alveolar 
macrophages, neutrophils, dendritic cells, monocytes) and host soluble 
microbiocidal and signalling factors (Dudek et al., 2016b; Smith et al., 2018). 
Phagocytes contribute to the first line of defence against pneumococci, by 
pathogen recognition, phagocytosis, bacterial killing, as well as providing a linkage 
between dendritic cells and T-cells (Aberdein et al., 2013; Byrne et al., 2015; 
Collini et al., 2018; Gordon et al., 2000; Jambo et al., 2014a; Morales-Nebreda et 
al., 2015). Phagocytes bind and recognise pneumococci via germline coded 
receptors called PRRs which bind to conserved molecular structures found on 
large groups of pathogens, termed PAMPs (Byrne et al., 2015; Janssens and 
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Beyaert, 2003; Kohler et al., 2016c; Medzhitov and Janeway, 1997; Mogensen, 
2009). Phagocytes may also recognise pneumococci bound to an immunoglobulin 
via the fragment crystallisable (Fc) receptors present on its surface or via 
complement through the C3b deposited on the pneumococci (through receptors 
CR1, CR3 and CR4) (Dustin, 2016; Gordon et al., 2000; Guilliams et al., 2014; 
Walport, 2001). AMs constitutively express three classes of FcgR namely 
FcgRI/CD64, FcgRII/CD32, FcgRIII/CD16 and utilise these receptors to internalize 
antibody-opsonized pathogens, potentially leading to antibody-mediated 
clearance (Guilliams et al., 2014; Hunegnaw et al., 2019; Taylor et al., 2005).  
 
AMs are the most abundant phagocytes in the lower airway lumen of a healthy 
human lung under homeostatic conditions  (Byrne et al., 2015; Gordon et al., 
2013; Jambo et al., 2014a) and are thought to be integral in defence against 
pneumococcal infection in the lung (Aberdein et al., 2013; Collini et al., 2018; 
Gordon et al., 2001; Wilson et al., 2015). Consequently, this has traditionally 
driven the focus to AM-mediated anti-pneumococcal immune control during HIV 
infection (Collini et al., 2018). In untreated HIV-infected adults, AMs exhibit 
normal binding and internalisation of pneumococci (Gordon et al., 2001, 2013). 
However, whether other airway phagocytes such as neutrophils also show similar 
behaviour is unclear. Furthermore, the impact of ART on anti-pneumococcal 
immunity in the airway is also unclear, but it has been shown that ART is 
associated with increased carriage and increased frequency of pneumococcal-
specific Th17 cells (Glennie et al., 2013; Heinsbroek et al., 2015; Peno et al., 2018; 
Sepako et al., 2014). I therefore hypothesized that airway phagocyte subsets from 
HIV-infected adults on short-term ART are differentially impaired in their 





4.1.1. Research question 
Are airway phagocytes pneumococcal-binding/internalisation capacity 
differentially impaired in HIV-infected adults on short-term ART?   
 




To determine whether HIV-infected adults on short-term ART possess 
differentially impaired airway phagocyte pneumococcal-binding/internalisation 
capacity 
 
Specific objectives  
1. To determine the proportions of airway phagocyte subsets in asymptomatic 
HIV-uninfected compared to HIV-infected adults on short-term or long-term 
ART. 
2. To assess the pneumococcal binding and internalisation amongst airway 
phagocyte subsets in asymptomatic HIV-uninfected adults.  
3. To determine the airway phagocyte pneumococcal binding and internalisation 
in asymptomatic HIV-uninfected adults compared to HIV-infected adults on 




4.2. Methods  
4.2.1. Study participants and design 
This was a comparative cross-sectional study of asymptomatic adults namely, HIV 
uninfected, HIV-infected on short-term ART and long-term ART. Participants were 
recruited from the MLW’s Clinical Investigation Unit at the Queen Elizabeth 
Hospital in Blantyre, Malawi. All participants underwent clinical assessment and a 
questionnaire was administered to collect information relating to previous 
respiratory infections and social demographic characteristics (such as high 
exposure to carbon/soot) that could potentially impact their alveolar cell 
functional response ex vivo before recruitment. The recruitment criteria used has 
been discussed elsewhere (see Chapter 2.4). 
 
4.2.2. Sample collection and processing 
Bronchoalveolar lavage and per nasal swab samples were collected from all 
participants and transported to the MLW laboratories within 30-minutes of 
collection. Sample collection and processing have been described (see Chapter 2).  
 
4.2.3. Laboratory assays  
The laboratory assays associated with this chapter on the ex vivo infection model 
of primary cells have been described in Chapter 2. In particular, for specific details 
on fluorescent tagging of pneumococci (2.6.5); opsonisation of pneumococci with 
IgG (2.6.4), BAL processing and resting of cells (2.6.6), BAL ex vivo infections 
(2.6.9) and per nasal swab processing and pneumococci identification (2.6.15).   
 
4.2.3.1. Alveolar cell surface immunophenotyping  
Neutrophils and AMs associated with pneumococci were characterised using 
immunophenotyping. In brief, after harvesting the alveolar cells as described in 
section 2.6.9, six tubes of opsonised, unopsonised and uninfected cells were 
immunophenotyped as described in section 2.6.8. Antibody used are described in 
Table 4.1. Acquisition was done on the BD LSR II Fortessa flow cytometer 
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(Beckman Dickinson, USA). The gating strategy used is shown in macrophages and 
neutrophils is shown in Figure 4.1. 
 




Function Fluorochrome Concentration Cells 
identified  
CD66b Adhesion and 
activation 
APC 2.5:100 Neutrophils 
CD163 Scavenger receptor BV421 3:100 AMs 
CD206 Mannose binding 
receptor 
FITC 5:100 AMs 
CD19 Transmembrane 
glycoprotein 
PE 2.5:100 B-cells 
CMTPX  Qdot -605  ST3 
 
This panel was used to characterise the abundance of AMs and neutrophils from airway samples. 
Abbreviations: AMs – alveolar macrophages, APC – allophycocyanin, BV – brilliant violet, CD - 




a. Gating strategy for macrophages and neutrophils 
 
Figure 4.1. Alveolar macrophage and neutrophil gating strategy. Alveolar macrophages and 
neutrophils were identified after exclusion of doublets, debris and lymphocytes. This was after the 
identification of alveolar phagocytes based on side scatter area (SSC-A) and forward scatter area 
(FSC-A). AMs were identified as cells expressing CD206 and CD163. In the same panel, non-AMs 
were identified from cells expressing low levels of CD206 and CD163, and then neutrophils were 
identified as cells expressing high levels of CD66b. Non-AMs non-Neut were identified as cells 
expressing low levels of CD206, CD163 and CD66b. A fluorescent-minus-one (FMO) was used to 
help gate for neutrophils. Abbreviations: AMs – alveolar macrophages, APC – allophycocyanin, BV 
– brilliant violet, CD – cluster of differentiation, FITC – fluorescein isothiocyanate, FSC-A – forward 
scatter area, FSC-H – forward scatter height, Neut – neutrophils, PE – phycoerythrin. 
  
CD66b – FMO sample CD66b Stained sample 
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b. Gating strategy for the binding and internalisation of pneumococci by AMs 
 
 
Figure 4.1b. Gating strategy for pneumococcal-AMs binding and association. Flow plots comparing 
IgG opsonised pneumococci at MOI:10 and MOI:50. AMs associated with pneumococci were 
identified by subtracting the gating frequency of AMs infected with CMTPX stained ST3 from the 
uninfected AMs. Abbreviations:  MOI – multiplicity of infection, AMs – alveolar macrophages, SSC-
A – side scatter area. 
  














Figure 4.1c. Gating strategy for pneumococcal-neutrophil binding and association. Flow plots 
comparing IgG opsonised pneumococci at MOI:10 and MOI:50. Neutrophils associated with 
pneumococci were identified by subtracting the gating frequency of neutrophils infected with 
CMTPX stained ST3 from the uninfected neutrophils. Abbreviations:  MOI – multiplicity of 
infection, Neut – neutrophils, SSC-A – side scatter area. 
 
4.2.3.2. Confocal microscopy  
Confocal microscopy was used to demonstrate the association between S. 
pneumoniae with airways cells after infection. The full details have been described 
elsewhere (see Chapter 2.6.11).   
 
  






4.2.4. Statistical analysis  
Descriptive statistics were used to for continuous variables by calculating medians 
and interquartile ranges. Groups were compared using non-parametric tests 
(Wilcoxon rank sum or Wilcoxon signed-rank test, Kruskal Wallis tests) depending 
on the distribution. For multiple pairwise comparisons the Dunn test was used to 
adjust for p-values. Categorical data were summarised as proportions and 
compared using the χ2 or Fisher’s exact tests. All statistical tests were two-sided 
at α value of 0.05 (p<0.05*, p<0.01**, p<0.001***, p<0.0001****) and all 





4.3. Results  
 
4.3.1. Demographic characteristics of the population 
A total of 76 healthy and asymptomatic individuals were recruited into this study, 
with 31 (41.3%) being HIV-uninfected, 29 (38.6%) HIV-infected and on short-term 
ART and 16 (21.3%) HIV-infected and on long-term ART. Only 2/29 recruited in the 
HIV-infected on short-term ART, were ART naïve. All participants had not received 
any form of pneumococcal vaccine, were negative for both influenza-like illness 
and influenza infection. The demographic and baseline laboratory data for the 
study participants are shown in Table 4.2. 
 














(22 – 41) 
31.5  
(27.0 – 38.3) 
41.0 
(38.5 – 46.5) 
0.021 
Gender 
(Female) n (%) 














plasma HIV viral RNA  
n/a 10 (37.0)  12 (75.0) 0.0268* 












8 (25.8) 8 (27.6) 1 (6.25) 0.2210 
 
Analysis were done c2- test* for gender but the rest of the analysis was done using Kruskal-Wallis. 
Abbreviations: ART – antiretroviral therapy, BAL – bronchoalveolar lavage, CD – cluster of 
differentiation, IQR – interquartile range. **Limit of plasma viral load (log10) <2.42 copies/ml. 
 
The HIV-infected on long-term ART were the oldest of the 3 groups and this was 
significant when compared with the HIV-uninfected (p=0.0010) and HIV-infected 
on short-term ART (p=0.0032). Only the HIV-infected on short-term ART had 
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lower CD4+ counts when compared to the other 2 groups and this was 
considerable different with the HIV-uninfected individuals (p=0.0008). Plasma HIV 
viral load was undetectable in 22/43 (51.2%) of the treated HIV-infected 
individuals on ART, with 75% of HIV-infected on long-term having undetectable 
viral loads. The median bronchoalveolar lavage fluid volume collected from all 
participants were similar (p>0.05) amongst all the three groups. The proportions 
of pneumococcal carriage were similar between the 3 groups (p>0.05). 
 
4.3.2. Proportions of AMs and neutrophils are preserved during 
short-term and long-term ART.  
I sought to investigate the proportional distribution of AMs and neutrophils in the 
airway and the impact of HIV and ART on the proportions. Bronchoalveolar lavage 
cells collected from asymptomatic HIV-uninfected, HIV-infected on short-term 
ART, HIV-infected on long-term ART individuals were stained with fluorochrome-
conjugated antibodies and phenotyped using flow cytometry. AMs were the most 
abundant phagocytes in airway (AMs vs neutrophils; median (interquartile range), 
92.12% [IQR; 88.92 – 95.67] vs. 0.58% [0.18 – 1.85], p<0.0001). Furthermore, I 
compared the proportions of AMs between the 3 groups. I found no significant 
difference in the proportion of AMs in the HIV-uninfected compared HIV-infected 
adults on short-term (92.12% vs. 94.74%; p>0.05) or long-term ART (92.12% vs. 
90.26%; p>0.05) (Figure 4.3.2). Similarly, there was no significant difference in the 
proportion of neutrophils in HIV-uninfected adults compared HIV-infected adults 
on short-term (0.86% vs. 0.49%; p>0.05) or long-term ART (0.86% vs. 0.70%; 
p>0.05) (Figure 4.2). Taken together these findings show that the proportions of 





Proportions of AMs and neutrophils in airway fluid 
 
Figure 4.2. Proportions of AM and neutrophils in BAL fluid collected from asymptomatic HIV-
uninfected, HIV-infected on ART <3-months, HIV-infected ART>3-years individuals. Proportion of 
AMs, and neutrophils. Bars represent median and interquartile range. All analyses were done 
using Kruskal Wallis and Dunn Test; p>0.05. HIV-uninfected (n=27), HIV-infected on ART <3-
months (n=17), HIV-infected ART>3-years (n=12 individuals). Abbreviations: AMs – alveolar 









































4.3.3. Alveolar macrophages exhibit an increased pneumococcal-
ST3 association with an increase in multiplicity of infection. 
Having observed preserved proportions of AM and neutrophils in airway, even 
following ART initiation, I then measured the frequency of AMs associated with 
pneumococcal-ST3 following ex vivo infection with fluorescent-labelled bacteria. 
Human airway cells obtained from asymptomatic HIV-uninfected, HIV-infected on 
ART <3-months (short-term), HIV-infected ART>3-years (long-term) individuals 
were infected ex vivo with opsonised IgG CMTPX stained pneumococcal -ST3 at 
MOI 10 and MOI 50. An MOI 50 was associated with an increased AMs-
pneumococcal binding/internalisation in all the 3 groups from baseline (MOI 10), 
median increase in HIV-uninfected (4.03-fold increase, n=27, p<0.0001); short-
term ART (4.38-fold increase, n=17,  p<0.0001); long-term ART (4.39-fold 
increase, n=12, p=0.0005) Figure 4.3. These results show a dose-dependent 
increase in the number of AMs associated with pneumococci following ex vivo 
infection. 
 











































































Figure 4.3. Frequency of AMs associated with  pneumococcal-ST3  post ex vivo infection; 
asymptomatic HIV-uninfected (n=27), HIV-infected on ART <3months (n=17), HIV-infected ART>3-
years (n=12) by Wilcoxon signed-rank test, **** p<0.0001, ***p=0.0005. Opsonised 
pneumococcal-ST3 bacteria at a multiplicity of infection 10 and 50 were used in all experiments. 
Abbreviations: AMs – alveolar macrophages, ART – antiretroviral therapy, HIV – Human 
immunodeficiency virus, ST3 –serotype 3.  
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4.3.4. Defining the contribution of lymphocytes to the binding/ 
internalisation of pneumococci by AMs during first hour of 
infection. 
 
I further investigated the influence of lymphocytes on the binding and 
internalisation of pneumococci by AMs within the first 1-hour of infection. Airway 
cells from HIV-uninfected individuals were rested for 2-hours to allow the AMs to 
adhere to the 12 well plate. Non adherent cells were removed and sorted on the 
BD FACSAria™ III, to deplete the number of lymphocytes in the non-adherent 
fraction. Controls (lymphocyte replete fraction) were not passed through the 
sorter. After sorting, the lymphocyte depleted fraction was centrifuged, 
supernatant decanted and combined with its cognate adherent cell well faction. 
The cells were further rested for 2-hours, before being infected with CMTPX 
stained opsonised pneumococci at MOI 50 for an hour. Post infection, the cells 
were harvested, phenotyped and acquired on the LSR Fortessa flow cytometer. 
Depleting the airway fraction of lymphocytes did not affect the binding and 
internalisation of pneumococci-ST3 by AMs at MOI 10 (median, IQR; 0.8303 
[0.5381 – 1.965] vs 0.9911 [0.5921 – 1.763], p>0.9999) and MOI 50 (median, IQR; 
1.576 [0.8933 – 5.083] vs 2.191[1.390 – 5.425], p=0.1250) as shown in Figure 4.4. 
These findings suggest that lymphocyte depletion did not impact AMs 
binding/internalisation of pneumococci. 
 










Figure 4.4. Contribution of lymphocytes to the binding of pneumococci by AMs. A. Flow plots 
comparing lymphocyte depleted and replete airway cells. B. Comparison of pneumococci-ST3 
binding by AMs from HIV-uninfected asymptomatic individuals (n=4), by Wilcoxon signed rank test 
























































Impact of lymphocytes on the binding of pneumococci to AMs 
at MOI 10 and MOI 50






4.3.5. Evidence of binding and internalisation of pneumococcal-
ST3 within alveolar cells post ex vivo infection. 
 
To confirm the binding and internalisation of pneumococcal-ST3 by airway 
phagocytic cells. Airway cells infected with opsonised CMTPX stained 
pneumococcal-ST3 at MOI 10 and 50 were imaged using confocal microscopy 
(samples from HIV-uninfected individuals). I observed low binding/internalisation 
at MOI 10 (Figure 4.5 A) and increased binding/internalisation at MOI 50 (Figure 
4.5 B) as demonstrated earlier using flow cytometry. At higher magnification, the 
images showed pneumococcal-ST3 binding to the airway cells (Figure 4.5 C) and 
also being internalised in others (Figure 4.5 D). These findings demonstrate that 
pneumococcal-ST3 binds and is also internalised by airway phagocytes following 
ex vivo infection. 













A-B. Representative single fluorescent field images demonstrating the association of alveolar cells 
(WGA – purple; DAPI – nucleus) with pneumococci-ST3 (bacteria – green) at MOI 10 and 50 (at 
magnification x63) respectively shown with the arrow (orange). C. Representative single 
fluorescent field of pneumococcal-ST3 at MOI 50 (at magnification x126) demonstrating 
pneumococci-ST3 (bacteria – green) binding to AMs (WGA – purple; DAPI – nucleus) shown with 
the arrow (orange). D. Representative single fluorescent field of pneumococci-ST3 at MOI 50 (at 
magnification x 252), with arrow demonstrating internalised pneumococci-ST3 (bacteria – green) 
within AMs (WGA – purple; DAPI – nucleus) show with the arrow (orange).  Abbreviations: DAPI – 





AMs are the predominant airway phagocytes associated with pneumococcal-ST3 
following ex vivo infection. 
To identify the airway phagocyte population that associates more with 
pneumococcal-ST3 following ex vivo infection. I compared the proportion of 
airway cells associated with pneumococcal-ST3 within the AMs population when 
compared to the neutrophil population, amongst the three study groups (Figure 
4.6). A higher proportion of AMs were associated with pneumococcal-ST3 when 
compared to neutrophils in all the study groups and this was statistically 
significant (p<0.0001). These data show that AMs were the predominant airway 




Figure 4.6. Proportions of airway phagocyte subsets associated with pneumococcal-ST3 ex vivo. 
Comparison of proportions of AMs and neutrophils associated with pneumococcus at MOI 10 post 
infection ex vivo in asymptomatic HIV-uninfected (n=24), HIV-infected on ART <3months (n=14), 
HIV-infected ART>3-years (n=11). Wilcoxon signed-rank test was used to compare the populations 
****p<0.0001. Abbreviations: AMs – alveolar macrophages, ART – antiretroviral therapy, HIV – 
























































Comparison of subsets - Proportions Ops MOI 10 (2 proportions) 






4.3.6. Neutrophils from HIV-infected adults on short-term ART 
exhibit increased binding to pneumococcal-ST3 compared 
to AMs following ex vivo infection. 
Next, I investigated the binding index between the two airway phagocyte subsets. 
The binding index represents the number of bound or internalised bacteria per 
individual cell. I observed no statistically significant differences in the binding 
index at lower MOI between AMs and neutrophils (MOI 10, p=0.3224), but 
statistically significant differences in binding index were observed at higher MOI 
between AMs and neutrophils (MOI, p=0.0319) amongst the HIV-uninfected 
individuals (Figure 4.7. A-B). In contrast, for the HIV-infected adults on short-term 
ART, the pneumococcal-ST3 binding index was significantly higher in neutrophils 
compared to AMs (MOI 10, p=0.0079; MOI 50, p=0.0037) (Figure 4.7. A-B). Lastly, 
when I compared the binding index between AMs and neutrophils amongst HIV-
infected adults on long-term ART, I found no statistically significant differences at 
lower and higher MOI (all p>0.05). These data show that neutrophils were equal 












































Comparison of subsets - MFI Ops 10 (2 subsets)







Figure 4.7.  Alveolar phagocyte subsets and pneumococcus binding index ex vivo at MOI 10 and 
50. A. Comparison of AMs and neutrophils pneumococcal binding index post ex vivo infection in 
asymptomatic HIV-uninfected (n=24), HIV-infected on ART<3-months (n=14), HIV-infected on 
ART>3-years (n=11) at MOI 10. B. Comparison of AMs and neutrophils pneumococcus binding 
index post ex vivo infection in asymptomatic HIV-uninfected (n=24), HIV-infected on ART<3-
months (n=14), HIV-infected on ART>3-years (n=11) at MOI 50. Kruskal-Wallis and Dunn multiple 
comparison test were done and *p<0.05. Abbreviations: AMs – alveolar macrophages, ART – 
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4.3.7. Proportions of AMs and neutrophils associated with 
pneumococcal-ST3 are not altered in HIV-infected adults 
during ART following ex vivo infection. 
Having demonstrated that pneumococcal-ST3 associates with alveolar phagocyte 
either by binding or internalisation, I next investigated whether alveolar 
phagocytes interaction with pneumococcal-ST3 was altered in HIV-infected adults 
on ART. I compared the proportion of AMs or neutrophils associated with 
pneumococcal-ST3 in HIV-uninfected compared to HIV-infected adults on short-
term ART or long-term ART. There were no statistically significant differences in 
the proportion of AMs associated with pneumococcal-ST3 in HIV-uninfected 
compared to HIV-infected adults on short-term ART or long-term ART at lower or 
higher MOI (MOI 10, p=0.7036; MOI 50 p=0.7157) (Figure 4.8 A-B). Similarly, 
there were no statistically significant differences in the proportion of neutrophils 
associated with pneumococcal-ST3 in HIV-uninfected compared to HIV-infected 
adults on short-term ART or long-term ART at lower or higher MOI (MOI 10, 
p=0.5758; MOI 50, p=0.7998) (Figure 4.8). These findings demonstrate that the 
proportion of AMs or neutrophils associated with pneumococcal-ST3 following ex 


























Figure 4.8. Proportions of alveolar phagocyte subsets associated with pneumococcal-ST3 ex vivo. 
A. Proportion of AMs and neutrophils associated with opsonised pneumococcal-ST3 at MOI 10 
post ex vivo infection in asymptomatic HIV-uninfected (n=27), HIV-infected on ART <3-months 
(n=17), HIV-infected ART>3-years (n=12). B. Proportion of AMs and neutrophils associated with 











































































































































(n=27), HIV-infected on ART <3-months (n=17), HIV-infected ART>3-years (n=12). Boxplots 
represent the median (centre line) and interquartile range (box), minima and maxima (whiskers). 
Kruskal-Wallis and Dunn multiple comparison test were done and p>0.05 in all analysis done. 
Abbreviations: AMs – alveolar macrophages, ART – antiretroviral therapy, MOI – multiplicity of 





4.3.8. Neutrophils from HIV-infected adults on short-term ART 
exhibit increased binding to pneumococcal-ST3 following ex 
vivo infection. 
Lastly, I compared the pneumococcal-ST3 binding index of AMs or neutrophils 
amongst the 3 groups, to observe if it was altered in HIV-infected adults on ART. 
The AMs binding index was not significantly different between HIV-uninfected and 
HIV-infected adults on long-term ART at lower MOI and higher MOI (all p>0.05) as 
shown in Figure 4.9. In contrast, statistically significant differences in binding 
indices were observed at a lower MOI (MOI 10; 1.77-fold increase, p=0.0378) 
between HIV-infected adults on short-term ART compared to HIV-uninfected 
individuals (see Figure 4.9 A). At a higher MOI, there were no statistically 
significant differences in the neutrophil binding index between HIV-uninfected 
and HIV-infected adults on short-term or long-term ART (p>0.05). These findings 































































Figure 4.9. Alveolar phagocyte subsets and pneumococci-ST3 binding index ex vivo at MOI 10 and 
50. A. Comparison of alveolar phagocyte subset pneumococcal-ST3 binding index at MOI 10. B. 
Comparison of alveolar phagocyte subset pneumococci-ST3 binding index at MOI 50. Boxplots 
represent the median (centre line) and interquartile range (box), minima and maxima (whiskers). 
Asymptomatic HIV-uninfected (n=24), HIV-infected on ART <3months (n=14), HIV-infected ART>3-
years (n=11). Kruskal-Wallis and Dunn multiple comparison test were done and *p<0.05, 
*p=0.0258. Abbreviations: AMs – alveolar macrophages, ART – antiretroviral therapy, HIV – 




























































4.4. Discussion  
In this study, using an ex vivo infection model of primary cells, I made several 
findings regarding the interaction of pneumococcal-ST3 and airway phagocytes. 
Firstly, I demonstrated that AMs are the principal phagocytic cell in the airway and 
the major cell associated with IgG-opsonised pneumococcal-ST3 following ex vivo 
infection. Secondly, AMs from HIV-infected adults on short-term or long-term ART 
do not exhibit impaired binding and internalisation of IgG-opsonised 
pneumococcal-ST3 with AM. Lastly, I demonstrated differentially enhanced 
binding of IgG-opsonised pneumococcal-ST3 to neutrophils, but not to alveolar 
macrophages, in HIV-infected adults on short-term ART.  
 
AMs are known to be critical in the control and clearance of pneumococci in the 
airway during early infection in mice models, with the efficacy of AMs mediated 
control being affected by the pneumococci inoculum size or prior respiratory viral 
infections (Bansal et al., 2018; Camberlein et al., 2015; Ghoneim et al., 2013; 
Knapp et al., 2003; Mitsi et al., 2019). Consistent with previous findings, AMs were 
the predominant (~90%) phagocytic cell population, while neutrophils were less 
abundant but consistently detectable in airway cells of asymptomatic adults 
(Jambo et al., 2014a; Mwale et al., 2018). AMs were the predominant airway 
phagocyte associated with binding and internalisation of pneumococcal-ST3 
following ex vivo infection likely due to their abundance in airway, but neutrophils 
were also able to bind and internalise pneumococci. Although neutrophils were 
present at significantly lower frequencies in the airway of asymptomatic adults, 
their ability to bind and internalise IgG opsonised pneumococcal-ST3 per cell was 
higher than AMs in HIV-infected adults on short-term ART. This trend was similar 
in the HIV-uninfected and HIV-infected on long-term ART. During active infection 
AMs trigger the induction of pro-inflammatory cytokines and chemokines, such as 
IL-8, at the site of infection resulting in neutrophil recruitment into the lung and 
causing their activation and degranulation (Domon et al., 2016; Jhelum et al., 
2018; Silva and Correia-Neves, 2012). This observed association of pneumococcal-
ST3 with AMs and neutrophils supports previous suggestions that these airway 
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phagocytes play a role in the immune response against pneumococcal lung 
infection in humans (Byrne et al., 2015; Camberlein et al., 2015; Gordon et al., 
2000).   
 
Untreated HIV infection is not associated with impaired AMs binding and 
internalisation of pneumococci (Gordon et al., 2001, 2013). This is consistent with 
observations in this study showing similar binding and internalisation of 
pneumococci by AMs between HIV-uninfected and HIV-infected adults on short-
term or long-term ART. This is in agreement with observations that AMs 
proportions are preserved during HIV infection as shown in this study and others 
(Hunegnaw et al., 2019; Jambo et al., 2014a). Unlike T cells, AMs are long-lived 
and are relatively resistant to the cytopathic effects of HIV (Boliar et al., 2019; 
Collini et al., 2018; Kumar and Herbein, 2014). These results suggest that similar 
to other AM-mediated processes, surface Fc receptors on AMs responsible for 
binding and internalisation IgG-opsonised pneumococci are likely less impacted by 
HIV infection in ART treated individuals. 
  
Interestingly, the pneumococcal-ST3 binding index on neutrophils was higher in 
the HIV-infected adults on short-term ART than in HIV-uninfected individuals. 
Enhanced binding and internalisation of neutrophils could be attributed to 
immune activation. Basal hyperactivation has been observed in peripheral blood 
neutrophils in HIV-infected individuals on ART (Campillo-Gimenez et al., 2014). 
Activation of neutrophils either by infection or inflammatory cytokines (TNF, IFN-
g or granulocyte colony stimulating factor) is known to drive an upregulation of Fc 
receptors (CD64 and CD32A) leading to an efficient binding of IgG-opsonised 
bacteria (Alemán et al., 2016; Guyre et al., 1990; Schiff et al., 1997; Wang and 
Jönsson, 2019). On the other hand, previous studies have shown that HIV impairs 
several functions of peripheral neutrophils including chemotaxis, down regulation 
of the FcgRIII/CD16, phagocytosis, bactericidal activity and oxidative burst 
(Campillo-Gimenez et al., 2014; Elbim et al., 1994; Heit et al., 2006; Lazzarin et al., 
1986). Whether the phagocytic and killing potentials of these tissue-associated 
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neutrophils is preserved or altered by HIV remains to be explored and warrants 
further investigation (Hensley-McBain and Klatt, 2018).  
 
This study had some limitations, the lungs are complex organs with various cells 
and antimicrobial proteins involved in the clearance of pneumococci. Current 
findings were only limited to AMs and neutrophils airway phagocytes and might 
not perfectly reflect the interaction of pneumococcus and alveolar phagocytes in 
vivo. Second, although these findings were exclusively based on experiments with 
S. pneumoniae-ST3 from the over 96 pneumococcal serotypes, but  
they are likely to have broad impact and important implications on other 
pneumococcus serotypes. Third, these findings are derived from a fairly young 
healthy adults, who are “not at high risk” of pneumococcal disease and might not 
reflect the changes in high risk groups such as elderly or children under the age of 
5 years, but have a broader impact on pneumococcal responses in treated HIV-
infected individuals. Lastly, it would have been ideal to include a population of 
ART-naïve HIV-infected adults, however due to the HIV Test and Treat policy, it 
was extremely challenging to recruit this group.  
 
4.5. Conclusion 
In conclusion, these findings suggest that AMs and neutrophils are not 
differentially impaired in their pneumococcal binding capacity in HIV-infected 
adults on short-term or long-term ART. Neutrophils were however associated 
with enhanced binding and internalisation capacity during short-term ART. The 
preserved S. pneumoniae binding and internalisation capacity of AM provides a 
potential cell to target for vaccine development or immunological boosting in the 
control of pneumococcus in the lung. Nonetheless, binding and internalisation is 
the first step in control against extracellular pathogens, the next step is 
intracellular killing of the internalised bacteria, and this could also be a potential 
step that could be impacted by HIV infection. In the next chapter, I will investigate 
AM-mediated intracellular killing of pneumococci and whether this is different in 
HIV-uninfected compared to HIV-infected adults on ART. 
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CHAPTER 5  
5.0. Alveolar macrophage intracellular killing and within cell survival of S. 
pneumoniae in asymptomatic adults residing in Malawi. 
 
5.1. Introduction  
HIV infection is known to infect and impair a variety of cell types including CD4+ T-
cells, dendritic cells, macrophages and monocytes, and it’s also known to affect 
bystander cells (Benichou and Bouchet, 2018; Boliar et al., 2019; Collins et al., 
2015; Doitsh and Greene, 2016; Richard et al., 2018; Wong et al., 2019). Evidence 
from asymptomatic HIV-infected individuals living in high transmission settings 
show that pneumococcal-specific antibodies and pneumococcal-specific CD4+ T 
cells are preserved in the airway (Collins et al., 2013; Eagan et al., 2007; Gordon et 
al., 2003; Jambo et al., 2011; Peno et al., 2018). Untreated HIV infection has been 
shown not to impair the binding and internalisation of S. pneumoniae by alveolar 
macrophages (AMs) (Gordon et al., 2001, 2013). I have shown in the previous 
chapter that AMs and neutrophils are not differentially impaired in their 
pneumococcal binding and internalisation capacity in HIV-infected adults on 
short-term or long-term ART (Chapter 4).    
 
AMs phagocytosis and clearance of S. pneumoniae from the lungs is enhanced by 
the opsonisation of bacteria by complement and antibody (Cole et al., 2014; 
Dockrell et al., 2003b; Gordon et al., 2000). Internalisation of opsonised S. 
pneumoniae facilitates intracellular killing bacterial (Aberdein et al., 2013; Collini 
et al., 2018). In murine models of pulmonary infection, AMs clear S. pneumoniae 
to a defined threshold without overt features of pneumonia but when AMs fail to 
control these subclinical infections this results in the recruitment of neutrophils 
and other inflammatory cells to aid in controlling the infection (Aberdein et al., 
2013; Dockrell et al., 2003b; Duan et al., 2012). On the other hand, uncontrolled 
inflammation in the lung results in the clinical syndrome of pneumonia, and this 
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highlights the role of AM-mediated killing threshold as an important factor in 
protection against pneumococcal pneumonia. 
 
In humans, HIV persists in the lung even during suppressive ART (Costiniuk et al., 
2018; Honeycutt et al., 2017). It has also been shown that HIV gp120 impairs the 
intracellular late killing of S. pneumoniae by AMs in HIV-infected adults on ART in 
a low pneumococcal transmission setting (Collini et al., 2018). It has been 
reported that S. pneumoniae is able to replicate within CD169+ metalophillic 
splenic macrophages, after an eclipse period from the blood (Ercoli et al., 2018). 
AMs express CD169 (Morrell et al., 2018) and have been shown to harbour 
pneumococci for months following human experimental challenge (Mitsi et al., 
2019). However, the extent to which HIV persistence impacts the AMs threshold 
of S. pneumoniae control in high pneumococcal transmission setting remains 
unclear. Furthermore, whether pneumococci evasion of AM intracellular killing is 
enhanced in HIV-infected adults on ART is still unclear. Therefore, I hypothesised 
that pneumococci evade AM intracellular killing leading to their intracellular 
survival, and this is exacerbated during HIV infection even following ART initiation.  
 
5.1.1. Research question 
Does S.  pneumoniae evade alveolar macrophage killing leading to their sustained 
intracellular survival, and is this exacerbated by HIV infection?   
 
5.1.2. Aims and Objectives 
 
Aim 
To determine whether HIV infection is associated with impaired AM killing of S. 











1. To determine the human AMs intracellular killing kinetics of internalised S. 
pneumoniae ex vivo in HIV-uninfected adults. 
2. To compare the human AMs intracellular killing kinetics of internalised S. 
pneumoniae between HIV-uninfected individuals and HIV-infected adults on 
short-term or long-term ART. 
3. To investigate the impact of active pneumococcal carriage on human AM 




This section covers some of the methods used in chapter 4 as the same group of 
participants were used though the analysis done was different. 
 
5.2.1. Study participants and design 
This was a comparative cross-sectional study of asymptomatic HIV uninfected, 
HIV-infected on ART<3-months and ART>3-years. Participants were recruited from 
the Malawi-Liverpool Wellcome-Trust’s (MLW) Clinical investigation unit at the 
Queen Elizabeth Hospital in Blantyre, Malawi. All participants completed a specific 
questionnaire relating to their previous clinical history and social demographic 
characteristics that could potentially impact their alveolar cell functional response 
ex vivo before recruitment. The recruitment criteria used has been discussed 
elsewhere (see Chapter 2.4). 
 
5.2.2. Ethical approval and study clearance 
The study received ethical approval from both College of Medicine Research 
Ethics Committee (COMREC), Malawi and Liverpool School of Tropical Medicine 
Research Ethics Committee (LSTMREC), United Kingdom and this together with 
the recruitment criteria used have previously been described (see Chapter 2.3). 
 
5.2.3. Sample collection and processing 
Bronchoalveolar lavage and per nasal swab samples were collected from all 
participants and transported to the MLW laboratories within 30-minutes of 
collection. Sample collection and processing have been described (see Chapter 2).  
 
5.2.4. Laboratory assays  
The laboratory assays associated with this chapter have been described in 
Chapter 2. In particular for specific details S. pneumoniae growth inhibition (2.6) 
and gentamicin protection assay (2.6); BAL processing and resting of cells (2.6.6), 
BAL ex vivo infections (2.6.9) and per nasal swab processing and S. pneumoniae 
identification (2.6.15), identification of intracellular S. pneumoniae through 
confocal microscopy (2.6).  
 
 134 
5.2.5. Statistical analysis  
Descriptive statistics were used to for continuous variables by calculating medians 
and interquartile ranges. Groups were compared using non-parametric tests 
(Wilcoxon rank sum or Wilcoxon signed-rank test, Kruskal Wallis tests) depending 
on the distribution. For multiple pairwise comparisons, the Dunn test was used. 
Categorical data were summarised as proportions and compared using the χ2 
tests. The relationship between within AMs pneumococci and extracellular 
pneumococci during the late killing phase was estimated using the Pearson 
correlation. All statistical tests were two-sided and were deemed statistically 
significant at an α value of 0.05 (p<0.05*, p<0.01**, p<0.001***, p<0.0001****) 




5.3.  Results  
5.3.1. Intracellular survival of S. pneumoniae in ex vivo infected 
alveolar macrophages from HIV-uninfected individuals. 
As earlier demonstrated in Chapter 4, AMs are the main phagocytic population 
associated with S. pneumoniae following ex vivo infection. I sought to investigate 
the human AMs intracellular killing kinetics of internalised S. pneumoniae in 
asymptomatic adults (n=31) following addition of gentamicin (100µg/ml), 1-hour 
post infection (the dose shown to kill extracellular pneumococci). As expected, I 
found a significant reduction of intracellular bacteria burden 3-hours post 
infection (1hr vs 2hrs post infection,  3267[IQR; 500 – 15644] vs 84 [IQR; 10 – 419] 
colony forming units (cfu)/ml, p<0.0001; 1hr vs 3hrs post infection, 3267 [IQR; 
500 – 15644] vs 10 [IQR; 10 – 83] cfu/ml, p<0.0001) (Figure 5.1 A). However, no 
significant difference was observed in intracellular bacteria counts between 2-
hours and 3-hours post infection (p>0.05). This demonstrates that AM-mediated 
intracellular killing of S. pneumoniae is rapid and happens predominantly within 
the first three hours following bacterial internalisation.  
 
It was observed that the 3hr time point was the “eclipse phase” with 61.2% 
(n=18) of the individuals having no microbiologically detectable S. pneumoniae 
within their AMs (limit of detection 33 cfu/ml). However, I observed an outgrowth 
of intracellular S. pneumoniae-ST3 bacteria in 41.9% (n=13) of the individuals 24-
hours post-infection. Individuals with S. pneumoniae present within their AMs 24-
hours post-infection, were termed “persisters” and those that completely cleared 
S. pneumoniae-ST3 within their AMs as “non persisters”. I then decided to 
investigate if the early killing kinetics represented by the area under the curve 
(AUC) for the time points (1 – 3hrs) could help in distinguishing between 
persisters and non-persisters. Persisters had a higher AUC value compared to the 
non-persisters (7339 [IQR; 2022 – 9696] vs. 972.5 [IQR; 146.8 – 2494], p=0.0118; 
Figure 5.1B), demonstrating that persisters tend to kill intracellular S. pneumoniae 
at a slower rate compared to the non-persisters. These findings demonstrate that 
slower early killing kinetics of intracellular S. pneumoniae in AMs is associated 
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with intracellular bacterial survival, which could render AM as potential reservoirs 




Figure 5.1. AMs S. pneumoniae-ST3 intracellular killing kinetics in HIV-uninfected individuals 
(n=31). A. Comparison of the reduction in AMs intracellular S. pneumoniae-ST3 overtime between 























































Differences between the early killing (AUC) of persisters and 






1-hour and 24-hours post infection; by Kruskal Wallis and Dunn multiple comparison test, 
****p<0.0001, ***p=0.0002. B. Comparison of the early killing kinetics of persisters and non-
persisters as demonstrated by the area under the curve (AUC), by Wilcoxon rank sum test, 
*p=0.0118. Abbreviations: AUC – area under the curve, cfu – colony forming units, SPN – S. 




5.3.2. Intracellular survival of S. pneumoniae in ex vivo infected 
alveolar macrophages of HIV-infected adults on short-term 
and long-term ART. 
 
To investigate the human AMs intracellular killing kinetics of internalised S. 
pneumoniae in asymptomatic HIV-infected adults on short-term and long-term 
ART. AMs were infected with S. pneumoniae-ST3 and then exposed to gentamicin 
(100µg/ml) 1-hour post infection as above. Among short-term ART participants, I 
found a significant reduction of intracellular bacteria burden 3-hours post 
infection, (1hr vs 2hrs post infection, [3039 (IQR; 1862 – 20622) vs 10 (IQR; 10 – 
100.5) cfu/ml, p<0.0001; 1hr vs 3hrs post infection 10 [IQR; 10 – 2400] cfu/ml, 
p<0.0001, Figure 5.2A). However, no difference was observed in intracellular 
bacteria counts between 2-hrs and 3-hrs post infection (p>0.05). Between 2-hours 
and 3-hours post infection, 67% and 86% of the individuals did not have any 
microbiologically detectable S. pneumoniae within their AMs, respectively. In 
those on long-term ART, I observed a significant reduction intracellular bacterial 
burden 3hrs post infection, (1hr vs 2hrs post infection, 1677 [IQR; 133 – 7200] vs 
10 [IQR; 10 – 62.25] cfu/ml, p<0.0214; 1hr vs 3hrs post infection, 1677 [IQR; 133 – 
7200] vs. 10 [IQR; 10 – 10] cfu/ml, p=0.0050; Figure 5.2B). Between 2hrs and 3hrs, 
I did not observe any significant differences in viable intracellular S. pneumoniae 
load post infection. At 2hrs and 3hrs post infection, 70% and 100% of the 
individuals had no microbiologically detectable S. pneumoniae within their AMs, 
respectively.  
 
Furthermore, similar to earlier observations of persisters within the HIV-
uninfected group, I also observed an outgrowth of intracellular S. pneumoniae-
ST3 bacteria, in 43% (n=9) of AMs from individuals on short-term ART, and 30% 
(n=3) in individuals on long-term ART, 24-hrs post-infection. I further compared 
the early killing kinetics (AUC) for the time points (1-hr – 3-hrs) between the 
persisters and non-persisters. In contrast to the HIV-uninfected group, I did not 
observe any difference between the early killing kinetics of persisters and non-
persisters during short-term ART (2230 [IQR; 785.3 – 60528] vs 1491 [IQR; 880.5 – 
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9392], p=0.4639) or long term ART (2429 [IQR; 1112 – 6952] vs 1062 [IQR; 528.5 – 
2624], p=0.2667) see Figure 5.2 C. Taken together, these findings demonstrate 
that survival of S. pneumoniae within AMs 24-hours post infection is a common 




























































Figure 5.2. AMs S. pneumoniae-ST3 intracellular killing kinetics in HIV-infected individuals on short-
term and long-term ART. A. Comparison of the reduction in AMs intracellular S. pneumoniae-ST3 
overtime between 1-hour and 24-hours post infection in HIV-infected adults on short-term ART; 
by Kruskal Wallis and Dunn multiple comparison test, ****p<0.0001, ***p=0.0002 (n=21). B. 
Comparison of the reduction in AMs intracellular S. pneumoniae-ST3 overtime between 1-hour 
and 24-hours post infection in HIV-infected adults on long term ART; by Kruskal Wallis and Dunn 
multiple comparison test, **p=0.0030, **p=0.0050, *p=0.0214, *p=0.017 (n=10). C. Comparison 
of the early killing kinetics of persisters and non-persisters as demonstrated by the area under the 
curve (AUC) in HIV-infected adults on ART< 3-months and HIV-infected adults on ART>3-years, by 
Wilcoxon rank sum test, p>0.05. Abbreviations: AMs – alveolar macrophages, AUC – area under 








































Differences between the early killing (AUC) of persisters and 
non-persister - HIV on ART>3-years
HIV+ ART<3-months HIV+ ART>3-yearsC. 
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5.3.3. Early or long-term ART is not associated with impaired early 
intracellular AMs killing of S. pneumoniae. 
To determine whether HIV-infected individuals on short-term or long-term ART 
exhibit altered killing of intracellular S. pneumoniae within AMs, I compared the 
microbiologically viable intracellular S. pneumoniae between the 3 groups (n=62) 
at each time point. Analyses of intracellular S. pneumoniae bacteria load at 1hr, 
2hrs and 24hrs post infection showed no statistically significant difference among 
the three participant groups (all p>0.05). However, during the eclipse phase 
(Figure 5.3. A – B), the intracellular killing burden of S. pneumoniae was 
significantly different between the 3 groups (Kruskal-Wallis p=0.0332), with a 
marginal difference observed in the intracellular bacterial burden (3hrs post 
infection) between the HIV-uninfected adults and the HIV-infected individuals on 
long-term ART (10 [IQR, 10 – 83] vs 10 [10 – 10] cfu/ml; p=0.0530).  
 
Next, I compared the early AM mediated killing kinetics amongst the three groups 
as measured by the AUC (1hr – 3hrs post infection). There was no statistically 
significant difference in the early killing kinetics amongst the three study groups 
(p>0.05). Even after pooling the groups of HIV-infected individuals on ART 
together, there was still no statistically significant differences in AMs-mediated 
early killing kinetics between HIV-uninfected adults and the ART group, (AUC: 
1552 [IQR, 935 – 9536] vs 2058 [IQR, 294 – 7906]; p=0.6515, see figure 5.3 D). 
These findings show that AMs from individuals on short-term or long-term ART kill 
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Figure 5.3. Comparison of intracellular bacterial killing between HIV-uninfected adults and HIV-
infected individuals on ART. A-B. Comparison of intracellular bacterial load killing between HIV-
negative, HIV-infected on ART<3-months and ART>3months (1hr, 2hrs, 3hrs, 24hrs post infection), 
HIV-uninfected (n=31), HIV-infected individuals ART<3-months (n=21), HIV-infected individuals 
ART>3years (n=10); analysis by Kruskal Wallis and Dunn multiple comparison test, *p<0.0332. B. A 










































































between the 3 groups (HIV-uninfected (n=31), HIV-infected individuals ART<3-months (n=21), HIV-
infected individuals ART>3years (n=10); analysis by Kruskal Wallis and Dunn multiple comparison 
test, p>0.05. C. A comparison of early intracellular bacterial killing kinetics represented by the area 
under the curve between the HIV-uninfected (n=31) and HIV-infected on ART individuals (n=31), 
(ART<3-months and ART>3-years, n=31); analysis by Kruskal Wallis and Dunn multiple comparison 
test, p>0.05. Abbreviations: AMs – alveolar macrophages, ART – antiretroviral therapy, AUC – area 
under the curve, cfu – colony forming units, GPA – gentamicin protection assay, HIV – Human 





5.3.4. Treated HIV infection associated with a higher propensity of 
intracellular S. pneumoniae persistence within AMs ex vivo. 
I next investigated the proportion of persisters within AMs between HIV-
uninfected individuals and HIV-infected individuals on ART (n=60). When I 
compared the proportions of persisters (3hrs: 24hrs post infection), I observed 
higher proportion of persisters within the AMs from HIV-infected on short-term 
ART (2.60-fold increase, p=0.0107) and HIV-infected on long-term ART (22.42-fold 
increase, p<0.0001) when compared to the HIV-negative individuals (Figure 5.4 
A). Furthermore, the HIV-infected on long-term ART also had higher proportion of 
persisters within the AMs compared to the HIV-infected on short-term ART 
(11.22-fold increase, p=0.0017). Lastly, I looked at the combined effect of treated 
HIV infection on the presence of persisters 24-hrs post infection. Treated HIV-
infected individuals had higher proportions of intracellular S. pneumoniae 
persistence of 24-hours post infection (2.82-fold increase, p=0.0206) compared to 
their HIV-uninfected counterparts see Figure 5.4 B. These findings demonstrate 
that HIV-infected individuals on ART have reduced late intracellular S. pneumoniae 
killing capacity within AMs and an increased intracellular persistence of S. 


























Figure 5.4. HIV and ART is associated with a higher propensity of the persister phenotype during 
the late killing phase. A. A comparison of the proportion of individuals with the persister 
phenotype stratified by HIV and ART status between the early killing phase (3-hrs post infection) 
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ART<3-months (n=21), HIV-infected individuals ART>3years (n=10); analyses by c2- test, 
****p<0.0001. B. Impact of HIV on the proportion of persisters (HIV-infected on ART<3-months 
and HIV-infected on ART>3-years combined, n=31; HIV-uninfected n=24); analyses by c2- test, 






5.3.5. Pneumococcal nasal carriage is not associated with an 
enhanced AMs early intracellular killing propensity ex vivo. 
It was recently shown in an experimental human pneumococcal challenge (EHPC) 
model that previous S. pneumoniae carriage (29 – 120 days post carriage) is 
associated with a heightened AMs uptake and responsiveness, attributed to 
trained immunity (Mitsi et al., 2019). With this in mind, I decided to investigate 
the impact of contemporaneous S. pneumoniae natural nasopharyngeal carriage 
on AMs mediated intracellular killing of S. pneumoniae-ST3. First, I explored the 
impact of S. pneumoniae natural nasopharyngeal carriage on time dependent 
killing in HIV uninfected, HIV-infected on ART<3-months and the HIV-infected on 
ART>3-years (Figure 5.5 A-C). I observed no difference between the S. 
pneumoniae carriage positive and carriage negative individuals in within 
intracellular killing capacity of AMs at all the time points (1hr, 2hrs, 3hrs and 24hrs 
post infection; all p>0.05). I further investigated whether S. pneumoniae carriage 
had an impact on the within early intracellular killing kinetics and we found no 
difference between the carriage positive and negative individuals (p>0.05, Figure 
5.5 D). These findings report comparable AMs mediated intracellular killing 
kinetics between individuals with contemporaneous S. pneumoniae carriage 
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Impact of concurrent carriage on AMs mediated intracellular killing of S. 
pneumoniae in HIV-uninfected individuals 
 
 
Impact of concurrent carriage on early killing kinetics (AUC)  
 
Figure 5.5. Impact of pneumococcal carriage on AMs mediated intracellular killing activity. A. A 
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in HIV-uninfected individuals (n=31) at time points 1-hour, 2-hours, 3-hours and 24-hours post 
infection; by Wilcoxon rank sum test, p>0.05. B. A comparison of the impact of carriage on AMs 
mediated intracellular killing activity in HIV-infected individuals on ART<3months (n=21) at time 
points 1-hour, 2-hours, 3-hours and 24-hours post infection; by Wilcoxon rank sum test, p>0.05. C. 
A comparison of the impact of carriage on AMs mediated intracellular killing activity in HIV-
infected individuals on ART>3 years (n=10) at time points 1-hour, 2-hours, 3-hours and 24-hours 
post infection; by Wilcoxon rank sum test, p>0.05. D. A comparison of the impact of carriage on 
the early killing phase represented by the area under the curve (AUC) between HIV-uninfected 
individuals (n=31), HIV-infected individuals on ART<3-months (n=21) and HIV-infected individuals 
on ART>3 years (n=10); by Wilcoxon rank sum test, p>0.05. Abbreviations: AMs – alveolar 
macrophages, ART – antiretroviral therapy, AUC – area under the curve, HIV – HIV – Human 





5.3.6. The persister phenomenon and S. pneumoniae-ST3 survival 
can be detected using both microbiological and confocal 
microscopy analyses. 
 To further investigate the persister phenomenon and the presence of within AMs 
S. pneumoniae during the late killing phase using the gentamycin protection 
assay,  AMs infected with opsonised S. pneumoniae-ST3, 3hrs and 24hrs post-
infection were stained and imaged using confocal microscopy from a total of 14 
individuals and data compared with microbiological analyses. As observed via 
microbiological culture, microscopy confirmed that not all AMs had cleared their 
intracellular S. pneumoniae-ST3 (Figure 5.6 A and B). Using confocal microscopy, 
S. pneumoniae was detected in 50% (n=7/14) of the individuals, with 35.7% 
(n=5/14) having intracellular or extracellular bacteria detected (Table 5.1). Only 
1/14 individuals had S. pneumoniae on the surface and associated with AMs. 
Whereas, 57.1% (8/14) had viable culturable S. pneumoniae as detected by 
microbiological techniques, with 35.7% (n=5/14) having intracellular pneumococci 
and 50% (n=7/14) of the individuals having extracellular bacteria burden. These 
findings demonstrate that both confocal and microbiological analyses are able to 
demonstrate the presence of within AMs, extracellular bacteria and bacteria 
















Figure 5.6. Evidence of S. pneumoniae internalisation and survival within alveolar macrophage ex 
vivo. A Representative single fluorescent field image demonstrating the clearance of S. 




nucleus) with S. pneumoniae (bacteria capsule– green), arrow (red) indicates AMs that cleared S. 
pneumoniae. B. Representative single fluorescent field image demonstrating the presence, 
internalisation and survival of S. pneumoniae-ST3 within AMs 24-hours post gentamicin 
application; AMs (WGA – purple; DAPI – nucleus) with S. pneumoniae (bacteria – green), arrow 
(orange) S. pneumoniae within AMs, arrow (red) indicates AMs that cleared S. pneumoniae. 




Table 5.1. S. pneumoniae association with AMs as detected by microbiological and culture confocal microscopy*. 
 
ID Time point post 
infection 
Quantitative microbiology count Average AMs 
counted 
S. pneumoniae associated bacteria by confocal microscopy 
Intracellular Extracellular Surface Intracellular Extracellular 
PN1045S T3 0 0 100 0 0 0 
PN10990 T3 0 0 100 0 0 0 
PN10990 T24 0 8.53x103 30 0 10 5 
PN10958 T24 0 2.34x105 200 0 10 0 
PN1077C T24 33 5.58x105 100 1 0 0 
PN10878 T24 5.42x103 1.53x107 100 0 8 4 
PN1033X T24 1.02x105 4.92x106 200 0 2 15 
PN1044U T24 217 1.50x106  200 0 4 6 
PN1054Q T24 0 0 200 0 0 2 
PN1074L T24 0 0 200 0 0 0 
PN10470 T24 0 0 200 0 0 0 
PN10305 T24 33 0 200 0 0 0 
PN10894 T24 0 1.93x105 200 0 0 0 
PN1072M T24 0 0 200 0 0 0 
PN10295 T24 0 0 200 0 0 0 
 






5.3.7. The S. pneumoniae-ST3 persister phenomenon is associated with CD206+ 
alveolar macrophages 24-hours post infection. 
I further used confocal microscopy to visualise the location of S. pneumoniae-ST3 
within AMs, quantitate the bacteria and confirm the phenotype of AMs associated 
with the persister phenomenon ex vivo. Cytospin slides of AMs infected with S. 
pneumoniae-ST3 (24hrs post-infection) were stained with anti-CD206, DAPI, 
wheat germ hemagglutinin and FITC (bacteria) to identify AMs harbouring any S. 
pneumoniae. S. pneumoniae was observed within CD206+ AMs internalised is 
shown in Figure 5.7. This data confirms that CD206+ AM were the phagocytes 



















Figure 5.7. 3D reconstruction of deconvolved Z-stack images demonstrating evidence of the 






24-hrs post infection ex vivo infection. A-D Representative 3D Z-stack images on different planes 
demonstrating the internalised S. pneumoniae-ST3 within CD206+ alveolar macrophages (WGA; 
cell membranes – purple; DAPI – nucleus, red – monoclonal anti-CD206) with S. pneumoniae-ST3 
(bacteria capsule, FITC– green). Abbreviations: CD – Cluster of differentiation, DAPI - 4ʹ,6-
diamidino-2-phenylindole, FITC - Fluorescein isothiocyanate, S. pneumoniae-ST3 – S. pneumoniae 





5.3.8. AMs serve as a reservoir for extracellular S. pneumoniae 
within the supernatants detected in some individuals during 
the late killing phase ex vivo. 
Following the observation of S. pneumoniae persistence within AMs, I investigated 
whether AMs were acting as reservoirs for extracellular S. pneumoniae within the 
supernatants. I cultured the supernatants 3hrs and 24hrs post-infection for S. 
pneumoniae. Only individuals with paired samples were included in this analysis 
(n=14) (see Figure 5.8 A). I found higher extracellular burden of S. pneumoniae 24-
hrs post infection 188.5 (IQR; 10 – 722 134) compared to 3-hrs post infection 10 
(10 – 15.75; p=0.0156). Furthermore, I found a moderate strong positive 
correlation between presence of intracellular S. pneumoniae and extracellular S. 
pneumoniae during the late killing phase [r=0.6433 (95% confidence interval, 
0.3850 – 0.8081); p<0.0001] (see Figure 5.8 B). These findings demonstrate that 
during the late killing phase (24hrs post-infection) survival of intracellular bacteria 
in AMs could serve as a reservoir to propagate pneumococcal infection. 
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Figure 5.8. Relationship between within AMs pneumococci and extracellular pneumococci during 
the late killing phase ex vivo. A. Differential pneumococcal extracellular burden during the early 
killing (3hours post infection) and late killing phase (24hours post infection) n=14; by Wilcoxon 
signed rank test, *p=0.0156. B. A positive correlation between within AMs pneumococci and 
extracellular pneumococci (n=33) during the late killing phase (24hours post infection) ex vivo; by 
Pearson correlation test (r) and linear regression line shown; r=0.6433, p<0.0001. Abbreviations: 






































5.4. Discussion  
 
HIV-infected individuals are at an increased risk (at least 25-fold) of pneumococcal 
pneumonia compared to the general population (Cilloniz et al., 2014; Segal et al., 
2011). The success of S. pneumoniae to cause disease in the lung depends on its 
ability to evade the lung chief resident phagocytic cell, the alveolar macrophages 
(AMs), consequently inducing inflammation whilst facilitating its spread and 
replication within the lung (Aberdein et al., 2013). In this study, I developed a 
gentamycin protection assay for understanding the early AMs-mediated 
intracellular control of pneumococcus. First, I demonstrated using microbiological 
methods and confocal microscopy that pneumococci persist in CD206+AMs 24hrs 
post-infection. Second, slow early killing kinetics of intracellular bacteria within 
the first 3hrs post-infection in HIV-uninfected adults but not HIV-infected 
individuals on ART are associated with increased propensity for bacterial 
persistence in CD206+AMs 24hrs post-infection. Third, treated HIV infection is 
associated with a reduced AMs-mediated intracellular killing capacity of S. 
pneumoniae during the late killing phase (24-hours post infection) leading to a 
higher propensity of intracellular S. pneumoniae persistence. Fourth, there was a 
direct correlation between presence of intracellular S. pneumoniae and 
extracellular S. pneumoniae during the late killing phase. Lastly, I did not find 
evidence to demonstrate that natural S. pneumoniae carriage augments AMs-
mediated intracellular killing kinetics, as observed in the experimental human 
pneumococcal challenge model.  
 
The early control mechanisms for pneumococcal infection within the lung 
depends on both the innate and adaptive immune responses (Wilson et al., 2015). 
Understanding the host-microbial interactions in humans is crucial in order to 
decipher the early events of pneumococcal control. It has recently been described 
in murine and porcine models that CD169+ splenic macrophages can harbour S. 
pneumoniae and provide a site for intracellular replication with which after a S. 
pneumoniae eclipse phase in the blood, CD169+ macrophages reseeds S. 
 
 160 
pneumoniae into the blood to cause septicaemia (Ercoli et al., 2018). Consistent, 
with this observation, I found that that pneumococci exhibit an eclipse phase and 
persist within CD206+ AMs 24hrs post-infection ex vivo, resulting in continued 
propagation of infection. This potentially serves as the S. pneumoniae invasion 
strategy into the lung parenchyma in susceptible individuals. Furthermore, 
recently it was discovered that pneumolysin (a cholesterol binding and pore 
forming toxin found on S. pneumoniae) dampens inflammatory cytokine 
responses by upregulating cytokine suppressor-1 (SOCS1), thereby facilitating 
lysosomal escape of S. pneumoniae in macrophages and dendritic cells by directly 
binding to the mannose receptor (CD206+), thus promoting intracellular residency 
of S. pneumoniae (Subramanian et al., 2019). In another study it was shown that 
CD206+ influences S. pneumoniae uptake and internalization in Schwann cells 
found in the peripheral nervous system (Macedo-Ramos et al., 2014). CD206+ is a 
transmembrane glycoprotein and an endocytic receptor found abundantly 
expressed on AMs, responsible for binding mannose, fucose and 
acetylglucosamine including the present on pathogens (Byrne et al., 2016; 
Macedo-Ramos et al., 2014; Martinez-Pomares, 2012; Misharin et al., 2013; Varki, 
2011). The binding of pneumolysin to the CD206+ on the AM potentially gives 
insight to the persister phenomenon found in both HIV-uninfected and HIV-
infected on ART individuals, however, this warrants further investigation.  
 
Previously, it was shown that the efficient control of S. pneumoniae by AMs is 
dependent on IgG antibodies and HIV-infection does not impair the binding and 
internalisation of S. pneumoniae by AMs ex vivo (Gordon et al., 2000, 2001). 
However, recent evidence suggest that the HIV envelope glycoprotein (gp120) 
inhibits the mitochondrial-ROS (mROS) dependent killing in monocyte-derived-
macrophages (MDM) and with a reduction in apoptosis-associated S. pneumoniae 
killing in ART-treated individuals (Collini et al., 2018). Consistent with previous 
findings (Collini et al., 2018), in this study I show that treated HIV infection is 
associated with a reduced AMs-mediated intracellular killing capacity of S. 
pneumoniae during the late killing phase (24-hours post infection), leading to a 
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higher propensity of intracellular S. pneumoniae persistence. In MDMs, HIV 
reduces caspase-dependent induction of mROS thereby facilitating survival of 
internalised S. pneumoniae (Collini et al., 2018). Furthermore, upregulation of the 
anti-apoptotic protein, the myeloid cell leukaemia 1 gene (mcl-1) a regulator for 
apoptosis, has been demonstrated to interfere with the late microbiocidal killing 
mechanism of AMs and is upregulated particularly in individuals with HIV or the 
chronic obstructive pulmonary disease (COPD) (Bewley et al., 2017; Collini et al., 
2018; Preston et al., 2019). In mice models, lack of programmed death cell 
protein-1 (PD-1) expression is linked to significant protection against subsequent 
lethal pneumococcal challenge (McKay et al., 2015b). In a Simian 
immunodeficiency virus (SIV) rhesus macaque model, SIV infection is associated 
with increased (PD-1) expression in AMs (Hunegnaw et al., 2019). It is therefore 
plausible that HIV-mediated alterations of mROS and PD-1 expression could result 
in poor intracellular killing of pneumococci in human AMs. Persistence of 
pneumococci in AM is extremely important, as I further show that it results in 
AMs serving as reservoirs for extracellular S. pneumoniae. Survival of S. 
pneumoniae within the extracellular environment is propagated in an 
environment with high nutrients thus, bacteria can rapidly replicate to overcome 
AMs-mediated immune responses, resulting in neutrophil and inflammatory 
monocyte infiltration in the airway (Aberdein et al., 2013; Quinton et al., 2018). 
These processes could lead to an uncontrollable inflammation, which can cascade 
into pneumococcal pneumonia disease. 
 
Previous nasal S. pneumoniae carriage was found to be associated with an 
heightened AMs responsiveness to bacterial pathogens including S. pneumoniae 
in the controlled human challenge model (Mitsi et al., 2019). Contrary to the 
earlier findings, contemporaneous S. pneumoniae natural carriage did not 
augment AMs-mediated intracellular killing kinetics and similar kinetics were 
observed in carriage negative individuals. This could be due to serotype 
differences; as I used serotype 3 which is an invasive strain whilst the EHPC used 
serotype 6B a carriage strain, hence their virulence and evasion capability might 
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be different. Furthermore, there was more serotype diversity amongst 
participants in my study as a result of natural carriage, whilst in the EHPC, the 
challenge serotype is the same as the laboratory experimental serotype (6B). 
Moreover, the differences observed could be due to the fact that this study 
investigated the effects of contemporaneous S. pneumoniae carriage as opposed 
to the effects of trained immunity as investigated in the EHPC model (Mitsi et al., 
2019).The study setting is a high pneumococcal transmission setting, hence the 
impact of natural carriage on AMs-mediated immunity could be difficult to 
ascertain due to the lack of knowledge on the day of carriage acquisition and 
duration of carriage amongst the participants. These findings potentially point 
towards altered tolerance as a result of natural carriage and through repeated 
carriage exposure, though this needs to be further ascertained with a follow up 
longitudinal study.  
 
The main limitation of this study, is the failure to include lysosomal associated 
membrane protein-1 (LAMP-1) or CD107a, a reading for lysosomal acidification 
(Gordon et al., 2001), to demonstrate whether the S. pneumoniae escaped the 
phagolysosomes or it was colocalized with the lysosomes. Furthermore, it was 
difficult to recruit antiretroviral therapy naïve individuals due to the Test and 
Treat strategy adopted by Malawi (Alhaj et al., 2019). Nevertheless, it is important 
to decipher effects of short- and long-term ART on early control of pneumococcus 
as the majority of HIV-infected adults will be on ART going forward.  
 
5.5. Conclusion  
This study demonstrates that although AMs readily internalize and kill S. 
pneumoniae within the first three hours of infection with intracellular killing being 
a rate-limiting step for bacterial clearance. The evasion of AM intracellular killing 
is exacerbated in HIV-infected adults on ART (short-term and long-term). This 
finding potentially uncovers why certain population groups are more susceptible 
to pneumococcal pneumonia. Nonetheless, intracellular killing is one of the 
mechanisms to control extracellular outgrowth of pneumococci, hence evasion of 
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intracellular killing is likely to have a direct impact on overall control of 
pneumococcal infection. In the next chapter, I will explore the control of 
pneumococcus outgrowth by alveolar cells and investigate the key mechanisms 




6.0. Airway cell control of S. pneumoniae extracellular outgrowth in 
asymptomatic adults residing in Malawi. 
 
6.1. Introduction 
The spread of S. pneumoniae to the lung is thought to be through microaspiration 
and this can lead to pneumonia if not cleared successfully by the host immunity 
(Mitsi et al., 2019; Ritchie and Evans, 2019). Airway phagocytic cells control 
extracellular bacteria like S. pneumoniae and S. aureus through bacterial 
internalisation, phagolysosomal killing, engagement of microbiocidal factors, 
cellular enzymes and metal intoxication (Ercoli et al., 2018; Flannagan et al., 2016; 
Johnson et al., 2015; Jubrail et al., 2016). In the previous chapter, I demonstrated 
that during the late killing phase AMs serve as a reservoir for extracellular 
pneumococci with HIV-infected individuals on ART having a higher propensity for 
intracellular persistence. Decreased late bacterial killing leads to neutrophil 
recruitment into the airway, which is the hallmark of pneumonia (Stout-Delgado, 
2019). 
 
It has been shown that intracellular bacterial killing is a finite process, as 
phagocytic cells (macrophages) have a bacteria internalisation threshold. This 
could result in some bacteria propagating in the extracellular space and persisting 
intracellularly as demonstrated with S. aureus (Aberdein et al., 2013; Jubrail et al., 
2016; Preston et al., 2019; Stout-Delgado, 2019). This implies that intracellular 
killing alone will not suffice in controlling the bacteria burden, hence a secondary 
mechanism must be reengaged in controlling bacteria outgrowth. Moreover, the 
S. pneumoniae capsule and other virulence factors are known to profoundly 
inhibit bacterial phagocytosis, complement opsonisation as well as mucus 
entrapment (Andre et al., 2017; Hyams et al., 2010a, 2013a; Pathak et al., 2018). 
Phagocytic cells in the airway may employ other means like release of 
microbiocidal factors (reactive oxygen species (ROS), H2O2, hydroxyl radicals 
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(OH•), reactive nitrogen species (RNS), or regulate metal homeostasis within the 
extracellular space, to control the pneumococcal burden (Farshchi Andisi et al., 
2012; Shenoy and Orihuela, 2016; Ullah et al., 2017; White et al., 2009).  
With the growing antimicrobial resistance, pneumonia burden, pneumococcus 
serotype replacement, and low pneumococcal vaccine efficacy against 
pneumonia, understanding the contribution of extracellular killing is fundamental 
to the effective development of immunotherapies targeted enhancing the airway 
phagocytic killing activities. Furthermore, the role of extracellular control of S. 
pneumoniae outgrowth by human airway cells is still unclear and whether HIV 
infection perturbs this important function is equally unresolved. I hypothesised 
that airway cells from HIV-uninfected adults inhibit extracellular bacterial growth 
during early pneumococcal infection, but this process is impaired in HIV-infected 





















6.1.1. Research question 
Do airway cells from HIV-infected individuals on short-term ART exhibit impaired 
control of S. pneumoniae extracellular outgrowth ex vivo?   
 




To investigate whether bronchoalveolar lavage airway cells from HIV-infected 
individuals on short-term ART show impaired control of S. pneumoniae 
extracellular outgrowth ex vivo.  
 
Objectives 
1. To determine the human bronchoalveolar lavage airway cell control of 
extracellular S. pneumoniae outgrowth in asymptomatic HIV-uninfected 
individuals. 
2. To compare human bronchoalveolar lavage airway cell control of extracellular 
S. pneumoniae outgrowth in HIV-uninfected compared to HIV-infected adults 
on short-term or long-term ART. 
3. To define the factors associated with human bronchoalveolar lavage airway 




6.2. Methods  
 
This section covers some of the methods used in chapter 4 as the same group of 
participants were used though the analysis done was different. 
 
6.2.1. Study participants and design 
This was a comparative cross-sectional study of asymptomatic HIV uninfected, 
HIV-infected on short-time ART (<3-months) and long-term ART (>3-years). 
Participants were recruited from the Malawi-Liverpool Wellcome-Trust’s (MLW) 
Clinical investigation unit at the Queen Elizabeth Hospital in Blantyre, Malawi. All 
participants completed a specific questionnaire relating to their previous clinical 
history and social demographic characteristics that could potentially impact their 
alveolar cell functional response ex vivo before recruitment. The recruitment 
criteria used has been discussed elsewhere (see Chapter 2.4). 
 
6.2.2. Ethical approval and study clearance 
The study received ethical approval from both College of Medicine Research 
Ethics Committee (COMREC), Malawi and Liverpool School of Tropical Medicine 
Research Ethics Committee (LSTMREC), United Kingdom and this together with 
the recruitment criteria used have previously been described (see Chapter 2.3). 
 
6.2.3. Sample collection and processing 
Bronchoalveolar lavage and per nasal swab samples were collected from all 
participants and transported to the MLW laboratories within 30-minutes of 
collection. Sample collection and processing have been described (see Chapter 2).  
 
6.2.4. Laboratory assays  
The laboratory assays associated with this chapter have been described in 
Chapter 2. In particular for specific details S. pneumoniae growth inhibition assay 
(2.6); BAL processing and resting of cells (2.6.6); BAL ex vivo infections (2.6.9); per 
nasal swab processing and S. pneumoniae identification (2.6.15); and the 
identification of intracellular S. pneumoniae in uninfected BAL samples through 
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confocal microscopy (2.6). S. pneumoniae serotype 3 was used in all the 
experiments. 
6.2.5. Statistical analysis  
Descriptive statistics were used to for continuous variables by calculating medians 
and interquartile ranges. Groups were compared using non-parametric tests 
(Wilcoxon rank sum or Wilcoxon signed-rank test, Kruskal Wallis tests) depending 
on the distribution. For multiple comparison the Dunn test was used to adjust for 
p-values. Categorical data were summarised as proportions and compared using 
the χ2 tests. The relationship between the gentamicin protection (invasion) assay 
and outgrowth assay within the early time points (1 – 3 hours) was summarised 
using a simple linear regression model. The relationship between the outgrowth 
assay (persistence) and each variable including; age, sex, persistence within the 
gentamicin protection assay, carriage, AMs proportion, AMs binding index, HIV 
status, CD4+ count and ART status were first summarised using univariate 
regression model. The relationship between the outgrowth assay (persistence) 
and all variable used in the univariate regression analysis namely; age, sex, 
persistence within the gentamicin protection assay, carriage, AMs proportion, 
AMs binding index, HIV status, CD4+ count and ART status were summarised using 
multivariable regression model. All statistical tests were two-sided and were 
deemed statistically significant at an α value of 0.05 (p<0.05*, p<0.01**, 






6.3. Results  
 
6.3.1. Bronchoalveolar lavage airway cells from HIV-uninfected 
individuals control S. pneumoniae outgrowth during early 
infection. 
S. pneumoniae is an extracellular pathogen with a polysaccharide capsule 
surrounding the bacterium that acts as a major virulence factor inhibiting 
phagocytosis, mucus entrapment and neutrophil extracellular traps (Hyams et al., 
2010a; Moorthy et al., 2016). To determine the early S. pneumoniae outgrowth 
kinetics in the presence of airway cells, S. pneumoniae was grown in the presence 
and absence (control) of airway cells for 1-hr and 3-hrs. For these assays, airway 
cells from HIV-uninfected adults were used to establish baseline control in 
absence of HIV. I observed a 1.75-fold median reduction in extracellular S. 
pneumoniae burden in the presence of airway cells (1hr, median (interquartile 
range); 4.8 [4.5 – 5.5]x107 vs 1.7 [0.9 – 3.0]x 107 cfu/ml; p<0.0001) (Figure 6.1 A). I 
further compared the S. pneumoniae outgrowth kinetics at 3-hrs post incubation, 
and I observed a 2.38-fold median decrease in extracellular S. pneumoniae burden 
in the presence of airway cells (3hrs, median (interquartile range); 9.6 [7.2 – 
13.8]x107 vs 2.8 [1.3 – 9.2]x 107 cfu/ml; p<0.0004) (see Figure 6.1 B). Taken 
together, these findings demonstrate that bronchoalveolar lavage airway cells 
from HIV-uninfected individuals control the S. pneumoniae extracellular 




Figure 6.3.1. S. pneumoniae outgrowth kinetics in the presence and absence of alveolar cells. A. 
Comparison of S. pneumoniae outgrowth kinetics in infection media in the presence and absence 
of airway cells 1-hour post incubation; by Wilcoxon rank sum test, ****p<0.0001; SPN (red circles 
– control bacteria; n=9); HIV-uninfected (grey circles, n=21). B. Comparison of S. pneumoniae 
outgrowth kinetics in infection media in the presence and absence of airway cells 3-hours post 
incubation; by Wilcoxon rank sum test, ***p=0.0004; SPN (red circles – control bacteria; n=17); 
HIV-uninfected (grey circles, n=21). Abbreviations: cfu – colony forming units, HIV- – HIV-
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6.3.2. HIV-infection and ART does not impair bronchoalveolar 
lavage airway cells early control of S. pneumoniae 
extracellular outgrowth ex vivo. 
Having established that bronchoalveolar lavage airway cells from HIV-uninfected 
individuals control the S. pneumoniae extracellular outgrowth during early 
infection. I next sought to investigate the control of extracellular S. pneumoniae 
outgrowth by airway cells in asymptomatic HIV-infected adults on short-term ART 
ex vivo (n=19). I observed no statistically significant difference in the S. 
pneumoniae extracellular bacteria burden between the HIV-uninfected adults and 
HIV-infected adults on short-term ART at 1-hr post infection (median, IQR; 1.7 [0.9 
– 3.0]x 107 vs 2.2 [0.9 – 3.6]x107 cfu/ml; p=0.7226) (Figure 6.2 A). At 3-hrs post 
infection, there was also no statistically significant differences (median, IQR; 2.8 
[1.3 – 9.2]x 107 vs 5.2 [0.9 – 9.8]x107 cfu/ml; p=0.9207) between the HIV-
uninfected adults and HIV-infected adults on short-term ART (Figure 6.2 B). I also 
compared the airway cell control of S. pneumoniae extracellular outgrowth in 
individuals on long-term ART. I observed no significant differences in the median 
between S. pneumoniae extracellular bacteria burden from HIV-uninfected 
individuals and HIV-infected adults on long-term ART at 1-hr post infection 
(median, IQR; 1.7 [0.9 – 3.0]x 107 vs 1.0 [0.3 – 2.1]x107 cfu/ml; p=0.3016) (see 
Figure 6.2 C). At 3-hrs post infection, no statistically significant differences 
(median, IQR; 2.8 [1.3 – 9.2]x 107 vs 3.9 [7.0 – 8.8]x107 cfu/ml; p=0.9503) were 
observed between the extracellular S. pneumoniae burden from HIV-uninfected 
individuals and HIV-infected adults on long-term ART (Figure 6.2 D). Collectively, 
this data show that short-term and long-term ART is not associated with impaired 
early control of extracellular S. pneumoniae outgrowth.  






Figure 6.2. Impact of HIV and ART on bronchoalveolar lavage airway control of extracellular S. 
pneumoniae. A. Comparison of the extracellular S. pneumoniae burden between HIV-uninfected 
(grey circles; n=21) and HIV-infected on ART<3-months (cyan circles; n=19) at 1-hour post 
infection. B. Comparison of the extracellular S. pneumoniae burden between HIV-uninfected (grey 
circles; n=21) and HIV-infected on ART<3-months (cyan circles; n=19) at 1-hour post infection. C. 
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n=21) and HIV-infected on ART>3-years (cyan circles; n=10) at 1-hour post infection. D. 
Comparison of the extracellular S. pneumoniae burden between HIV-uninfected (grey circles, 
n=21) and HIV-infected on ART>3-years (cyan circles; n=10) at 3-hour post infection. All analysis by 
Wilcoxon rank sum test, p>0.05. Abbreviations: ART – antiretroviral therapy, cfu – colony forming 





6.3.3. The presence of human bronchoalveolar lavage airway cells 
augments S. pneumoniae outgrowth ex vivo 24-hrs post 
infection. 
Following previous observations of extracellular S. pneumoniae control by 
bronchoalveolar lavage airway cells within the early phase of ex vivo infection (1-3 
hours), I investigated whether airway cells are capable of controlling the 
extracellular S. pneumoniae outgrowth during the late infection phase infection 
(24-hrs post infection). Firstly, I observed no statistically significant difference in 
the proportions between cell free conditions and airway cells from HIV-uninfected 
individuals (48% vs 47.6%; p>0.9999). I also observed no difference in S. 
pneumoniae extracellular bacteria burden (median, IQR; 10[10 – 189] vs 10[10 – 
255.3] cfu/ml; p=0.4366) between cell free conditions and airway cells from HIV-
uninfected individuals (Figure 6.3 A). Furthermore, when I looked at the impact of 
treated HIV infection on extracellular pneumococcal persistence 24hrs post 
infection, airway cells from HIV-uninfected individuals had higher proportions of 
persisters compared to airway cells from HIV-infected adults on short-term ART 
(48% vs 15.8%, p=0.0455) or HIV-infected adults on long-term ART (48% vs 10%, 
p=0.0550) see (Figure 6.3 B). Furthermore, I compared viable culturable 
pneumococci in the conditions with and without airway cells at 24hrs post 
infection. The airway cells had higher bacterial burden than those without 
(median, IQR; 3.7[0.2 – 230] x106 vs 2[0.5 – 9.8]x102 cfu/ml; p=0.0007) (Figure 6.3 
C). These findings show that during the late infection phase (24hrs post-infection), 
airway cells potentially promote pneumococcal survival, with HIV-infected 
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Figure 6.3. S. pneumoniae growth enhancement 24-hrs post infection ex vivo. A. Comparison 
of S. pneumoniae outgrowth bacterial load in the presence and absence of airway cells 24-
hours post incubation; by Wilcoxon rank sum test, p>0.05; SPN (red circles, control bacteria, 
n=25); HIV-uninfected (grey circles, n=21).B. Comparison of the proportions of outgrowth 
bacterial load between HIV-uninfected (grey circles, n=10/21), HIV-infected on ART<3-
months (purple circles, n=3/19) and HIV-infected individuals ART>3-years (cyan circles, 
n=1/10) 24-hr post infection; by Kruskal-Wallis (*p=0.0446) and Dunn multiple comparison 
test (*p=0.0455). C. Comparison of the extracellular S. pneumoniae burden in persisters 
[(individuals pooled from HIV-uninfected (n=10), HIV infected individuals ART<3-months 
(n=3), HIV-infected individuals ART>3-years (n=1), blue circles)] 24hrs post infection, and 
compared with SPN (red circles, n=11) in airway cell free condition; analysis by Wilcoxon 
rank-sum test, ***p=0.0007.Abbreviations: ART – antiretroviral therapy, cfu – colony forming 








































6.3.4. The relationship between early intracellular killing and 
bacterial outgrowth assay of S. pneumoniae ex vivo. 
Having established that airway cells could support the growth of S. pneumoniae 
during late infection, and that early intracellular killing kinetics (1 – 3 hours) in 
HIV-uninfected individuals predict S. pneumoniae intracellular persistence in the 
late killing phase (Chapter 5). I investigated whether there was a direct 
relationship between intracellular killing kinetics and extracellular bacterial 
outgrowth control during early infection (1-3hrs post infection), as this could 
dictate the outcome of S. pneumoniae clearance. I found a moderate positive 
correlation between the early intracellular killing kinetics and extracellular 
bacterial outgrowth control [r=0.5389 (95% confidence interval, 0.3037 – 0.7122); 
p<0.0001] (see figure 6.4). Taken together, this shows that a relationship exists 
between the intracellular and extracellular killing kinetics of S. pneumoniae within 
the first 3-hours of infection. 
 
Figure 6.4. Relationship between early intracellular killing and early bacterial outgrowth assay of S. 
pneumoniae ex vivo. A moderate positive correlation was observed between early intracellular 
within AMs pneumococci (gentamicin protection assay) and extracellular pneumococci (bacterial 
outgrowth assay) during the early killing phase (1-3hours post infection, n=49) ex vivo; by Pearson 
correlation test (r), linear regression line with 95% confidence interval are shown; r=0.5389, 95%CI 
0.3037 – 0.7122, p<0.0001. Abbreviations: AUC – area under the curve, GPA – gentamicin 
protection assay, EI – extracellular inhibition. 




























6.3.5. Early S. pneumoniae extracellular killing kinetics do not 
predict bacteria persistence ex vivo. 
I then investigated whether early extracellular outgrowth control kinetics 
represented by the area under the curve (AUC) for time points (1 – 3hrs) could 
distinguish between extracellular persistence and non-persistence of 
pneumococcus. Within the HIV-uninfected individuals, I found no statistically 
significant difference in the extracellular outgrowth control kinetics between 
persisters and non-persisters during the early time points (AUC, 9.3 [IQR; 2.1 – 
10.8]x107 vs. 5.7 [1.2 – 8.2]x107, p=0.2877) (Figure 6.5 A). I found no statistically 
significant differences between persisters and non-persisters from the combined 
treated HIV-infected individuals (AUC, 11.1 [IQR; 3.8 – 15.0]x107 vs. 5.1 [IQR; 1.3 – 
9.7]x108, p=0.5593) (Figure 6.5 B). I was not able to do any analysis in HIV infected 
individuals on long-term ART as there were not enough data points (Figure 6.5. C).  
Collectively, these findings demonstrate that persistence of S. pneumoniae 24hrs 



































Figure 6.5. A comparison of early killing kinetics between persister and non-persisters. A. 
Comparison of the early outgrowth bacterial load between persisters and non-persisters within 
the HIV-uninfected individuals as demonstrated by the area under the curve (AUC), by Wilcoxon 
rank sum test, p>0.05. B. Comparison of the early outgrowth bacterial load between persisters and 
non-persisters within the combined ART treated HIV infected individuals as demonstrated by the 
area under the curve (AUC), by Wilcoxon rank sum test, p>0.05. Abbreviations: AUC – area under 
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6.3.6. Intracellular bacterial persistence predicts survival of 
extracellular S. pneumoniae 24hrs post infection 
Next, I used univariate and multivariate analysis to determine key factors that 
could explain the extracellular persistence of S. pneumoniae 24hrs post infection, 
using demographic data and experimental parameters describe in Chapter 4, 5 
and 6. I found a positive association between intracellular S. pneumoniae 
persistence and extracellular S. pneumoniae persistence on univariate analysis 
(coefficient estimate, 95% CI: 0.354, 95%CI 0.096 to 0.61; p =0.008) (Table 6.1.). 
This association between intracellular S. pneumoniae persistence and extracellular 
S. pneumoniae persistence remained marginally significant following multivariate 
analyses (0.304, 95%CI 0.001 to 0.606; p=0.049), after adjusting for AMs 
proportion, carriage, age, sex, proportion of alveolar macrophages associated 
with S. pneumoniae, binding index, HIV status, CD4+ count and ART status. 
However, the other variables like sex (coefficient estimate, 95% CI: -0.330, 95%CI 
-0.600 to -0.061; p=0.017), HIV status (coefficient estimate, 95% CI: -0.418, 95%CI 
-0.672 to -0.165; p=0.002), ART duration (short-term ART; coefficient estimate, 
95% CI:  -0.418, 95%CI -0.760 to -0.077, p=0.018; Long-term ART, (coefficient 
estimate, 95% CI: -0.418, 95%CI -0.699 to -0.138, p=0.004) were only positively 
associated with extracellular pneumococcal persistence on univariate analysis but 
the association was lost in multivariable analysis. Collectively, the survival of 
extracellular S. pneumoniae 24hrs post infection is likely driven by intracellular 





Table 6.1. Factors associated with the presence of extracellular S. pneumoniae 






estimate (95% CI)                     p-value 
Multivariable analysis 
Coefficient  
estimate (95% CI)                      p-value 
T24 GPA- P 0.354 (0.096 – 0.61) 0.008 0.304 (0.001 – 0.606) 0.049 
AM prop 0.009 (-0.009 – 0.026) 0.338 0.003 (-0.014 – 0.020) 0.737 
Carriage  0.019 (-0.279 – 0.317) 0.898 0.033 (-0.277 – 0.344) 0.828 
Age  -0.009 (-0.025 – 0.007) 0.253 -0.006 (-0.022 – 0.009) 0.413 
Sex  -0.330 (-0.600 – -0.061) 0.017 -0.115 (-0.426 – 0.197) 0.456 
AM ST3 Prop 0.002 (-0.003 – 0.007) 0.432 0.004 (-0.003 – 0.012) 0.257 
AM binding 
index 
-0.002 (-0.069 – 0.064) 0.07 -0.028 (-0.137 – 0.080) 0.597 
HIV status -0.418 (-0.672 – -0.165) 0.002 -0.272 (-0.635 – 0.091) 0.137 
CD4+ 0.0003 (-0.0002 – 0.0009) 0.243 -9.92e-06 (-0.0007 – 0.0007) 0.976 
ART status (1) 
(2) 
-0.418 (-0.760 – -0.077) 
-0.418 (-0.699 – -0.138) 
0.018 
0.004 
0.012 (-0.361 – 0.386) 
– q  
0.946 
 
Definition of abbreviation  
GPA-P – gentamicin protection assay (intracellular persistence 24-hours post 
infection) 
AM prop – alveolar macrophage proportion 
AM ST3 prop – proportion of alveolar macrophages associated with S. 
pneumoniae (serotype 3) 1-hr post infection 
AM binding index – Proportion of S. pneumoniae bound to each alveolar 
macrophage 1hr post infection 
CD4+ - cluster of differentiation 4 
ART – antiretroviral therapy 
(1) These are HIV infected individuals on ART<3-months 
(2) These are HIV infected individuals on ART>3-years  
q - omitted from the multivariable analysis because of collinearity with HIV status 
In bold are the p-values that were significant following univariable and 





6.4. Discussion  
The success of S. pneumoniae to cause infection in the airway depends on its 
ability to evade airway cell mediated killing mechanisms. Previous studies have 
shown that peripheral CD4+ T-cells depletion, predisposes individuals to higher 
carriage densities and bacterial pneumonia amongst the HIV-infected individuals 
(Glennie et al., 2013; Hirschtick et al., 1995). In this study, I developed a primary 
airway cell model for understanding the early kinetics of airway cell-mediated 
control of S. pneumoniae extracellular outgrowth ex vivo. Using this approach, 
first, I demonstrated that airway cells from HIV-uninfected adults control S. 
pneumoniae extracellular outgrowth during early infection. Secondly, HIV 
infection does not impair the airway cell-mediated control of extracellular S. 
pneumoniae outgrowth during early infection. Thirdly, during the late killing phase 
(24hrs post-infection), airway cells promote S. pneumoniae survival. Lastly, 
presence of extracellular S. pneumoniae 24hrs post infection is propagated by 
intracellular bacterial persistence. 
 
Airway cells play a key role in lung immune homeostasis including early control of 
bacterial pathogens in the airspaces (Boehme et al., 2017; Byrne et al., 2015; 
Collini et al., 2018; Wilson et al., 2015). In this study, airway cells from HIV-
uninfected individuals were able to control the extracellular S. pneumoniae 
outgrowth during early infection. Previous studies have primarily focused on 
single populations particularly AMs, shorter infection studies, as well as 
intracellular killing (cell invasion) probably due to their increased proportions of 
AMs in the airway (Gordon et al., 2000, 2013; Mitsi et al., 2019). However, this 
study provides a more holistic insight using unfractionated airway cells to 
understand early control of extracellular outgrowth of S. pneumoniae, as this 
process is likely critical for development of pneumonia. In line with the increased 
susceptibility to pneumococcal pneumonia in HIV-infected individuals, we 
expected to observe poor early control of pneumococcal outgrowth during HIV 
infection. However, short-term or long-term ART-treated HIV infection was not 
associated with poor control of pneumococcal extracellular outgrowth during 
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early infection ex vivo. This is consistent with previous findings focusing on AM, 
that demonstrated no impairment in the binding, internalisation and intracellular 
killing of opsonised pneumococci (Gordon et al., 2000, 2001, 2013), as well as 
results in Chapter 4 and 5.. This suggests that HIV infection may not significantly 
impact early control of pneumococcal infection.  
 
Intriguingly, the presence of airway cells enhanced S. pneumoniae outgrowth 24-
hrs post-infection, leading to a higher propensity of extracellular S. pneumoniae 
burden in conditions with cells compared to those without cells. This observation 
could be serotype dependent as the isolate used in this study was isolated as a 
meningitis causing isolate (serotype 3, sequence type 700), therefore it could 
have developed mechanism to evade host extracellular killing. The meningitis 
strain was only used in this study to model invasive disease as we did not have 
access to a strain known to cause pneumococcal pneumonia. On the other hand, 
the observed phenomenon could be a mechanism S. pneumoniae has evolved to 
exploit host immunity by obtaining micronutrients such as zinc, iron and 
manganese that are necessary for its propagation and maintenance (Cao et al., 
2018; Eijkelkamp et al., 2019; Martin, 2020; Miao et al., 2018; Ong et al., 2013; 
Plumptre et al., 2014).  
 
This study demonstrates that the presence of extracellular S. pneumoniae 24hrs 
post infection is associated with persistence of intracellular bacteria. The strength 
of this observation is confirmed through a multivariate analysis, as well as the fact 
the parameters were generated from two separate assays (Chapter 5 and 6). 
Furthermore, this study demonstrates that pneumococcal infection in the airway 
is a dynamic process as evidenced by the association between extracellular and 
intracellular pneumococcal survival, which could potentially influence the 
outcome of the infection. This dynamic survival mechanism through evasion of 
extra-intracellular killing has been shown to promote survival of other pathogens 
such Cryptococcus and S. aureus in macrophages (Flannagan et al., 2016; 
Goldman et al., 2000; Jubrail et al., 2016; Rollin et al., 2017; Shourian and Qureshi, 
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2019). Intracellular persistence of S. pneumoniae in alveolar macrophages could 
be a major driver of pneumonia due to its potential to propagate extracellular 
bacterial outgrowth. Therefore, understanding the mechanisms of intracellular 
pneumococcal survival in airway cells is critical and warrants further investigation.  
 
Phagocytes are able to control extracellular burden of bacteria through 
production of H2O2 (which can be toxic to epithelia cells), reactive oxygen and 
nitrogen species. However, pneumococcus has developed mechanisms to survive 
in high oxygen tension environments, ROS and H2O2 detoxifying enzymes such as 
NADH oxidase, superoxide dismutase, thiol peroxidase and alkyl hydroperoxidase 
and metal scavengers such as manganese (Mn2+) (Erttmann and Gekara, 2019; 
Hajaj et al., 2012; Rai et al., 2015; Yesilkaya et al., 2013). The host is also able to 
sequestrate metal cofactors such as Fe, Mn, Zn, Ni which are critical for the 
function pneumococcal enzymes used in ROSN detoxification, like superoxide 
dismutase (Cao et al., 2018; Eijkelkamp et al., 2019; Miao et al., 2018). The host 
can also control extracellular growth of pneumococci by producing excess Zn 
which prevents the uptake of manganese by binding irreversibly to the high 
affinity manganese solute binding protein PsaA, resulting in it becoming 
hypersensitive to oxidative stress (Ong et al., 2015; Yesilkaya et al., 2013). The 
host can also increase intracellular Zn as shown with murine phagocytic cells from 
zinc restricted mice, which demonstrated poor pneumococcal control, increased 
bacterial burden and reduced survival times (Eijkelkamp et al., 2019). 
 
The main limitations of this study are that I did not measure any microbiocidal 
factors like reactive oxygen and nitrogen species (RONS), transitional metals, 
cytokine milieu that could be key in the clearance of extracellular pneumococci 
and further explain my findings. However, the strength of this study is that it 
provides a more holistic insight using unfractionated airway cells critical to the 
control of extracellular control pneumococcus. This model acts as proxy and helps 






6.5. Conclusion  
Collectively, this study elucidates how S. pneumoniae exploits host airway cells for 
its extracellular survival ex vivo and this could be a critical step in pneumococcal 
pathogenesis. This work highlights the importance of both intracellular (cell 
invasion) and extracellular killing (outgrowth) assays in understanding the 





7.0. Overall Discussion  
7.1. Introduction  
S. pneumoniae is the leading cause of community-acquired pneumonia in all ages, 
with the greatest incidence occurring in children, the elderly and HIV-infected 
individuals (Aston et al., 2019; Azzari et al., 2016; Troeger et al., 2017). The airway 
is the major port of entry for respiratory pathogens, with the lung serving as the 
main site of pulmonary defence. Pneumococcal pneumonia is preceded by 
asymptomatic colonisation and both pneumonia and colonisation are highest 
amongst children and the HIV infected individuals (Bogaert et al., 2004; 
Heinsbroek et al., 2015, 2016). Alveolar macrophages (AMs) are the major 
effector cells found in the airway, responsible for the early clearance and control 
of respiratory pathogens. To date, few studies exist in humans on the lower 
airway mediated immunity against S. pneumoniae, although most of the 
knowledge gathered is derived from studies done in animal models.  
 
This thesis tested the primary hypothesis that HIV infection is associated with 
impaired airway alveolar phagocyte killing function, leading to survival and 
propagation of pneumococci. The secondary hypotheses tested that: (i) HIV-
infected adults on short-term antiretroviral therapy (ART) possess differentially 
impaired lower airway phagocyte pneumococcal binding and internalisation 
capacity to S. pneumoniae, (ii) HIV is associated with impairment of AMs killing of 
S. pneumoniae leading to its intracellular survival, and (iii) HIV-infected adults on 
short-term ART show impairment of airway control of extracellular outgrowth of 
S. pneumoniae ex vivo.  
 
To answer the research question, three groups of individuals aged between 18 – 
60 years were recruited consisting of asymptomatic HIV-uninfected adults, HIV-
infected adults on short-term and long-term ART residing in Blantyre, Malawi. 
Lower airway samples (bronchoalveolar lavage fluid) were collected from the 
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participants and used to investigate airway mediated defence immunity against S. 
pneumoniae in an ex vivo model. The study was a comparative cross-sectional 
design, which allowed a direct comparison of airway pulmonary immunity 
amongst the three groups and also shedding light on the possible mechanisms 
involved that render HIV-infected individuals more susceptible to pneumococcal 
pneumonia. This chapter focuses the discussion on the major findings in this 
thesis, their implications, and ideas for future work. 
 
7.2. Summary of research findings in context 
This thesis has generated three major conclusions arising from the airway ex vivo 
model and were centred on 1) the binding and internalisation of pneumococcus 
by alveolar macrophages (AMs) and neutrophils 2) the AMs intracellular killing 
kinetics of pneumococcus and 3) airway cell extracellular killing kinetics of 
pneumococcus. The findings generated in this thesis are summarised in Figure 
7.1. 
 
Figure 7.1. The model summarises the thesis findings. A. Individuals who are able to control 
pneumococci (non-persisters), their alveolar macrophages internalise opsonised pneumococci 
through their Fc portion resulting in pneumococcal killing and clearance from the intracellular and 
extracellular compartments. B. Individuals who are able to unable clear pneumococci (persisters), 
their alveolar macrophages internalise opsonised pneumococci through their Fc portion resulting 
in the failure to kill internalised pneumococci from the intracellular compartments. Internalised 
pneumococci propagate the survival of extracellular pneumococci. Abbreviations: AMs – alveolar 
macrophage. This figure contains some artwork produced by Servier Medical Art 
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Firstly, the thesis investigated whether HIV-infected adults on short-term ART 
possess differentially impaired airway phagocyte pneumococcal binding and 
internalisation capacity. Using an ex vivo infection model of primary airway cells, it 
was observed that AMs are the principal phagocytic cell in the airway and the 
major cell associated with IgG-opsonised pneumococcal-ST3 following ex vivo 
infection, irrespective of HIV status. It was also observed that HIV-infected adults 
on short-term or long-term ART do not exhibit impaired association of IgG-
opsonised pneumococcal-ST3 with AM. Furthermore, it was demonstrated that 
HIV-infected adults on short-term ART exhibited enhanced binding of IgG-
opsonised pneumococcal-ST3 to neutrophils, but not to AMs.  
 
Secondly, this thesis investigated whether HIV-infection was associated with an 
impaired AMs killing of S. pneumoniae resulting in its intracellular survival. Using 
the gentamycin protection (invasion) assay which I developed for investigating 
early AMs-mediated intracellular control of pneumococcus. Using confocal 
microscopy, it was observed that pneumococci persist in CD206+AMs 24hrs post-
infection. It was also observed that slow early killing kinetics of intracellular 
pneumococci within the first 3hrs post-infection in HIV-uninfected adults but not 
HIV-infected individuals on ART was associated with increased propensity for 
bacterial persistence in CD206+AMs 24hrs post-infection. Furthermore, HIV-
infection and ART were associated with a reduced AMs-mediated intracellular 
killing capacity of S. pneumoniae during the late killing phase (24-hours post 
infection) leading to a higher propensity of intracellular S. pneumoniae 
persistence. It also was demonstrated that natural S. pneumoniae carriage did not 
augment AMs-mediated intracellular killing kinetics.  
 
Lastly, this thesis investigated whether airway cells from HIV-infected individuals 
on short-term ART show impaired control of S. pneumoniae extracellular 
outgrowth. This thesis demonstrated that airway cells from HIV-uninfected adults 
control S. pneumoniae extracellular outgrowth during early infection. It was also 
shown that HIV-infection did not impair the airway cell-mediated control of 
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extracellular S. pneumoniae outgrowth during early infection. It was further 
demonstrated that the presence of extracellular S. pneumoniae 24hrs post 
infection is propagated by intracellular bacterial persistence. 
 
7.3. Implications of findings 
The data presented in this thesis have plausible implications on future studies 
particularly on airway mucosal immunity (human and animal), disease 
pathogenesis and vaccine development. Implications of findings from this thesis 
are discussed in sections below.  
 
7.3.1. Airway mucosal immunity 
The thesis demonstrated a reduced AMs-mediated intracellular killing capacity of 
S. pneumoniae during the late killing phase (24-hours post infection) leading to a 
higher propensity of intracellular S. pneumoniae persistence HIV-infected on ART. 
These findings concur with previous work from Dockrell’s group; where HIV gp120 
was found to be associated with an impairment in apoptosis intracellular 
pneumococci killing in MDM (Collini et al., 2018). These findings have also been 
shown in other human lung respiratory disease states such COPD (Bewley et al., 
2017). The same group has also shown that CD68.hMcl-1 transgenic mouse model 
with macrophage-specific overexpression of the human anti-apoptotic Mcl-1 
protein resulted in a blunted microbiocidal killing response of internalised 
pneumococci (Preston et al., 2019). Taken together these findings suggest that 
chronic disease conditions impair AMs response to pneumococci and possibly 
render these individuals more susceptible to pneumococcal pneumonia. 
Furthermore, we also uncovered that the use of single immune cell type and 
global airway immune cells both aids in deciphering deficits in the broad 
pneumococcal immune responses as shown in the findings. 
 
However, since it is challenging to obtain airway samples, previous studies have 
shown that using monocyte derived macrophages (MDMs) or monocyte derived 
dendritic cells (MoDCs), can be used as a surrogate immune cells to decipher AMs 
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and DCs pneumococcal intracellular immune kinetics (Collini et al., 2018; 
Subramanian et al., 2019). What remains to be shown though is to demonstrate 
whether MDMs and MoDCs can be used as a substitute for primary airway cells 
(AMs and DCs) in studying pneumococcal immunity in a high carriage setting. 
Many other studies use epithelial cell lines but not airway epithelial cells due to 
the challenge associated with their limited numbers during collection (Weight et 
al., 2019). The use of animal studies to investigate airway pneumococcal 
immunity could offer an alternative model. However, in our setting it maybe more 
challenging to use animal studies due to the costs associated with the 
programme. In Malawi, an experimental human pneumococcal challenge has 
been established (Gordon et al., 2017) and it offers a better alternative of 
studying mucosal immunity against S. pneumoniae.  
 
7.3.2. Pneumococcal pathogenesis within the airway 
This thesis has also demonstrated that the presence of extracellular S. 
pneumoniae 24hrs post infection is propagated by intracellular bacterial 
persistence. This suggests that though, S. pneumoniae is believed to be an 
extracellular pathogen, its fate in the airway depends on the ability of phagocytes 
to kill the internalised bacteria irrespective of HIV status. These observations also 
suggest that it is plausible that the S. pneumoniae might have an intracellular 
propagation phase in airway phagocytes, though this merits further experimental 
investigations to elucidate this postulation. No human studies exist so far with 
which to compare our results. These findings have an implication on our 
understanding of the pneumococcal pathogenesis within the airway and the 
establishment of infection. Previously, in a murine model of sepsis it was shown 
that sepsis is established by a single pneumococci bacterium (Ercoli et al., 2018). 
This aligns well with our invasion ex vivo experiment, whereby during the eclipse 
phase the bacteria were virtually cleared from the AMs but re-emerged during 
the late infection phase. Macrophages may represent an immune-privileged 
sanctuary and a reservoir for the reseeding of bacteria into the extracellular 
compartment to cause pneumococcal infection in the airway (Ercoli et al., 2018). 
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AMs have been shown to serve as a reservoir for other pathogens such as HIV, S. 
aureus, Mycobacterium tuberculosis and C. neoformans (Boliar et al., 2019; 
Flannagan et al., 2016; Honeycutt et al., 2017; Shourian and Qureshi, 2019).  
 
I have also demonstrated that the pneumococci establishes persistence within 
CD206+AMs and this concurs with the recent findings showing that pneumolysin 
and CD206 interactions mediate pneumococcal internalisation into non-lysosomal 
compartments thus promoting its survival (Subramanian et al., 2019). Notably, 
these findings are not exclusively based on primary airway cell model, but have 
previously been shown in different models such as an MoDc, murine AMs and 
AMs from EHPC model (Mitsi et al., 2019; Subramanian et al., 2019). These 
findings are a departure from the commonly accepted dogma of S. pneumoniae 
being an obligate extracellular pathogen, but are in alignment with previous 
findings which demonstrated that pneumococcal septicaemia is initiated by a 
single bacterial cell within murine splenic macrophages (Ercoli et al., 2018). This is 
despite the belief that AMs are efficient in the clearance and control of 
pneumococcus. As a field we may need to shift our focus of pneumococci only 
being a classic obligate extracellular pathogen but also consider that the bacteria 
might be able to establish intracellular residency before being reseeded 
extracellularly to cause serious infections. Furthermore, these findings are unique 
and novel in our setting of both high HIV burden and pneumococcal carriage. This 
opens a new avenue for further investigations into the insights of human immune 
responses elicited in the pulmonary mucosa. At the same time, our findings affirm 
previous findings which demonstrated that HIV infection or being on ART does not 
impair the binding and internalisation of opsonised pneumococci by AMs (Gordon 
et al., 2001, 2013). This shifts the focus of the field to understanding events 
occurring within the AMs between the early and late killing phase and virulence 






7.3.3. Vaccine development 
This thesis sheds some insights into why the current PCVs and PPSV-23 are not 
effective pneumococcus serotype 3 strains. This might be debatable because we 
used an invasive serotype-3 strain and it could behave differently from carriage 
serotypes. However, evidence from literature shows that the current vaccines are 
not effective against pneumococcus serotype 3 due to its clonal diversity (Azarian 
et al., 2018; Groves et al., 2019; Swarthout et al., 2020). More research needs to 
be carried out in understanding the differences in global pneumococcal serotype 
strains and their preponderance for vaccine escape. 
  
 AMs are the most abundant cell type within the airway and its proportions are 
less affected by HIV and antiretroviral therapy. Previously, it was shown that AMs 
from carriage positive individuals had a heightened opsonophagocytic capacity, 
and also displayed non-specific response to pneumococcal stimulus (Mitsi et al., 
2019). This demonstrates that AMs are excellently placed to initiate an immune 
response in the lower airway should they encounter pneumococcus. Thus, they 
provide a critical target for pneumococcal vaccine research and could be boosted 
to elicit non-specific responses against common respiratory pathogens thus 
successfully preventing pneumonia in susceptible individuals. The administration 
of a live- attenuated intranasal pneumococcal vaccine could augment the 
pulmonary immune-responses and confer serotype-independent protection (Mitsi 
et al., 2019).  
 
7.4. Limitations  
Though this thesis produced intriguing findings, it also has limitations which affect 
the generalisability of some of the findings. In this section, I will focus on the 
limitations that were not discussed in the previous chapters. 
 
The main limitation was the lack of a sufficient sample size, we recruited fewer 
individuals than expected especially in the HIV-infected individuals on ART>3-
years (12 vs 30). This was due to study time constraints, we lost 5-months of 
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recruitment as our two research bronchoscopes malfunctioned around the same 
time, and we could not continue with recruitment till a replacement 
bronchoscope had been purchased and shipped to Malawi. In, addition not all the 
experiments that were done (invasion assay, bacteria outgrowth, uptake assay), 
had the expected number of individuals per group (n=30), because of the limited 
number of airways cells returned during the bronchoscope procedure. In such 
circumstance, airway cells were first prioritised for the binding and internalisation 
and invasion assays, rather than the outgrowth assay. To resolve the limited 
number of cells for the experiments, the use of MDMs and peripheral 
lymphocytes in optimised ratios could have been adopted for the invasion assay.   
 
In addition, I was not able to decipher the mechanism that differentiates 
individuals found to be persisters and non-persisters in this thesis. This unusual 
phenomenon could possibly be strain related, or a natural phenomenon 
associated with all clinically relevant pneumococcus. To solve this, we could have 
included other strains of pneumococcus (carriage and invasive) or mutant strains 
as comparators to observe if we could replicate similar findings before trying to 
understand deficits associated with the intracellular killing pathways. 
Furthermore, I could have also increased the earlier killing time points to six hours 
and the late killing phase to include time point 20, 22- and 24-hours post infection 
for us to observe the exact time points when AMs reached the limit of 
intracellular detection of pneumococcus by microbiological methods. 
 
Lastly, another possible methodological criticism could be that all participants 
recruited were asymptomatic middle-aged adults. It is unknown if the findings 
described in this thesis would be reflective of results in children, the elderly, or 
the immunocompromised. However, our results are hypothesis generating, 
pointing to deficits within the intracellular killing of phagocytic pathways, which 
could have a bearing on all the susceptible populations on how their phagocytic 




7.5. Future studies  
The findings in this thesis have addressed several hypotheses and some intriguing 
points came up that warrant further investigation and if addressed would better 
the understanding of the early events leading to pneumococcal infection in the 
airways. 
 
7.5.1. Deciphering the mechanism of survival for serotype 3 
pneumococcus in human macrophages 
 
It will be desirable to understand the biology of pneumococcus serotype 3 and 
virulence factors used for its evasion of the airway immunity. Pneumococcus 
serotype 3 has been shown previously to be clonally diverse and this is one of the 
possible reasons why the current vaccines are not effective against it (Azarian et 
al., 2018; Binsker et al., 2017; Swarthout et al., 2020). In Malawi, majority of the 
serotype 3 found are sequence type 700 and are different from those found in 
other African and European countries (Azarian et al., 2018; Everett et al., 2012; 
Groves et al., 2019). It will be interesting to research the difference between 
carriage and invasive pneumococcus serotype 3 found in Malawi and whether 
have the same invasive and evasion potential.  
 
Since, airway samples are difficult to obtain than peripheral samples; it will also 
be worth verifying the use of MoDCs or the MDM as alternative models of airway 
for studying the control of pneumococcus by DCs and AMs in a high carriage 
setting. This knowledge for the alternate model will be crucial for us to further 
demonstrate the main biological differences between persisters and non-persister 
individuals at gene (transcriptomics) and metabolic level (seahorse). To date, we 
still don’t know which cellular pathways are differentially upregulated and 
downregulated between persisters and non-persister individuals. Previous studies 
have used MDMs and MoDCs, but this was in regions of low pneumococcal 
carriage (Collini et al., 2018; Subramanian et al., 2019). So, it remains to be 




Recently, it has been shown that pneumolysin (haemolytic region) is able to 
interact with CD206 found on DCs and AMs and mediate pneumococcal 
internalisation into non-lysosomal compartments (Subramanian et al., 2019). We 
were not able to show in this study how the pneumococcus was able to evade the 
phagocytic killing and survive intracellularly as this needed more time to develop 
fully. Further work is required to investigate whether pneumolysin or other 
virulence factors are key in the evasion of the killing machinery and by which 
mechanism it exerts these effects. Creation of S. pneumoniae ST3 pneumolysin 
mutants will be required to demonstrate whether the pneumolysin virulence 
factor is used by the bacteria in the evasion of intracellular killing machinery. In 
addition, we suggest doing time-lapse experiments, to prove this hypothesis and 
at the same time demonstrate which cell structures pneumococcus localises as it 
evades the phagolysosome. Single cell analysis of the AMs might also be critical to 
investigate molecular signatures associated with the intracellular survival of 
pneumococcus and the AMs subpopulations associated with this phenomenon.  
 
Lastly, it will be critical to demonstrate the pro-and anti-inflammatory cytokine 
profile from the supernatants of ex vivo infections between the persisters and 
non-persister individuals at earlier and late time-points during the infection. 
Preliminary data generated exist from few individuals recruited earlier into the 
study, but this is not substantial to support our hypothesis. Furthermore, it will 
also be important to show whether the pneumolysin is associated with pro-





7.6. Concluding remarks   
In summary, I have observed that pneumococcal binding and internalisation by 
alveolar macrophages is not impaired in treated HIV infection, but that deficits 
exists in the intracellular killing pathways leading to reduced bacterial killing. The 
data shows that the survival of extracellular S. pneumoniae during the late killing 
phase of infection is largely driven by intracellular bacterial persistence. 
Importantly, deficits in intracellular killing were observed in alveolar macrophages 
amongst all the three groups recruited comprising of asymptomatic adults 
namely; HIV-uninfected, HIV-infected on short-term and those on long-term 
antiretroviral therapy. A failure of AMs to kill internalised pneumococci could 
explain an important role underlying the increased risk pneumococcal pneumonia 
in susceptible populations. There is a need for further research on pneumococcal 
serotype 3 and evasion of airway cellular immunity and the role of natural 
carriage on the early events of pneumococcal infection in the lower airways. The 
work conducted for this thesis adds to current understanding of the early cellular 
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Appendix 10: Chichewa participant information sheet (HIV on short-term ART) 
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